

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
8 May 2003 (08.05.2003)

PCT

(10) International Publication Number
WO 03/037891 A1

(51) International Patent Classification⁷: **C07D 403/12**,
401/04, 213/53, A61K 31/435, 31/50, 31/505, A61P 3/10

(21) International Application Number: PCT/EP02/12077

(22) International Filing Date: 29 October 2002 (29.10.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
01204196.8 1 November 2001 (01.11.2001) EP

(71) Applicant (for all designated States except US):
JANSSEN PHARMACEUTICA N.V. [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **FREYNE, Eddy, Jean, Edgard** [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). **BUIJNSTERS, Peter, Jacobus, Johannes, Antonius** [NL/NL]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). **WILLEMS, Marc** [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). **EMBRECHTS, Werner, Constant, Johan** [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). **LOVE, Christopher, John** [GB/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). **JANSSEN, Paul, Adriaan, Jan** [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). **LEWI, Paulus, Joannes** [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). **HEERES, Jan** [NL/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). **DE**

JONGE, Marc, René [NL/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). **KOYMANS, Lucien, Maria, Henricus** [NL/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). **VINKERS, Hendrik, Maarten** [NL/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). **VAN AKEN, Koen, Jeanne, Alfons** [BE/BE]; Bruyningstraat 3, B-8500 Kortrijk (BE). **DIELS, Gaston, Stanislas, Marcella** [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE).

(74) Common Representative: **JANSSEN PHARMACEUTICA N.V.**; Turnhoutseweg 30, B-2340 Beerse (BE).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: HETEROARYL AMINES AS GLYCOGEN SYNTHASE KINASE 3BETA INHIBITORS (GSK3 INHIBITORS)



(57) Abstract: This invention concerns a compound of formula (I), a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine and a stereochemically isomeric form thereof, wherein ring A is a 6-membered heterocycle; R¹ is hydrogen; aryl; formyl; C₁₋₆alkylcarbonyl; optionally substituted C₁₋₆alkyl; C₁₋₆alkyloxycarbonyl; optionally substituted C₁₋₆alkyloxy C₁₋₆alkylcarbonyl; X is a direct bond or a linker atom or group; Z is a direct bond or a linker atom or group; R² is hydrogen, C₁₋₁₀alkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, a carbocycle or a heterocycle, each of said groups may optionally be substituted; R³ is hydrogen; hydroxy; halo;

optionally substituted C₁₋₆alkyl or C₁₋₆alkenyl or C₂₋₆alkynyl; C₁₋₆alkyloxy; C₁₋₆alkylthio; C₁₋₆alkyloxycarbonyl; C₁₋₆alkylcarbonyloxy; carboxyl; cyano; nitro; amino; mono- or di(C₁₋₆alkyl)amino; polyhaloC₁₋₆alkyl; polyhaloC₁₋₆alkyloxy; polyhaloC₁₋₆alkylthio; R²¹; R²¹-C₁₋₆alkyl; R²¹-O-; R²¹-S-; R²¹-C(=O)-; R²¹-S(=O)p-; R²¹-S(=O)p-NH-; R²¹-S(=O)p-NH-; R²¹-C(=O)-; -NHC(=O)H; -C(=O)NHNH₂; R²¹-C(=O)-NH-; R²¹-C(=O)-NH-; -C(=NH)R²¹; -C(=NH)R²¹; R⁰ is an optionally substituted heterocycle provided that -X-R² and/or R³ is other than hydrogen; their use, pharmaceutical compositions comprising them and processes for their preparation.

HETEROARYL AMINES AS GLYCOGEN SYNTHASE KINASE 3BETA INHIBITORS (GSK3 INHIBITORS)

The present invention concerns a novel group of heterocyclic derivatives, their use as a
5 medicine, their use for the manufacture of a medicament for the treatment of diseases
mediated through glycogen synthase kinase 3; processes for their preparation and
pharmaceutical compositions comprising them.

WO 01/72745 describes 2-substituted 4-heteroaryl-pyrimidines useful in the treatment
10 of proliferative disorders.

WO 98/41512 relates to substituted 2-anilinopyrimidines useful as protein kinase
inhibitors.

WO 95/09851 describes pyrimidineamine derivatives useful in the treatment of tumour
diseases.

15 WO 01/12621 describes inhibitors of c-JUN-N-terminal kinases and other protein
kinases.

WO 01/60816 describes pyrimidine derivatives useful as kinase inhibitors.

WO 97/19065 discloses substituted 2-anilinopyrimidines useful as p56^{lck}, p59^{fyn},
ZAP-70 and protein kinase C inhibitors.

20 WO 91/18887 discloses diaminopyrimidine compounds as inhibitors of gastric acid
secretion.

WO 99/50250 concerns HIV inhibiting aminopyrimidine derivatives.

US 5,516,775 concerns the use of 2-anilinopyrimidines as protein kinase C inhibitors.

WO 95/09853 describes *N*-phenyl-2-pyrimidineamine derivatives for the treatment of
25 tumor diseases.

WO 98/18782 concerns 2-pyrimidineamine derivatives as selective protein tyrosine
kinase inhibitors.

EP 0,337,943 discloses *N*-phenyl-*N*-pyrimidin-2-yl derivatives having herbicidal plant
growth regulating activity.

30 EP 0,164,204 concerns 2-aminopyrimidines which augment the immune respons.


EP 0,233,461 relates to 4,5,6-substituted 2-pyrimidineamines having anti-asthmatic
activity.

WO 00/62778 describes cyclic protein tyrosine kinase inhibitors.

US 5,521,184 describes pyrimidine derivatives for the treatment of tumoral diseases.

The present invention relates to compounds which are distinguishable from the prior art in structure, pharmacological activity, potency or selectivity.

The present invention concerns a compound of formula (I)



a *N*-oxide, a pharmaceutically acceptable addition salt, a quaternary amine and a stereochemically isomeric form thereof, wherein

ring A is pyridyl, pyrimidinyl, pyrazinyl or pyridazinyl;

R^1 is hydrogen; aryl; formyl; C_{1-6} alkylcarbonyl; C_{1-6} alkyl; C_{1-6} alkyloxycarbonyl;

C_{1-6} alkyl substituted with formyl, C_{1-6} alkylcarbonyl, C_{1-6} alkyloxycarbonyl, C_{1-6} alkylcarbonyloxy; C_{1-6} alkyloxy C_{1-6} alkylcarbonyl optionally substituted with C_{1-6} alkyloxycarbonyl;

X is $-NR^1-$; $-NH-NH-$; $-N=N-$; $-O-$; $-C(=O)-$; $-C(=S)-$; $-O-C(=O)-$; $-C(=O)-O-$;

$-O-C(=O)-C_{1-6}alkyl-$; $-C(=O)-O-C_{1-6}alkyl-$; $-O-C_{1-6}alkyl-C(=O)-$;

$-C(=O)-C_{1-6}alkyl-O-$; $-O-C(=O)-NR^1-$; $-NR^1-C(=O)-O-$; $-O-C(=O)-C(=O)-$;

$-C(=O)-NR^1-$; $-NR^1-C(=O)-$; $-C(=S)-NR^1-$; $-NR^1-C(=S)-$; $-NR^1-C(=O)-NR^1-$;

$-NR^1-C(=S)-NR^1-$; $-NR^1-S(=O)-NR^1-$; $-NR^1-S(=O)_2-NR^1-$; $-C_{1-6}alkyl-C(=O)-NR^1-$;

$-O-C_{1-6}alkyl-C(=O)-NR^1-$; $-C_{1-6}alkyl-O-C(=O)-NR^1-$; $-C_{1-6}alkyl-$; $-O-C_{1-6}alkyl-$;

$-C_{1-6}alkyl-O-$; $-NR^1-C_{1-6}alkyl-$; $-C_{1-6}alkyl-NR^1-$; $-NR^1-C_{1-6}alkyl-NR^1-$;

$-NR^1-C_{1-6}alkyl-C_{3-7}cycloalkyl-$; $-C_{2-6}alkenyl-$; $-C_{2-6}alkynyl-$; $-O-C_{2-6}alkenyl-$;

$-C_{2-6}alkenyl-O-$; $-NR^1-C_{2-6}alkenyl-$; $-C_{2-6}alkenyl-NR^1-$; $-NR^1-C_{2-6}alkenyl-NR^1-$;

$-NR^1-C_{2-6}alkenyl-C_{3-7}cycloalkyl-$; $-O-C_{2-6}alkynyl-$; $-C_{2-6}alkynyl-O-$;

$-NR^1-C_{2-6}alkynyl-$; $-C_{2-6}alkynyl-NR^1-$; $-NR^1-C_{2-6}alkynyl-NR^1-$;

$-NR^1-C_{2-6}alkynyl-C_{3-7}cycloalkyl-$; $-O-C_{1-6}alkyl-O-$; $-O-C_{2-6}alkenyl-O-$;

$-O-C_{2-6}alkynyl-O-$; $-CHOH-$; $-S-$; $-S(=O)-$; $-S(=O)_2-$; $-S(=O)-NR^1-$; $-S(=O)_2-NR^1-$;

$-NR^1-S(=O)-$; $-NR^1-S(=O)_2-$; $-S-C_{1-6}alkyl-$; $-C_{1-6}alkyl-S-$; $-S-C_{2-6}alkenyl-$;

$-C_{2-6}alkenyl-S-$; $-S-C_{2-6}alkynyl-$; $-C_{2-6}alkynyl-S-$; $-O-C_{1-6}alkyl-S(=O)_2-$ or a direct bond;

Z is a direct bond, $C_{1-6}alkanediyl$, $C_{2-6}alkenediyl$, $C_{2-6}alkynediyl$; $-O-$; $-O-C_{1-6}alkyl-$;

$-S-$; $-C(=O)-$; $-C(=O)-O-$; $-O-C(=O)-$; $-C(=S)-$; $-S(=O)-$; $-S(=O)_2-$; $-NR^1-$; $-NR^1-C_{1-6}alkyl-$;

$-NR^1-C(=O)-$; $-O-C(=O)-NR^1-$; $-NR^1-C(=O)-O-$; $-NR^1-C(=S)-$; $-S(=O)-NR^1-$;

$-S(=O)_2-NR^1-$; $-NR^1-S(=O)-$; $-NR^1-S(=O)_2-$; $-NR^1-C(=O)-NR^1-$; $-NR^1-C(=S)-NR^1-$;

$-NR^1-S(=O)-NR^1-$; $-NR^1-S(=O)_2-NR^1-$;

- R^2 is hydrogen, C_{1-10} alkyl, C_{2-10} alkenyl, C_{2-10} alkynyl, R^{20} , each of said groups representing R^2 may optionally be substituted where possible with one or more substituents each independently being selected from =S; =O; R^{15} ; hydroxy; halo; nitro; cyano; R^{15} -O-; SH; R^{15} -S-; formyl; carboxyl; R^{15} -C(=O)-; R^{15} -O-C(=O)-; R^{15} -C(=O)-O-; R^{15} -O-C(=O)-O-; -SO₃H; R^{15} -S(=O)-; R^{15} -S(=O)₂-; R^5R^6N ; R^5R^6N -C₁₋₆alkyl; R^5R^6N -C₃₋₇cycloalkyl; R^5R^6N -C₁₋₆alkyloxy; R^5R^6N -C(=O)-; R^5R^6N -C(=S)-; R^5R^6N -C(=O)-NH-; R^5R^6N -C(=S)-NH-; R^5R^6N -S(=O)_n-; R^5R^6N -S(=O)_n-NH-; R^{15} -C(=S)-; R^{15} -C(=O)-NH-; R^{15} -O-C(=O)-NH-; R^{15} -S(=O)_n-NH-; R^{15} -O-S(=O)_n-NH-; R^{15} -C(=S)-NH-; R^{15} -O-C(=S)-NH-; $R^{17}R^{18}N$ -Y_{1a}-; $R^{17}R^{18}N$ -Y₂-NR¹⁶-Y₁-; R^{15} -Y₂-NR¹⁹-Y₁-; H-Y₂-NR¹⁹-Y₁-;
- R^3 is hydrogen; hydroxy; halo; C_{1-6} alkyl; C_{1-6} alkyl substituted with cyano, hydroxy or -C(=O) R^7 ; C_{2-6} alkenyl; C_{2-6} alkenyl substituted with one or more halogen atoms or cyano; C_{2-6} alkynyl; C_{2-6} alkynyl substituted with one or more halogen atoms or cyano; C_{1-6} alkyloxy; C_{1-6} alkylthio; C_{1-6} alkyloxycarbonyl; C_{1-6} alkylcarbonyloxy; carboxyl; cyano; nitro; amino; mono- or di(C_{1-6} alkyl)amino; polyhalo C_{1-6} alkyl; polyhalo C_{1-6} alkyloxy; polyhalo C_{1-6} alkylthio; R^{21} ; R^{21} -C₁₋₆alkyl; R^{21} -O-; R^{21} -S-; R^{21} -C(=O)-; R^{21} -S(=O)_p-; R^7 -S(=O)_p-; R^7 -S(=O)_p-NH-; R^{21} -S(=O)_p-NH-; R^7 -C(=O)-; -NHC(=O)H; -C(=O)NHNH₂; R^7 -C(=O)-NH-; R^{21} -C(=O)-NH-; -C(=NH) R^7 ; -C(=NH) R^{21} ;
- R^4 is a monocyclic, bicyclic or tricyclic saturated heterocycle; a monocyclic, bicyclic or tricyclic partially saturated heterocycle or a monocyclic, bicyclic or tricyclic aromatic heterocycle, each of said heterocycles optionally being substituted where possible with one or more substituents each independently being selected from =S; =O; R^{15} ; hydroxy; halo; nitro; cyano; R^{15} -O-; SH; R^{15} -S-; formyl; carboxyl; R^{15} -C(=O)-; R^{15} -O-C(=O)-; R^{15} -C(=O)-O-; R^{15} -O-C(=O)-O-; -SO₃H; R^{15} -S(=O)-; R^{15} -S(=O)₂-; R^5R^6N ; R^5R^6N C₁₋₆alkyl; R^5R^6N C₃₋₇cycloalkyl; R^5R^6N C₁₋₆alkyloxy; R^5R^6N -C(=O)-; R^5R^6N -C(=S)-; R^5R^6N -C(=O)-NH-; R^5R^6N -C(=S)-NH-; R^5R^6N -S(=O)_n-; R^5R^6N -S(=O)_n-NH-; R^{15} -C(=S)-; R^{15} -C(=O)-NH-; R^{15} -O-C(=O)-NH-; R^{15} -S(=O)_n-NH-; R^{15} -O-S(=O)_n-NH-; R^{15} -C(=S)-NH-; R^{15} -O-C(=S)-NH-; $R^{17}R^{18}N$ -Y_{1a}-; $R^{17}R^{18}N$ -Y₂-NR¹⁶-Y₁-; R^{15} -Y₂-NR¹⁹-Y₁-; H-Y₂-NR¹⁹-Y₁-;
- R^5 and R^6 each independently are hydrogen, R^8 , -Y₁-NR⁹-Y₂-NR¹⁰ R^{11} , -Y₁-NR⁹-Y₁- R^8 , -Y₁-NR⁹ R^{10} , or
- R^5 and R^6 may together with the nitrogen to which they are attached form a saturated or partially saturated monocyclic 3 to 8 membered heterocycle or an aromatic 4 to 8 membered monocyclic heterocycle, each of said heterocycles may optionally be substituted with one or more substituents selected from R^{12} , R^{13} and R^{14} , or each of

- said heterocycles may optionally be fused with a benzene ring, said benzene ring being optionally substituted with one or more substituents selected from R^{12} , R^{13} and R^{14} ;
- R^7 is C_{1-6} alkyl, C_{1-6} alkyloxy, amino, mono- or di(C_{1-6} alkyl)amino or polyhalo C_{1-6} alkyl;
- 5 R^8 is C_{1-6} alkyl; C_{2-6} alkenyl; C_{2-6} alkynyl; a monocyclic, bicyclic or tricyclic saturated carbocycle; a monocyclic, bicyclic or tricyclic partially saturated carbocycle; a monocyclic, bicyclic or tricyclic aromatic carbocycle; a monocyclic, bicyclic or tricyclic saturated heterocycle; a monocyclic, bicyclic or tricyclic partially saturated heterocycle; a monocyclic, bicyclic or tricyclic aromatic heterocycle; C_{1-6} alkyl
- 10 substituted with a monocyclic, bicyclic or tricyclic saturated carbocycle or with a monocyclic, bicyclic or tricyclic partially saturated carbocycle or with a monocyclic, bicyclic or tricyclic aromatic carbocycle or with a monocyclic, bicyclic or tricyclic saturated heterocycle or with a monocyclic, bicyclic or tricyclic partially saturated heterocycle or with a monocyclic, bicyclic or tricyclic aromatic heterocycle; each of
- 15 said groups representing R^8 may optionally be substituted with one or more substituents selected from R^{12} , R^{13} and R^{14} ;
- R^9 , R^{10} and R^{11} each independently are hydrogen or R^8 , or any two of R^9 , R^{10} and R^{11} may together be C_{1-6} alkanediyl or C_{2-6} alkenediyl thereby forming a saturated or partially saturated monocyclic 3 to 8 membered heterocycle
- 20 or an aromatic 4 to 8 membered monocyclic heterocycle together with the nitrogen atoms to which they are attached, each of said heterocycles may optionally be substituted with one or more substituents selected from R^{12} , R^{13} and R^{14} ;
- R^{12} , R^{13} and R^{14} each independently are hydrogen; R^{15} ; hydroxy; halo; nitro; cyano; R^{15} -O-; SH; R^{15} -S-; formyl; carboxyl; R^{15} -C(=O)-; R^{15} -O-C(=O)-; R^{15} -C(=O)-O-;
- 25 R^{15} -O-C(=O)-O-; $-SO_3H$; R^{15} -S(=O)-; R^{15} -S(=O)₂-; $R^{15}R^{16}N$ -S(=O)-; $R^{15}R^{16}N$ -S(=O)₂-; $R^{17}R^{18}N$ -Y₁-; $R^{17}R^{18}N$ -Y₂-NR¹⁶-Y₁-; R^{15} -Y₂-NR¹⁹-Y₁-; H-Y₂-NR¹⁹-Y₁-; oxo, or
- any two of R^{12} , R^{13} and R^{14} may together be C_{1-6} alkanediyl or C_{2-6} alkenediyl thereby forming a saturated or partially saturated monocyclic 3 to 8 membered carbo – or
- 30 heterocycle or an aromatic 4 to 8 membered monocyclic carbo – or heterocycle together with the atoms to which they are attached, or
- any two of R^{12} , R^{13} and R^{14} may together be $-O-(CH_2)_r-O-$ thereby forming a saturated, partially saturated or aromatic monocyclic 4 to 8 membered carbo – or heterocycle together with the atoms to which they are attached;
- 35 R^{15} is C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, a monocyclic, bicyclic or tricyclic saturated carbocycle; a monocyclic, bicyclic or tricyclic partially saturated carbocycle; a monocyclic, bicyclic or tricyclic aromatic carbocycle; a monocyclic, bicyclic or

tricyclic saturated heterocycle; a monocyclic, bicyclic or tricyclic partially saturated heterocycle; a monocyclic, bicyclic or tricyclic aromatic heterocycle; C₁₋₆alkyl substituted with a monocyclic, bicyclic or tricyclic saturated carbocycle or with a monocyclic, bicyclic or tricyclic partially saturated carbocycle or with a monocyclic, bicyclic or tricyclic aromatic carbocycle or with a monocyclic, bicyclic or tricyclic saturated heterocycle or with a monocyclic, bicyclic or tricyclic partially saturated heterocycle or with a monocyclic, bicyclic or tricyclic aromatic heterocycle; each of said substituents representing R¹⁵ may optionally be substituted with one or more substituents selected from R¹², R¹³ and R¹⁴; or each of said carbocycles or heterocycles may optionally be fused with a benzene ring, said benzene ring being optionally substituted with one or more substituents selected from R¹², R¹³ and R¹⁴; R¹⁶, R¹⁷, R¹⁸ and R¹⁹ each independently are hydrogen or R¹⁵, or R¹⁷ and R¹⁸, or R¹⁵ and R¹⁹ may together be C₁₋₆alkanediyl or C₂₋₆alkenediyl thereby forming a saturated or partially saturated monocyclic 3 to 8 membered heterocycle or an aromatic 4 to 8 membered monocyclic heterocycle, each of said heterocycles may optionally be substituted with one or more substituents selected from R¹², R¹³ and R¹⁴; or R¹⁷ and R¹⁸ together with R¹⁶ may be C₁₋₆alkanediyl or C₂₋₆alkenediyl thereby forming a saturated or partially saturated monocyclic 3 to 8 membered heterocycle or an aromatic 4 to 8 membered monocyclic heterocycle together with the nitrogen atoms to which they are attached, each of said heterocycles may optionally be substituted with one or more substituents selected from R¹², R¹³ and R¹⁴; R²⁰ is a monocyclic, bicyclic or tricyclic saturated carbocycle; a monocyclic, bicyclic or tricyclic partially saturated carbocycle; a monocyclic, bicyclic or tricyclic aromatic carbocycle; a monocyclic, bicyclic or tricyclic saturated heterocycle; a monocyclic, bicyclic or tricyclic partially saturated heterocycle; a monocyclic, bicyclic or tricyclic aromatic heterocycle; R²¹ is a monocyclic, bicyclic or tricyclic saturated carbocycle; a monocyclic, bicyclic or tricyclic partially saturated carbocycle; a monocyclic, bicyclic or tricyclic aromatic carbocycle; a monocyclic, bicyclic or tricyclic saturated heterocycle; a monocyclic, bicyclic or tricyclic partially saturated heterocycle; a monocyclic, bicyclic or tricyclic aromatic heterocycle, each of said carbocycles or heterocycles representing R²¹ may optionally be substituted with one or more substituents selected from R¹², R¹³ and R¹⁴; Y_{1a} is -Y₃-S(=O)-Y₄-, -Y₃-S(=O)₂-Y₄-, -Y₃-C(=O)-Y₄-, -Y₃-C(=S)-Y₄-, -Y₃-O-Y₄-, -Y₃-S-Y₄-, -Y₃-O-C(=O)-Y₄- or -Y₃-C(=O)-O-Y₄-;

Y_1 or Y_2 each independently are a direct bond, $-Y_3-S(=O)-Y_4-$; $-Y_3-S(=O)_2-Y_4-$,
 $-Y_3-C(=O)-Y_4-$, $-Y_3-C(=S)-Y_4-$, $-Y_3-O-Y_4-$, $-Y_3-S-Y_4-$, $-Y_3-O-C(=O)-Y_4-$ or
 $-Y_3-C(=O)-O-Y_4-$;

Y_3 or Y_4 each independently are a direct bond, C_{1-6} alkanediyl, C_{2-6} alkenediyl or

5 C_{2-6} alkynediyl;

n is 1 or 2;

m is 1 or 2;

p is 1 or 2;


r is 1 to 5;

10 s is 1 to 3;

aryl is phenyl or phenyl substituted with one, two, three, four or five substituents each
independently selected from halo, C_{1-6} alkyl, C_{3-7} cycloalkyl, C_{1-6} alkyloxy, cyano,
nitro, polyhalo C_{1-6} alkyl and polyhalo C_{1-6} alkyloxy;


provided that $-X-R^2$ and/or R^3 is other than hydrogen; and

15 provided that when




$-Z$ is other than a direct bond or NH when R^1 is hydrogen or methyl, s is 2, R^3 is
methoxy, and $-X-R^2$ is methoxy;

$-Z-R^4$ is other than 3-pyridyl, 4-pyridyl or 4-pyridyl N-oxide when R^1 is hydrogen or
methyl, s is 1, R^3 is 3-chloro or 4-methoxy, and $-X-R^2$ is hydrogen;

20 $-Z-R^4$ is other than  when R^1 is hydrogen;

$-R^3$ and $-X-R^2$ are other than hydrogen when R^1 is hydrogen and $-Z-R^4$ is 3-pyridyl or
substituted 4-pyridyl;


and provided that when



25 $-R^4$ is other than pyridyl optionally substituted with methyl, pyridyl N-oxide, 1-methyl-
pyridinium, thienyl optionally substituted with one or two methyl groups, furanyl
optionally substituted with one or two methyl groups, benzofuranyl, quinolinyl,
indolyl, pyrrolyl optionally substituted with methyl, pyrimidinyl, phenothiazinyl;


-7-

and provided that the following compounds



are not included.

The present invention also relates to the use of a compound for the manufacture of a
 5 medicament for the prevention or the treatment of diseases mediated through GSK3,
 said compound being a compound of formula (I')



a *N*-oxide, a pharmaceutically acceptable addition salt, a quaternary amine and a
 stereochemically isomeric form thereof, wherein

10 ring A is pyridyl, pyrimidinyl, pyrazinyl or pyridazinyl;

R^1 is hydrogen; aryl; formyl; C_{1-6} alkylcarbonyl; C_{1-6} alkyl; C_{1-6} alkyloxycarbonyl;
 C_{1-6} alkyl substituted with formyl, C_{1-6} alkylcarbonyl, C_{1-6} alkyloxycarbonyl,
 C_{1-6} alkylcarbonyloxy; C_{1-6} alkyloxy C_{1-6} alkylcarbonyl optionally substituted with
 C_{1-6} alkyloxycarbonyl;

15 X is $-NR^1-$; $-NH-NH-$; $-N=N-$; $-O-$; $-C(=O)-$; $-C(=S)-$; $-O-C(=O)-$; $-C(=O)-O-$;
 $-O-C(=O)-C_{1-6}alkyl-$; $-C(=O)-O-C_{1-6}alkyl-$; $-O-C_{1-6}alkyl-C(=O)-$;
 $-C(=O)-C_{1-6}alkyl-O-$; $-O-C(=O)-NR^1-$; $-NR^1-C(=O)-O-$; $-O-C(=O)-C(=O)-$;
 $-C(=O)-NR^1-$; $-NR^1-C(=O)-$; $-C(=S)-NR^1-$; $-NR^1-C(=S)-$; $-NR^1-C(=O)-NR^1-$;
 $-NR^1-C(=S)-NR^1-$; $-NR^1-S(=O)-NR^1-$; $-NR^1-S(=O)_2-NR^1-$; $-C_{1-6}alkyl-C(=O)-NR^1-$;
 20 $-O-C_{1-6}alkyl-C(=O)-NR^1-$; $-C_{1-6}alkyl-O-C(=O)-NR^1-$; $-C_{1-6}alkyl-$; $-O-C_{1-6}alkyl-$;
 $-C_{1-6}alkyl-O-$; $-NR^1-C_{1-6}alkyl-$; $-C_{1-6}alkyl-NR^1-$; $-NR^1-C_{1-6}alkyl-NR^1-$;
 $-NR^1-C_{1-6}alkyl-C_{3-7}cycloalkyl-$; $-C_{2-6}alkenyl-$; $-C_{2-6}alkynyl-$; $-O-C_{2-6}alkenyl-$;
 $-C_{2-6}alkenyl-O-$; $-NR^1-C_{2-6}alkenyl-$; $-C_{2-6}alkenyl-NR^1-$; $-NR^1-C_{2-6}alkenyl-NR^1-$;
 $-NR^1-C_{2-6}alkenyl-C_{3-7}cycloalkyl-$; $-O-C_{2-6}alkynyl-$; $-C_{2-6}alkynyl-O-$;
 25 $-NR^1-C_{2-6}alkynyl-$; $-C_{2-6}alkynyl-NR^1-$; $-NR^1-C_{2-6}alkynyl-NR^1-$;

- $-NR^1-C_{2-6}alkynyl-C_{3-7}cycloalkyl-$; $-O-C_{1-6}alkyl-O-$; $-O-C_{2-6}alkenyl-O-$;
 $-O-C_{2-6}alkynyl-O-$; $-CHOH-$; $-S-$; $-S(=O)-$; $-S(=O)_2-$; $-S(=O)-NR^1-$; $-S(=O)_2-NR^1-$;
 $-NR^1-S(=O)-$; $-NR^1-S(=O)_2-$; $-S-C_{1-6}alkyl-$; $-C_{1-6}alkyl-S-$; $-S-C_{2-6}alkenyl-$;
 $-C_{2-6}alkenyl-S-$; $-S-C_{2-6}alkynyl-$; $-C_{2-6}alkynyl-S-$; $-O-C_{1-6}alkyl-S(=O)_2-$ or a direct
 5 bond;
- Z is a direct bond, $C_{1-6}alkanediyl$, $C_{2-6}alkenediyl$, $C_{2-6}alkynediyl$; $-O-$; $-O-C_{1-6}alkyl-$;
 $-S-$; $-C(=O)-$; $-C(=O)-O-$; $-O-C(=O)-$; $-C(=S)-$; $-S(=O)-$; $-S(=O)_2-$; $-NR^1-$;
 $-NR^1-C_{1-6}alkyl-$; $-NR^1-C(=O)-$; $-O-C(=O)-NR^1-$; $-NR^1C(=O)-O-$; $-NR^1-C(=S)-$;
 $-S(=O)-NR^1-$; $-S(=O)_2-NR^1-$; $-NR^1-S(=O)-$; $-NR^1-S(=O)_2-$; $-NR^1-(C=O)-NR^1-$;
 10 $-NR^1-C(=S)-NR^1-$; $-NR^1-S(=O)-NR^1-$; $-NR^1-S(=O)_2-NR^1-$;
- R^2 is hydrogen, $C_{1-10}alkyl$, $C_{2-10}alkenyl$, $C_{2-10}alkynyl$, R^{20} , each of said groups
 representing R^2 may optionally be substituted where possible with one or more
 substituents each independently being selected from $=S$; $=O$; R^{15} ; hydroxy; halo;
 nitro; cyano; $R^{15}-O-$; SH ; $R^{15}-S-$; formyl; carboxyl; $R^{15}-C(=O)-$; $R^{15}-O-C(=O)-$;
 15 $R^{15}-C(=O)-O-$; $R^{15}-O-C(=O)-O-$; $-SO_3H$; $R^{15}-S(=O)-$; $R^{15}-S(=O)_2-$; R^5R^6N ;
 $R^5R^6N-C_{1-6}alkyl$; $R^5R^6N-C_{3-7}cycloalkyl$; $R^5R^6N-C_{1-6}alkyloxy$; $R^5R^6N-C(=O)-$;
 $R^5R^6N-C(=S)-$; $R^5R^6N-C(=O)-NH-$; $R^5R^6N-C(=S)-NH-$; $R^5R^6N-S(=O)_n-$;
 $R^5R^6N-S(=O)_n-NH-$; $R^{15}-C(=S)-$; $R^{15}-C(=O)-NH-$; $R^{15}-O-C(=O)-NH-$;
 $R^{15}-S(=O)_n-NH-$; $R^{15}-O-S(=O)_n-NH-$; $R^{15}-C(=S)-NH-$; $R^{15}-O-C(=S)-NH-$;
 20 $R^{17}R^{18}N-Y_{1a}$; $R^{17}R^{18}N-Y_2-NR^{16}-Y_1-$; $R^{15}-Y_2-NR^{19}-Y_1-$; $H-Y_2-NR^{19}-Y_1-$;
- R^3 is hydrogen; hydroxy; halo; $C_{1-6}alkyl$; $C_{1-6}alkyl$ substituted with cyano, hydroxy or
 $-C(=O)R^7$; $C_{2-6}alkenyl$; $C_{2-6}alkenyl$ substituted with one or more halogen atoms or
 cyano; $C_{2-6}alkynyl$; $C_{2-6}alkynyl$ substituted with one or more halogen atoms or
 cyano; $C_{1-6}alkyloxy$; $C_{1-6}alkylthio$; $C_{1-6}alkyloxycarbonyl$; $C_{1-6}alkylcarbonyloxy$;
 25 carboxyl; cyano; nitro; amino; mono- or di($C_{1-6}alkyl$)amino; polyhalo $C_{1-6}alkyl$;
 polyhalo $C_{1-6}alkyloxy$; polyhalo $C_{1-6}alkylthio$; R^{21} ; $R^{21}-C_{1-6}alkyl$; $R^{21}-O-$; $R^{21}-S-$;
 $R^{21}-C(=O)-$; $R^{21}-S(=O)_p-$; $R^7-S(=O)_p-$; $R^7-S(=O)_p-NH-$; $R^{21}-S(=O)_p-NH-$;
 $R^7-C(=O)-$; $-NHC(=O)H$; $-C(=O)NHNH_2$; $R^7-C(=O)-NH-$; $R^{21}-C(=O)-NH-$;
 $-C(=NH)R^7$; $-C(=NH)R^{21}$;
 30 R^4 is a monocyclic, bicyclic or tricyclic saturated heterocycle; a monocyclic, bicyclic or
 tricyclic partially saturated heterocycle or a monocyclic, bicyclic or tricyclic
 aromatic heterocycle, each of said heterocycles optionally being substituted where
 possible with one or more substituents each independently being selected from $=S$;
 $=O$; R^{15} ; hydroxy; halo; nitro; cyano; $R^{15}-O-$; SH ; $R^{15}-S-$; formyl; carboxyl;
 35 $R^{15}-C(=O)-$; $R^{15}-O-C(=O)-$; $R^{15}-C(=O)-O-$; $R^{15}-O-C(=O)-O-$; $-SO_3H$; $R^{15}-S(=O)-$;
 $R^{15}-S(=O)_2-$; R^5R^6N ; $R^5R^6NC_{1-6}alkyl$; $R^5R^6NC_{3-7}cycloalkyl$; $R^5R^6NC_{1-6}alkyloxy$;
 $R^5R^6N-C(=O)-$; $R^5R^6N-C(=S)-$; $R^5R^6N-C(=O)-NH-$; $R^5R^6N-C(=S)-NH-$;

$R^5R^6N-S(=O)_n-$; $R^5R^6N-S(=O)_n-NH-$; $R^{15}-C(=S)-$; $R^{15}-C(=O)-NH-$;
 $R^{15}-O-C(=O)-NH-$; $R^{15}-S(=O)_n-NH-$; $R^{15}-O-S(=O)_n-NH-$; $R^{15}-C(=S)-NH-$;
 $R^{15}-O-C(=S)-NH-$; $R^{17}R^{18}N-Y_{1a}-$; $R^{17}R^{18}N-Y_2-NR^{16}-Y_1-$; $R^{15}-Y_2-NR^{19}-Y_1-$;
 $H-Y_2-NR^{19}-Y_1-$;

5 R^5 and R^6 each independently are hydrogen, R^8 , $-Y_1-NR^9-Y_2-NR^{10}R^{11}$, $-Y_1-NR^9-Y_1-R^8$,
 $-Y_1-NR^9R^{10}$, or

R^5 and R^6 may together with the nitrogen to which they are attached form a saturated or
 partially saturated monocyclic 3 to 8 membered heterocycle or an aromatic 4 to 8
 membered monocyclic heterocycle, each of said heterocycles may optionally be
 10 substituted with one or more substituents selected from R^{12} , R^{13} and R^{14} , or each of
 said heterocycles may optionally be fused with a benzene ring, said benzene ring
 being optionally substituted with one or more substituents selected from R^{12} , R^{13} and
 R^{14} ;

R^7 is C_{1-6} alkyl, C_{1-6} alkyloxy, amino, mono- or di(C_{1-6} alkyl)amino or polyhalo C_{1-6} alkyl;
 15 R^8 is C_{1-6} alkyl; C_{2-6} alkenyl; C_{2-6} alkynyl; a monocyclic, bicyclic or tricyclic saturated
 carbocycle; a monocyclic, bicyclic or tricyclic partially saturated carbocycle; a
 monocyclic, bicyclic or tricyclic aromatic carbocycle; a monocyclic, bicyclic or
 tricyclic saturated heterocycle; a monocyclic, bicyclic or tricyclic partially saturated
 heterocycle; a monocyclic, bicyclic or tricyclic aromatic heterocycle; C_{1-6} alkyl
 20 substituted with a monocyclic, bicyclic or tricyclic saturated carbocycle or with a
 monocyclic, bicyclic or tricyclic partially saturated carbocycle or with a monocyclic,
 bicyclic or tricyclic aromatic carbocycle or with a monocyclic, bicyclic or tricyclic
 saturated heterocycle or with a monocyclic, bicyclic or tricyclic partially saturated
 heterocycle or with a monocyclic, bicyclic or tricyclic aromatic heterocycle; each of
 25 said groups representing R^8 may optionally be substituted with one or more
 substituents selected from R^{12} , R^{13} and R^{14} ;

R^9 , R^{10} and R^{11} each independently are hydrogen or R^8 , or
 any two of R^9 , R^{10} and R^{11} may together be C_{1-6} alkanediyl or C_{2-6} alkenediyl thereby
 forming a saturated or partially saturated monocyclic 3 to 8 membered heterocycle
 30 or an aromatic 4 to 8 membered monocyclic heterocycle together with the nitrogen
 atoms to which they are attached, each of said heterocycles may optionally be
 substituted with one or more substituents selected from R^{12} , R^{13} and R^{14} ;

R^{12} , R^{13} and R^{14} each independently are hydrogen; R^{15} ; hydroxy; halo; nitro; cyano;
 $R^{15}-O-$; SH ; $R^{15}-S-$; formyl; carboxyl; $R^{15}-C(=O)-$; $R^{15}-O-C(=O)-$; $R^{15}-C(=O)-O-$;
 35 $R^{15}-O-C(=O)-O-$; $-SO_3H$; $R^{15}-S(=O)-$; $R^{15}-S(=O)_2-$; $R^{15}R^{16}N-S(=O)-$;
 $R^{15}R^{16}N-S(=O)_2-$; $R^{17}R^{18}N-Y_1-$; $R^{17}R^{18}N-Y_2-NR^{16}-Y_1-$; $R^{15}-Y_2-NR^{19}-Y_1-$;
 $H-Y_2-NR^{19}-Y_1-$; oxo, or

any two of R^{12} , R^{13} and R^{14} may together be C_{1-6} alkanediyl or C_{2-6} alkenediyl thereby forming a saturated or partially saturated monocyclic 3 to 8 membered carbo – or heterocycle or an aromatic 4 to 8 membered monocyclic carbo – or heterocycle together with the atoms to which they are attached, or

5 any two of R^{12} , R^{13} and R^{14} may together be $-O-(CH_2)_r-O-$ thereby forming a saturated, partially saturated or aromatic monocyclic 4 to 8 membered carbo – or heterocycle together with the atoms to which they are attached;

R^{15} is C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, a monocyclic, bicyclic or tricyclic saturated carbocycle; a monocyclic, bicyclic or tricyclic partially saturated carbocycle; a

10 monocyclic, bicyclic or tricyclic aromatic carbocycle; a monocyclic, bicyclic or tricyclic saturated heterocycle; a monocyclic, bicyclic or tricyclic partially saturated heterocycle; a monocyclic, bicyclic or tricyclic aromatic heterocycle; C_{1-6} alkyl substituted with a monocyclic, bicyclic or tricyclic saturated carbocycle or with a monocyclic, bicyclic or tricyclic partially saturated carbocycle or with a monocyclic,

15 bicyclic or tricyclic aromatic carbocycle or with a monocyclic, bicyclic or tricyclic saturated heterocycle or with a monocyclic, bicyclic or tricyclic partially saturated heterocycle or with a monocyclic, bicyclic or tricyclic aromatic heterocycle; each of said substituents representing R^{15} may optionally be substituted with one or more substituents selected from R^{12} , R^{13} and R^{14} ; or each of said carbocycles or

20 heterocycles may optionally be fused with a benzene ring, said benzene ring being optionally substituted with one or more substituents selected from R^{12} , R^{13} and R^{14} ; R^{16} , R^{17} , R^{18} and R^{19} each independently are hydrogen or R^{15} , or R^{17} and R^{18} , or R^{15} and R^{19} may together be C_{1-6} alkanediyl or C_{2-6} alkenediyl thereby forming a saturated or partially saturated monocyclic 3 to 8 membered heterocycle

25 or an aromatic 4 to 8 membered monocyclic heterocycle, each of said heterocycles may optionally be substituted with one or more substituents selected from R^{12} , R^{13} and R^{14} ; or

R^{17} and R^{18} together with R^{16} may be C_{1-6} alkanediyl or C_{2-6} alkenediyl thereby forming a saturated or partially saturated monocyclic 3 to 8 membered heterocycle or an

30 aromatic 4 to 8 membered monocyclic heterocycle together with the nitrogen atoms to which they are attached, each of said heterocycles may optionally be substituted with one or more substituents selected from R^{12} , R^{13} and R^{14} ;

R^{20} is a monocyclic, bicyclic or tricyclic saturated carbocycle; a monocyclic, bicyclic or tricyclic partially saturated carbocycle; a monocyclic, bicyclic or tricyclic

35 aromatic carbocycle; a monocyclic, bicyclic or tricyclic saturated heterocycle; a monocyclic, bicyclic or tricyclic partially saturated heterocycle; a monocyclic, bicyclic or tricyclic aromatic heterocycle;

- R²¹ is a monocyclic, bicyclic or tricyclic saturated carbocycle; a monocyclic, bicyclic or tricyclic partially saturated carbocycle; a monocyclic, bicyclic or tricyclic aromatic carbocycle; a monocyclic, bicyclic or tricyclic saturated heterocycle; a monocyclic, bicyclic or tricyclic partially saturated heterocycle; a monocyclic, bicyclic or tricyclic aromatic heterocycle, each of said carbocycles or heterocycles representing R²¹ may optionally be substituted with one or more substituents selected from R¹², R¹³ and R¹⁴;
- Y_{1a} is -Y₃-S(=O)-Y₄-; -Y₃-S(=O)₂-Y₄-; -Y₃-C(=O)-Y₄-; -Y₃-C(=S)-Y₄-; -Y₃-O-Y₄-; -Y₃-S-Y₄-; -Y₃-O-C(=O)-Y₄- or -Y₃-C(=O)-O-Y₄-;
- Y₁ or Y₂ each independently are a direct bond, -Y₃-S(=O)-Y₄-; -Y₃-S(=O)₂-Y₄-; -Y₃-C(=O)-Y₄-; -Y₃-C(=S)-Y₄-; -Y₃-O-Y₄-; -Y₃-S-Y₄-; -Y₃-O-C(=O)-Y₄- or -Y₃-C(=O)-O-Y₄-;
- Y₃ or Y₄ each independently are a direct bond, C₁₋₆alkanediyl, C₂₋₆alkenediyl or C₂₋₆alkynediyl;
- n is 1 or 2;
- m is 1 or 2;
- p is 1 or 2;
- r is 1 to 5;
- s is 1 to 3;
- aryl is phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from halo, C₁₋₆alkyl, C₃₋₇cycloalkyl, C₁₋₆alkyloxy, cyano, nitro, polyhaloC₁₋₆alkyl and polyhaloC₁₋₆alkyloxy; provided that -X-R² and/or R³ is other than hydrogen.
- As used herein C₁₋₃alkyl as a group or part of a group defines straight or branched chain saturated hydrocarbon radicals having from 1 to 3 carbon atoms such as methyl, ethyl, propyl, 1-methylethyl; C₁₋₄alkyl as a group or part of a group defines straight or branched chain saturated hydrocarbon radicals having from 1 to 4 carbon atoms such as the groups defined for C₁₋₃alkyl and butyl; C₁₋₆alkyl as a group or part of a group defines straight or branched chain saturated hydrocarbon radicals having from 1 to 6 carbon atoms such as the groups defined for C₁₋₄alkyl and pentyl, hexyl, 2-methylbutyl and the like; C₁₋₁₀alkyl as a group or part of a group defines straight or branched chain saturated hydrocarbon radicals having from 1 to 10 carbon atoms such as the groups defined for C₁₋₆alkyl and heptyl, octyl, nonyl, decyl and the like; C₁₋₆alkanediyl as a group or part of a group defines bivalent straight or branched chain saturated hydrocarbon radicals having from 1 to 6 carbon atoms such as methylene, 1,2-ethanediyl or 1,2-ethylidene, 1,3-propanediyl or 1,3-propylidene, 1,4-butanediyl or

1,4-butylidene and the like; C₂₋₆alkenyl defines straight and branched chain hydrocarbon radicals having from 2 to 6 carbon atoms containing a double bond such as ethenyl, propenyl, butenyl, pentenyl, hexenyl and the like; C₂₋₁₀alkenyl defines straight and branched chain hydrocarbon radicals having from 2 to 10 carbon atoms containing a double bond such as the groups defined for C₂₋₆alkenyl and heptenyl, octenyl, nonenyl, decenyl and the like; C₂₋₆alkenediyl defines bivalent straight and branched chain hydrocarbon radicals having from 2 to 6 carbon atoms containing one or more double bonds such as ethenediyl, propenediyl, butenediyl, pentenediyl, hexenediyl and the like; C₂₋₆alkynyl defines straight and branched chain hydrocarbon radicals having from 2 to 6 carbon atoms containing a triple bond such as ethynyl, propynyl, butynyl, pentynyl, hexynyl and the like; C₂₋₁₀alkynyl defines straight and branched chain hydrocarbon radicals having from 2 to 10 carbon atoms containing a triple bond such as the groups defined for C₂₋₆alkynyl and heptynyl, octynyl, nonynyl, decynyl and the like; C₂₋₆alkynediyl defines bivalent straight and branched chain hydrocarbon radicals having from 2 to 6 carbon atoms containing a triple bond such as ethynediyl, propynediyl, butynediyl, pentynediyl, hexynediyl and the like; C₃₋₇cycloalkyl is generic to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl; a monocyclic, bicyclic or tricyclic saturated carbocycle represents a ring system consisting of 1, 2 or 3 rings, said ring system being composed of only carbon atoms and said ring system containing only single bonds; a monocyclic, bicyclic or tricyclic partially saturated carbocycle represents a ring system consisting of 1, 2 or 3 rings, said ring system being composed of only carbon atoms and comprising at least one double bond provided that the ring system is not an aromatic ring system; a monocyclic, bicyclic or tricyclic aromatic carbocycle represents an aromatic ring system consisting of 1, 2 or 3 rings, said ring system being composed of only carbon atoms; the term aromatic is well known to a person skilled in the art and designates cyclically conjugated systems of $4n' + 2$ electrons, that is with 6, 10, 14 etc. π -electrons (rule of Hückel; n' being 1, 2, 3 etc.); a monocyclic, bicyclic or tricyclic saturated heterocycle represents a ring system consisting of 1, 2 or 3 rings and comprising at least one heteroatom selected from O, N or S, said ring system containing only single bonds; a monocyclic, bicyclic or tricyclic partially saturated heterocycle represents a ring system consisting of 1, 2 or 3 rings and comprising at least one heteroatom selected from O, N or S, and at least one double bond provided that the ring system is not an aromatic ring system; a monocyclic, bicyclic or tricyclic aromatic heterocycle represents an aromatic ring system consisting of 1, 2 or 3 rings and comprising at least one heteroatom selected from O, N or S.

Particular examples of monocyclic, bicyclic or tricyclic saturated carbocycles are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, bicyclo[4,2,0]octanyl, cyclononanyl, cyclodecanyl, decahydronaphthalenyl, tetradecahydroanthracenyl.

5

Particular examples of monocyclic, bicyclic or tricyclic partially saturated carbocycles are cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclo-octenyl, bicyclo[4,2,0]octenyl, cyclononenyl, cyclodecenyl, octahydronaphthalenyl, 1,2,3,4-tetrahydronaphthalenyl, 1,2,3,4,4a,9,9a,10-octahydro-anthracenyl.

10

Particular examples of monocyclic, bicyclic or tricyclic aromatic carbocycles are phenyl, naphthalenyl, anthracenyl.

Particular examples of monocyclic, bicyclic or tricyclic saturated heterocycles are

15 tetrahydrofuranyl, pyrrolidinyl, dioxolanyl, imidazolidinyl, thiazolidinyl, tetrahydrothienyl, dihydrooxazolyl, isothiazolidinyl, isoxazolidinyl, oxadiazolidinyl, triazolidinyl, thiadiazolidinyl, pyrazolidinyl, piperidinyl, hexahydropyrimidinyl, hexahydropyrazinyl, dioxanyl, morpholinyl, dithianyl, thiomorpholinyl, piperazinyl, trithianyl, decahydroquinolinyl, octahydroindolyl.

20

Particular examples of monocyclic, bicyclic or tricyclic partially saturated heterocycles are pyrrolinyl, imidazolynyl, pyrazolinyl, 2,3-dihydrobenzofuranyl, 1,3-benzodioxolyl, 2,3-dihydro-1,4-benzodioxinyl, indolynyl and the like.

25 Particular examples of monocyclic, bicyclic or tricyclic aromatic heterocycles are

azetyl, oxetylidenyl, pyrrolyl, furyl, thienyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, triazolyl, thiadiazolyl, oxadiazolyl, tetrazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, pyranyl, benzofuryl, isobenzofuryl, benzothienyl, isobenzothienyl, indolizynyl, indolyl, isoindolyl, benzoxazolyl, benzimidazolyl, indazolyl, benzisoxazolyl, benzisothiazolyl, benzopyrazolyl, benzoxadiazolyl, benzothiadiazolyl, benzotriazolyl, purinyl, quinolinyl, isoquinolinyl, cinnolinyl, quinolizynyl, phthalazinyl, quinoxalinyl, quinazolinyl, naphthiridinyl, pteridinyl, benzopyranyl, pyrrolopyridyl, thienopyridyl, furopyridyl, isothiazolopyridyl, thiazolopyridyl, isoxazolopyridyl, oxazolopyridyl, pyrazolopyridyl, imidazopyridyl, pyrrolopyrazinyl, thienopyrazinyl, furopyrazinyl, isothiazolopyrazinyl, thiazolopyrazinyl, isoxazolopyrazinyl, oxazolopyrazinyl, pyrazolopyrazinyl, imidazopyrazinyl, pyrrolopyrimidinyl, thienopyrimidinyl, fuopyrimidinyl,

35

isothiazolopyrimidinyl, thiazolopyrimidinyl, isoxazolopyrimidinyl, oxazolopyrimidinyl, pyrazolopyrimidinyl, imidazopyrimidinyl, pyrrolopyridazinyl, thienopyridazinyl, furopyridazinyl, isothiazolopyridazinyl, thiazolopyridazinyl, isoxazolopyridazinyl, oxazolopyridazinyl, pyrazolopyridazinyl, imidazopyridazinyl, 5 oxadiazolopyridyl, thiadiazolopyridyl, triazolopyridyl, oxadiazolopyrazinyl, thiadiazolopyrazinyl, triazolopyrazinyl, oxadiazolopyrimidinyl, thiadiazolopyrimidinyl, triazolopyrimidinyl, oxadiazolopyridazinyl, thiadiazolopyridazinyl, triazolopyridazinyl, imidazooxazolyl, imidazothiazolyl, imidazoimidazolyl, isoxazolotriazinyl, isothiazolotriazinyl, pyrazolotriazinyl, oxazolotriazinyl, thiazolotriazinyl, imidazotriazinyl, 10 oxadiazolotriazinyl, thiadiazolotriazinyl, triazolotriazinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl.

Particular examples of 5-membered aromatic heterocycles are pyrrolyl, furyl, thienyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, triazolyl, 15 thiadiazolyl, oxadiazolyl, tetrazolyl.

As used herein before, the term (=O) forms a carbonyl moiety when attached to a carbon atom, a sulfoxide moiety when attached to a sulfur atom and a sulfonyl moiety when two of said terms are attached to a sulfur atom.

20 The term halo is generic to fluoro, chloro, bromo and iodo. As used in the foregoing and hereinafter, polyhalomethyl as a group or part of a group is defined as mono- or polyhalosubstituted methyl, in particular methyl with one or more fluoro atoms, for example, difluoromethyl or trifluoromethyl; polyhaloC₁₋₆alkyl as a group or part of a 25 group is defined as mono- or polyhalosubstituted C₁₋₆alkyl, for example, the groups defined in halomethyl, 1,1-difluoro-ethyl and the like. In case more than one halogen atoms are attached to an alkyl group within the definition of polyhalomethyl or polyhaloC₁₋₆alkyl, they may be the same or different.

30 The term heterocycle as in the definition of for instance R⁴, R⁵, R⁶, R⁸ or R¹⁵ is meant to include all the possible isomeric forms of the heterocycles, for instance, pyrrolyl also includes 2*H*-pyrrolyl.

35 The hereinabove-mentioned carbocycles may be attached to the remainder of the molecule of formula (I) or (I') through any ring carbon as appropriate, if not otherwise specified. Thus, for example, when the partially saturated bicyclic carbocycle is

1,2,3,4-tetrahydronaphthalenyl, it may be 1,2,3,4-tetrahydronaphthalen-1-yl, 1,2,3,4-tetrahydronaphthalen-2-yl and the like.

5 The hereinabove-mentioned heterocycles may be attached to the remainder of the molecule of formula (I) or (I') through any ring carbon or heteroatom as appropriate, if not otherwise specified. Thus, for example, when the aromatic monocyclic heterocycle is imidazolyl, it may be 1-imidazolyl, 2-imidazolyl, 4-imidazolyl and the like.

10 When any variable (eg. R⁵, R⁶ etc.) occurs more than one time in any constituent, each definition is independent.

Lines drawn into ring systems from substituents indicate that the bond may be attached to any of the suitable ring atoms.

15 For therapeutic use, salts of the compounds of formula (I) or (I') are those wherein the counterion is pharmaceutically acceptable. However, salts of acids and bases which are non-pharmaceutically acceptable may also find use, for example, in the preparation or purification of a pharmaceutically acceptable compound. All salts, whether pharmaceutically acceptable or not are included within the ambit of the present
20 invention.

The pharmaceutically acceptable addition salts as mentioned hereinabove are meant to comprise the therapeutically active non-toxic acid addition salt forms which the compounds of formula (I) or (I') are able to form. The latter can conveniently be
25 obtained by treating the base form with such appropriate acids as inorganic acids, for example, hydrohalic acids, e.g. hydrochloric, hydrobromic and the like; sulfuric acid; nitric acid; phosphoric acid and the like; or organic acids, for example, acetic, propanoic, hydroxyacetic, 2-hydroxypropanoic, 2-oxopropanoic, oxalic, malonic, succinic, maleic, fumaric, malic, tartaric, 2-hydroxy-1,2,3-propanetricarboxylic,
30 methanesulfonic, ethanesulfonic, benzenesulfonic, 4-methylbenzenesulfonic, cyclohexanesulfamic, 2-hydroxybenzoic, 4-amino-2-hydroxybenzoic and the like acids. Conversely the salt form can be converted by treatment with alkali into the free base form.

35 The compounds of formula (I) or (I') containing acidic protons may be converted into their therapeutically active non-toxic metal or amine addition salt forms by treatment with appropriate organic and inorganic bases. Appropriate base salt forms comprise, for

example, the ammonium salts, the alkali and earth alkaline metal salts, e.g. the lithium, sodium, potassium, magnesium, calcium salts and the like, salts with organic bases, e.g. primary, secondary and tertiary aliphatic and aromatic amines such as methylamine, ethylamine, propylamine, isopropylamine, the four butylamine isomers,

5 dimethylamine, diethylamine, diethanolamine, dipropylamine, diisopropylamine, di-n-butylamine, pyrrolidine, piperidine, morpholine, trimethylamine, triethylamine, tripropylamine, quinuclidine, pyridine, quinoline and isoquinoline, the benzathine, *N*-methyl-D-glucamine, 2-amino-2-(hydroxymethyl)-1,3-propanediol, hydrabamine salts, and salts with amino acids such as, for example, arginine, lysine and the like.
10 Conversely the salt form can be converted by treatment with acid into the free acid form.

The term addition salt also comprises the hydrates and solvent addition forms which the compounds of formula (I) or (I') are able to form. Examples of such forms are e.g. hydrates, alcoholates and the like.

15

The term "quaternary amine" as used hereinbefore defines the quaternary ammonium salts which the compounds of formula (I) or (I') are able to form by reaction between a basic nitrogen of a compound of formula (I) or (I') and an appropriate quaternizing agent, such as, for example, an optionally substituted alkylhalide, arylhalide or
20 arylalkylhalide, e.g. methyl iodide or benzyl iodide. Other reactants with good leaving groups may also be used, such as alkyl trifluoromethanesulfonates, alkyl methanesulfonates, and alkyl *p*-toluenesulfonates. A quaternary amine has a positively charged nitrogen. Pharmaceutically acceptable counterions include chloro, bromo, iodo, trifluoroacetate and acetate. The counterion of choice can be introduced using ion
25 exchange resins.

It will be appreciated that some of the compounds of formula (I) or (I') and their *N*-oxides, addition salts, quaternary amines and stereochemically isomeric forms may contain one or more centers of chirality and exist as stereochemically isomeric forms.

30

The term "stereochemically isomeric forms" as used hereinbefore defines all the possible stereoisomeric forms which the compounds of formula (I) or (I'), and their *N*-oxides, addition salts, quaternary amines or physiologically functional derivatives may possess. Unless otherwise mentioned or indicated, the chemical designation of
35 compounds denotes the mixture of all possible stereochemically isomeric forms, said mixtures containing all diastereomers and enantiomers of the basic molecular structure as well as each of the individual isomeric forms of formula (I) or (I') and their

N-oxides, salts, solvates or quaternary amines substantially free, *i.e.* associated with less than 10%, preferably less than 5%, in particular less than 2% and most preferably less than 1% of the other isomers. In particular, stereogenic centers may have the *R*- or *S*-configuration; substituents on bivalent cyclic (partially) saturated radicals may have either the *cis*- or *trans*-configuration. Compounds encompassing double bonds can have an *E* or *Z*-stereochemistry at said double bond. Stereochemically isomeric forms of the compounds of formula (I) or (I') are obviously intended to be embraced within the scope of this invention.

The *N*-oxide forms of the present compounds are meant to comprise the compounds of formula (I) wherein one or several tertiary nitrogen atoms are oxidized to the so-called *N*-oxide.

Some of the compounds of formula (I) or (I') may also exist in their tautomeric form (e.g. keto-enol tautomerie). Such forms although not explicitly indicated in the above formula are intended to be included within the scope of the present invention.

Whenever used hereinafter, the term "compounds of formula (I)" or "compounds of formula (I) or (I') is meant to also include their *N*-oxide forms, their salts, their quaternary amines and their stereochemically isomeric forms. Of special interest are those compounds of formula (I) or (I') which are stereochemically pure.

Particular compounds are those compounds of formula (I) or (I') as defined hereinabove provided that the molecular mass of the compounds is at most 1000 u, in particular at most 800 u, more in particular at most 700 u (u stands for unified atomic mass unit and equals 1.66×10^{-27} kg).

Particular compounds are also those compounds of formula (I) or (I') as defined hereinabove provided that when R^3 is hydrogen then X is other than $-C(=O)-NR^1-$ or $-C(=S)-NR^1-$; and provided that when X is a direct bond and R^2 is hydrogen then R^3 is other than $R^7-C(=O)-$ with R^7 representing amino or mono- or di(C_{1-6} alkyl)amino; and provided that when X is a direct bond and R^2 is hydrogen then R^{21} is other than a heterocycle; and

provided that when R^3 is hydrogen then R^2 is other than a heterocycle.
Particular interesting compounds are those compounds of formula (I) or (I') as defined hereinabove, their *N*-oxides, pharmaceutically acceptable addition salts, quaternary amines and stereochemically isomeric forms thereof, wherein

ring A is pyridyl, pyrimidinyl, pyrazinyl or pyridazinyl;

R¹ is hydrogen; aryl; formyl; C₁₋₆alkylcarbonyl; C₁₋₆alkyl; C₁₋₆alkyloxycarbonyl;
C₁₋₆alkyl substituted with formyl, C₁₋₆alkylcarbonyl, C₁₋₆alkyloxycarbonyl,
C₁₋₆alkylcarbonyloxy; C₁₋₆alkyloxyC₁₋₆alkylcarbonyl optionally substituted with
5 C₁₋₆alkyloxycarbonyl;

X is -NR¹-; -NH-NH-; -N=N-; -O-; -C(=O)-; -C(=S)-; -O-C(=O)-; -C(=O)-O-;
-O-C(=O)-C₁₋₆alkyl-; -C(=O)-O-C₁₋₆alkyl-; -O-C₁₋₆alkyl-C(=O)-;
-C(=O)-C₁₋₆alkyl-O-; -O-C(=O)-NR¹-; -NR¹-C(=O)-O-; -O-C(=O)-C(=O)-;
-C(=O)-NR¹-; -NR¹-C(=O)-; -C(=S)-NR¹-; -NR¹-C(=S)-; -NR¹-C(=O)-NR¹-;
10 -NR¹-C(=S)-NR¹-; -NR¹-S(=O)-NR¹-; -NR¹-S(=O)₂-NR¹-; -C₁₋₆alkyl-C(=O)-NR¹-;
-O-C₁₋₆alkyl-C(=O)-NR¹-; -C₁₋₆alkyl-O-C(=O)-NR¹-; -C₁₋₆alkyl-; -O-C₁₋₆alkyl-;
-C₁₋₆alkyl-O-; -NR¹-C₁₋₆alkyl-; -C₁₋₆alkyl-NR¹-; -NR¹-C₁₋₆alkyl-NR¹-;
-NR¹-C₁₋₆alkyl-C₃₋₇cycloalkyl-; -C₂₋₆alkenyl-; -C₂₋₆alkynyl-; -O-C₂₋₆alkenyl-;
-C₂₋₆alkenyl-O-; -NR¹-C₂₋₆alkenyl-; -C₂₋₆alkenyl-NR¹-; -NR¹-C₂₋₆alkenyl-NR¹-;
15 -NR¹-C₂₋₆alkenyl-C₃₋₇cycloalkyl-; -O-C₂₋₆alkynyl-; -C₂₋₆alkynyl-O-;
-NR¹-C₂₋₆alkynyl-; -C₂₋₆alkynyl-NR¹-; -NR¹-C₂₋₆alkynyl-NR¹-;
-NR¹-C₂₋₆alkynyl-C₃₋₇cycloalkyl-; -O-C₁₋₆alkyl-O-; -O-C₂₋₆alkenyl-O-;
-O-C₂₋₆alkynyl-O-; -CHOH-; -S-; -S(=O)-; -S(=O)₂-; -S(=O)-NR¹-; -S(=O)₂-NR¹-;
-NR¹-S(=O)-; -NR¹-S(=O)₂-; -S-C₁₋₆alkyl-; -C₁₋₆alkyl-S-; -S-C₂₋₆alkenyl-;
20 -C₂₋₆alkenyl-S-; -S-C₂₋₆alkynyl-; -C₂₋₆alkynyl-S-; -O-C₁₋₆alkyl-S(=O)₂- or a direct
bond;

Z is a direct bond, C₁₋₆alkanediyl, C₂₋₆alkenediyl, C₂₋₆alkynediyl; -O-; -O-C₁₋₆alkyl-;
-S-; -C(=O)-; -C(=O)-O-; -O-C(=O)-; -C(=S)-; -S(=O)-; -S(=O)₂-; -NR¹-;
-NR¹-C₁₋₆alkyl-; -NR¹-C(=O)-; -O-C(=O)-NR¹-; -NR¹-C(=O)-O-; -NR¹-C(=S)-;
25 -S(=O)-NR¹-; -S(=O)₂-NR¹-; -NR¹-S(=O)-; -NR¹-S(=O)₂-; -NR¹-(C=O)-NR¹-;
-NR¹-C(=S)-NR¹-; -NR¹-S(=O)-NR¹-; -NR¹-S(=O)₂-NR¹-;

R² is hydrogen, C₁₋₁₀alkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, R²⁰, each of said groups
representing R² may optionally be substituted where possible with one or more
substituents each independently being selected from =S; =O; R¹⁵; hydroxy; halo;
30 nitro; cyano; R¹⁵-O-; SH; R¹⁵-S-; formyl; carboxyl; R¹⁵-C(=O)-; R¹⁵-O-C(=O)-;
R¹⁵-C(=O)-O-; R¹⁵-O-C(=O)-O-; -SO₃H; R¹⁵-S(=O)-; R¹⁵-S(=O)₂-; R⁵R⁶N;
R⁵R⁶N-C₁₋₆alkyl; R⁵R⁶N-C₃₋₇cycloalkyl; R⁵R⁶N-C₁₋₆alkyloxy; R⁵R⁶N-C(=O)-;
R⁵R⁶N-C(=S)-; R⁵R⁶N-C(=O)-NH-; R⁵R⁶N-C(=S)-NH-; R⁵R⁶N-S(=O)_n-;
R⁵R⁶N-S(=O)_n-NH-; R¹⁵-C(=S)-; R¹⁵-C(=O)-NH-; R¹⁵-O-C(=O)-NH-;
35 R¹⁵-S(=O)_n-NH-; R¹⁵-O-S(=O)_n-NH-; R¹⁵-C(=S)-NH-; R¹⁵-O-C(=S)-NH-;
R¹⁷R¹⁸N-Y_{1a}-; R¹⁷R¹⁸N-Y₂-NR¹⁶-Y₁-; R¹⁵-Y₂-NR¹⁹-Y₁-; H-Y₂-NR¹⁹-Y₁-;

- R^3 is hydrogen; hydroxy; halo; C_{1-6} alkyl; C_{1-6} alkyl substituted with cyano, hydroxy or $-C(=O)R^7$; C_{2-6} alkenyl; C_{2-6} alkenyl substituted with one or more halogen atoms or cyano; C_{2-6} alkynyl; C_{2-6} alkynyl substituted with one or more halogen atoms or cyano; C_{1-6} alkyloxy; C_{1-6} alkylthio; C_{1-6} alkyloxycarbonyl; C_{1-6} alkylcarbonyloxy; carboxyl; cyano; nitro; amino; mono- or di(C_{1-6} alkyl)amino; polyhalo C_{1-6} alkyl; polyhalo C_{1-6} alkyloxy; polyhalo C_{1-6} alkylthio; R^{21} ; $R^{21}-C_{1-6}$ alkyl; $R^{21}-O-$; $R^{21}-S-$; $R^{21}-C(=O)-$; $R^{21}-S(=O)_p-$; $R^7-S(=O)_p-$; $R^7-S(=O)_p-NH-$; $R^{21}-S(=O)_p-NH-$; $R^7-C(=O)-$; $-NHC(=O)H$; $-C(=O)NHNH_2$; $R^7-C(=O)-NH-$; $R^{21}-C(=O)-NH-$; $-C(=NH)R^7$; $-C(=NH)R^{21}$;
- R^4 is a monocyclic, bicyclic or tricyclic saturated heterocycle; a monocyclic, bicyclic or tricyclic partially saturated heterocycle or a monocyclic, bicyclic or tricyclic aromatic heterocycle, each of said heterocycles optionally being substituted where possible with one or more substituents each independently being selected from $=S$; $=O$; R^{15} ; hydroxy; halo; nitro; cyano; $R^{15}-O-$; SH ; $R^{15}-S-$; formyl; carboxyl; $R^{15}-C(=O)-$; $R^{15}-O-C(=O)-$; $R^{15}-C(=O)-O-$; $R^{15}-O-C(=O)-O-$; $-SO_3H$; $R^{15}-S(=O)-$; $R^{15}-S(=O)_2-$; R^5R^6N ; $R^5R^6NC_{1-6}$ alkyl; $R^5R^6NC_{3-7}$ cycloalkyl; $R^5R^6NC_{1-6}$ alkyloxy; $R^5R^6N-C(=O)-$; $R^5R^6N-C(=S)-$; $R^5R^6N-C(=O)-NH-$; $R^5R^6N-C(=S)-NH-$; $R^5R^6N-S(=O)_n-$; $R^5R^6N-S(=O)_n-NH-$; $R^{15}-C(=S)-$; $R^{15}-C(=O)-NH-$; $R^{15}-O-C(=O)-NH-$; $R^{15}-S(=O)_n-NH-$; $R^{15}-O-S(=O)_n-NH-$; $R^{15}-C(=S)-NH-$; $R^{15}-O-C(=S)-NH-$; $R^{17}R^{18}N-Y_{1a}-$; $R^{17}R^{18}N-Y_2-NR^{16}-Y_1-$; $R^{15}-Y_2-NR^{19}-Y_1-$; $H-Y_2-NR^{19}-Y_1-$;
- R^5 and R^6 each independently are hydrogen, R^8 , $-Y_1-NR^9-Y_2-NR^{10}R^{11}$, $-Y_1-NR^9-Y_1-R^8$, $-Y_1-NR^9R^{10}$;
- R^7 is C_{1-6} alkyl, C_{1-6} alkyloxy, amino, mono- or di(C_{1-6} alkyl)amino or polyhalo C_{1-6} alkyl;
- R^8 is C_{1-6} alkyl; C_{2-6} alkenyl; C_{2-6} alkynyl; a monocyclic, bicyclic or tricyclic saturated carbocycle; a monocyclic, bicyclic or tricyclic partially saturated carbocycle; a monocyclic, bicyclic or tricyclic aromatic carbocycle; a monocyclic, bicyclic or tricyclic saturated heterocycle; a monocyclic, bicyclic or tricyclic partially saturated heterocycle; a monocyclic, bicyclic or tricyclic aromatic heterocycle; C_{1-6} alkyl substituted with a monocyclic, bicyclic or tricyclic saturated carbocycle or with a monocyclic, bicyclic or tricyclic partially saturated carbocycle or with a monocyclic, bicyclic or tricyclic aromatic carbocycle or with a monocyclic, bicyclic or tricyclic saturated heterocycle or with a monocyclic, bicyclic or tricyclic partially saturated heterocycle or with a monocyclic, bicyclic or tricyclic aromatic heterocycle; each of said groups representing R^8 may optionally be substituted with one or more substituents selected from R^{12} , R^{13} and R^{14} ;
- R^9 , R^{10} and R^{11} each independently are hydrogen or R^8 ;

R^{12} , R^{13} and R^{14} each independently are hydrogen; R^{15} ; hydroxy; halo; nitro; cyano;
 R^{15} -O-; SH; R^{15} -S-; formyl; carboxyl; R^{15} -C(=O)-; R^{15} -O-C(=O)-; R^{15} -C(=O)-O-;
 R^{15} -O-C(=O)-O-; -SO₃H; R^{15} -S(=O)-; R^{15} -S(=O)₂-; $R^{15}R^{16}N$ -S(=O)-;
 $R^{15}R^{16}N$ -S(=O)₂-; $R^{17}R^{18}N$ -Y₁-; $R^{17}R^{18}N$ -Y₂-NR¹⁶-Y₁-; R^{15} -Y₂-NR¹⁹-Y₁-;

5 H-Y₂-NR¹⁹-Y₁-; oxo;

R^{15} is C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, a monocyclic, bicyclic or tricyclic saturated carbocycle; a monocyclic, bicyclic or tricyclic partially saturated carbocycle; a monocyclic, bicyclic or tricyclic aromatic carbocycle; a monocyclic, bicyclic or tricyclic saturated heterocycle; a monocyclic, bicyclic or tricyclic partially saturated heterocycle; a monocyclic, bicyclic or tricyclic aromatic heterocycle; C₁₋₆alkyl substituted with a monocyclic, bicyclic or tricyclic saturated carbocycle or with a monocyclic, bicyclic or tricyclic partially saturated carbocycle or with a monocyclic, bicyclic or tricyclic aromatic carbocycle or with a monocyclic, bicyclic or tricyclic saturated heterocycle or with a monocyclic, bicyclic or tricyclic partially saturated heterocycle or with a monocyclic, bicyclic or tricyclic aromatic heterocycle; each of said substituents representing R^{15} may optionally be substituted with one or more substituents selected from R^{12} , R^{13} and R^{14} ;

R^{16} , R^{17} , R^{18} and R^{19} each independently are hydrogen or R^{15} ;

R^{20} is a monocyclic, bicyclic or tricyclic saturated carbocycle; a monocyclic, bicyclic or tricyclic partially saturated carbocycle; a monocyclic, bicyclic or tricyclic aromatic carbocycle; a monocyclic, bicyclic or tricyclic saturated heterocycle; a monocyclic, bicyclic or tricyclic partially saturated heterocycle; a monocyclic, bicyclic or tricyclic aromatic heterocycle;

R^{21} is a monocyclic, bicyclic or tricyclic saturated carbocycle; a monocyclic, bicyclic or tricyclic partially saturated carbocycle; a monocyclic, bicyclic or tricyclic aromatic carbocycle; a monocyclic, bicyclic or tricyclic saturated heterocycle; a monocyclic, bicyclic or tricyclic partially saturated heterocycle; a monocyclic, bicyclic or tricyclic aromatic heterocycle, each of said carbocycles or heterocycles representing R^{21} may optionally be substituted with one or more substituents selected from R^{12} , R^{13} and R^{14} ;

Y_{1a} is -Y₃-S(=O)-Y₄-; -Y₃-S(=O)₂-Y₄-; -Y₃-C(=O)-Y₄-; -Y₃-C(=S)-Y₄-; -Y₃-O-Y₄-; -Y₃-S-Y₄-; -Y₃-O-C(=O)-Y₄- or -Y₃-C(=O)-O-Y₄-;

Y_1 or Y_2 each independently are a direct bond, -Y₃-S(=O)-Y₄-; -Y₃-S(=O)₂-Y₄-; -Y₃-C(=O)-Y₄-; -Y₃-C(=S)-Y₄-; -Y₃-O-Y₄-; -Y₃-S-Y₄-; -Y₃-O-C(=O)-Y₄- or -Y₃-C(=O)-O-Y₄-;

Y_3 or Y_4 each independently are a direct bond, C₁₋₆alkanediyl, C₂₋₆alkenediyl or C₂₋₆alkynediyl;

-21-

n is 1 or 2;

m is 1 or 2;

p is 1 or 2;


r is 1 to 5;

5 s is 1 to 3;

aryl is phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from halo, C₁₋₆alkyl, C₃₋₇cycloalkyl, C₁₋₆alkyloxy, cyano, nitro, polyhaloC₁₋₆alkyl and polyhaloC₁₋₆alkyloxy;

provided that -X-R² and/or R³ is other than hydrogen; and

10 provided that when




-Z is other than a direct bond or NH when R¹ is hydrogen or methyl, s is 2, R³ is methoxy, and -X-R² is methoxy;

-Z-R⁴ is other than 3-pyridyl, 4-pyridyl or 4-pyridyl *N*-oxide when R¹ is hydrogen or methyl, s is 1, R³ is 3-chloro or 4-methoxy, and -X-R² is hydrogen;

15 -Z-R⁴ is other than  when R¹ is hydrogen;



-R³ and -X-R² are other than hydrogen when R¹ is hydrogen and -Z-R⁴ is 3-pyridyl or substituted 4-pyridyl;

and provided that when



20 -R⁴ is other than pyridyl optionally substituted with methyl, pyridyl *N*-oxide, 1-methylpyridinium, thienyl optionally substituted with one or two methyl groups, furanyl optionally substituted with one or two methyl groups, benzofuranyl, quinoliny, indolyl, pyrrolyl optionally substituted with methyl, pyrimidinyl, phenothiazinyl; and provided that the following compounds

-22-



are not included.

Further interesting compounds are those compounds of formula (I) or (I') as defined hereinabove, their *N*-oxides, pharmaceutically acceptable addition salts, quaternary amines and stereochemically isomeric forms thereof, wherein

ring A is pyridyl, pyrimidinyl or pyridazinyl;

R^1 is hydrogen;

X is a direct bond, $-O-$ or $-O-C_{1-6}\text{alkyl}-$;

Z is a direct bond, $-NR^1-$, $-NR^1-C_{1-6}\text{alkyl}-$ or $-C(=O)-$;

R^2 is hydrogen or R^{20} ;

R^3 is hydrogen, halo, $C_{1-6}\text{alkyl}$, polyhalo $C_{1-6}\text{alkyl}$ or cyano;

R^4 is a monocyclic, bicyclic or tricyclic saturated heterocycle; a monocyclic, bicyclic or tricyclic partially saturated heterocycle or a monocyclic, bicyclic or tricyclic aromatic heterocycle, each of said heterocycles optionally being substituted where possible with one or more substituents each independently being selected from R^{15} , $R^{15}-O-$, $R^{15}-C(=O)-$ or halo;


R^{15} is $C_{1-6}\text{alkyl}$; a monocyclic, bicyclic or tricyclic saturated heterocycle; $C_{1-6}\text{alkyl}$ substituted with a monocyclic, bicyclic or tricyclic aromatic carbocycle;

R^{20} is a monocyclic, bicyclic or tricyclic aromatic carbocycle;


s is 1 to 3;

provided that $-X-R^2$ and/or R^3 is other than hydrogen; and

provided that when



represents




then

$-Z-R^4$ is other than 3-pyridyl, 4-pyridyl or 4-pyridyl *N*-oxide when s is 1,


R^3 is 3-chloro, and $-X-R^2$ is hydrogen;

-23-

-Z-R⁴ is other than




-R³ and -X-R² are other than hydrogen when -Z-R⁴ is 3-pyridyl or substituted 4-pyridyl; and provided that when



-R⁴ is other than pyridyl optionally substituted with methyl, pyridyl *N*-oxide, 1-methylpyridinium, thienyl optionally substituted with one or two methyl groups, furanyl optionally substituted with one or two methyl groups, benzofuranyl, quinolinyl, indolyl, pyrrolyl optionally substituted with methyl, pyrimidinyl, phenothiazinyl; .


Also interesting compounds are those compounds of formula (I) or (I') as defined hereinabove provided that the compound is other than

a)



X is -O-; R² is C₁₋₁₀alkyl, C₂₋₁₀alkenyl or C₂₋₁₀alkynyl, said groups representing R² may optionally be substituted; R^{3a} is C₁₋₆alkyloxy; R^{3b} is hydrogen, halo, optionally substituted C₁₋₁₀alkyl, optionally substituted C₂₋₁₀alkenyl, optionally substituted C₂₋₁₀alkynyl, hydroxy, amino, mono -or di(C₁₋₆alkyl)amino, C₁₋₆alkyl-C(=O)-NH-, C₁₋₆alkyloxy, polyhaloC₁₋₆alkyloxy, C₁₋₆alkylthio, polyhaloC₁₋₆alkylthio, aryloxy; R¹ is hydrogen or C₁₋₆alkyl and Z-R⁴ is as defined hereinabove;


b)



Z is C₁₋₆alkanediyl, C₂₋₆alkenediyl, -C(=O)- or -C(=S)-; ring A is as defined hereinabove; R⁴ is monocyclic, bicyclic or tricyclic saturated heterocycle; a monocyclic, bicyclic or tricyclic partially saturated heterocycle or a monocyclic, bicyclic or tricyclic aromatic heterocycle, said groups representing R⁴ may optionally be substituted; R¹ is hydrogen; aryl; C₁₋₆alkylcarbonyl; C₁₋₆alkyl; C₁₋₆alkyloxycarbonyl; C₁₋₆alkyl substituted with formyl, C₁₋₆alkylcarbonyl, C₁₋₆alkyloxycarbonyl, C₁₋₆alkylcarbonyloxy; C₁₋₆alkyloxyC₁₋₆alkylcarbonyl optionally substituted with


C₁₋₆alkyloxycarbonyl; X is a direct bond or C₁₋₆alkyl; R², R³ and s are as defined hereinabove;

c)




- X is a direct bond, -O-, -S-, -C(=O)-NH-, -C(=O)-O-; R² is hydrogen, CF₃, C₁₋₄alkyl;
 5 R³ is hydrogen, hydroxy, halo, CF₃, C₁₋₄alkyl, C₁₋₄alkyloxy, C₁₋₄alkylthio, cyano, amino, aminocarbonyl, carboxyl, C₁₋₄alkylcarbonyl; R¹ is hydrogen or C₁₋₄alkyl; R⁴, R³ and s are as defined hereinabove;

d)




- R⁴-Z represents indolyl-C₁₋₁₀alkyl or Z is a direct bond, -C₁₋₆alkyl-, -NR¹-, -NH-NH-,
 10 -N=N-, -O-, -(C=O)-, -CHOH-, -S-, -S(=O)-, -S(=O)₂-, -O-C₁₋₄alkyl-, -NR¹-C₁₋₄alkyl-,
 -S-C₁₋₄alkyl- and R⁴ is pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, said groups representing R⁴ may optionally be substituted; R¹ is hydrogen, aryl, C₁₋₆alkylcarbonyl, C₁₋₆alkyl, C₁₋₆alkyloxycarbonyl; X-R² is hydrogen, hydroxy, C₁₋₆alkyl, C₁₋₆alkyloxy, trihalomethyl, trihalomethyloxy, cyanoC₁₋₆alkyl; R^{3a} is halo, C₁₋₆alkyl, cyano, nitro,
 15 trihalomethyl, trihalomethyloxy or C₁₋₆alkyl substituted with cyano or aminocarbonyl; R^{3b} is hydroxy, halo, C₁₋₆alkyl, C₁₋₆alkyloxy, cyano, aminocarbonyl, nitro, amino, trihalomethyl, trihalomethyloxy; s is 0, 1 or 2;

e)



- R⁴ is 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-methyl-3-pyridyl, 4-methyl-3-pyridyl, 2-furyl,
 20 5-methyl-2-furyl, 2,5-dimethyl-3-furyl, 2-thienyl, 3-thienyl, 5-methyl-2-thienyl, 2-phenothiazinyl, 4-pyrazinyl, 2-benzofuryl, N-oxido-2-pyridyl, N-oxido-3-pyridyl, N-oxido-4-pyridyl, 1H-indol-2-yl, 1H-indol-3-yl, 1-methyl-1H-pyrrol-2-yl, 4-quinolinyl, 1-methyl-pyridinium-4-yl iodide; R¹ is hydrogen or C₁₋₃alkyl; X-R², R³ and s are as defined hereinabove;


f)



wherein

- R⁴ is *N*-methylpiperazinyl, piperidinyl, imidazolyl, triazolyl, benzimidazolyl, 4-phenyl-piperazin-1-yl wherein phenyl may optionally be substituted with C₁₋₃alkyl or C₁₋₃alkyloxy or halo or trifluoromethyl, 1*H*-imidazol-1-ylC₁₋₃alkyl, 1*H*-imidazol-1-ylC₁₋₃alkyloxy, 1*H*-imidazol-1-ylC₁₋₃alkylthio, morpholinylC₁₋₃alkyl, morpholinylC₁₋₃alkyloxy, morpholinylC₁₋₃alkylthio; X is a direct bond; R² is hydrogen, C₁₋₃alkyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-methyl-3-pyridyl, 4-methyl-3-pyridyl, 2-furyl, 5-methyl-2-furyl, 2,5-dimethyl-3-furyl, 2-thienyl, 3-thienyl, 5-methyl-2-thienyl, 2-phenothiazinyl, 4-pyrazinyl, 2-benzofuryl, *N*-oxido-2-pyridyl, *N*-oxido-3-pyridyl, *N*-oxido-4-pyridyl, 1*H*-indol-2-yl, 1 *H*-indol-3-yl, 1-methyl-1 *H*-pyrrol-2-yl, 4-quinolinyl, 1-methyl-pyridinium-4-ylidide; R³ is hydrogen, C₁₋₃alkyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-methyl-3-pyridyl, 4-methyl-3-pyridyl, 2-furyl, 5-methyl-2-furyl, 2,5-dimethyl-3-furyl, 2-thienyl, 3-thienyl, 5-methyl-2-thienyl, 2-phenothiazinyl, 4-pyrazinyl, 2-benzofuryl, *N*-oxido-2-pyridyl, *N*-oxido-3-pyridyl, *N*-oxido-4-pyridyl, 1 *H*-indol-2-yl, 1 *H*-indol-3-yl, 1-methyl-1 *H*-pyrrol-2-yl, 4-quinolinyl, 1-methyl-pyridinium-4-ylidide; s is as defined hereinabove;


g)



wherein

- R⁴ is pyridyl substituted with an optionally substituted monocyclic, bicyclic or tricyclic saturated heterocycle consisting of from 3 to 7 atoms, and X, R², R³ and s are as defined hereinabove;


h)



- wherein R⁴ is 4-pyridyl substituted in position 3; R^{3ᵃ} is hydrogen, halo, C₁₋₆alkyloxy or C₁₋₆alkyl; R^{3ᵇ} is as defined above for R³;


i)

-26-



wherein R^4 is 4-pyridyl substituted in position 3; R^{3a} is hydrogen, halo, C_{1-6} alkyloxy or C_{1-6} alkyl; $X-R^2$ is as defined above;

j)




5

wherein R^{3a} is halo, cyano, C_{1-4} alkyloxy, polyhalo C_{1-4} alkyloxy, C_{1-4} alkylthio, C_{1-4} alkyl-S(=O)-, C_{1-4} alkyl-S(=O)₂-, C_{1-4} alkyl, polyhalo C_{1-4} alkyl, C_{1-4} alkyloxycarbonyl, mono- or di(C_{1-4} alkyl)aminocarbonyl, aminocarbonyl, polyhalo C_{1-4} alkylthio; R^{3b} is hydrogen, halo, cyano, nitro, C_{1-4} alkyl, C_{1-4} alkyloxy, polyhalo C_{1-4} alkyl, C_{1-4} alkyloxycarbonyl, C_{1-4} alkylcarbonyl; R^{3c} is hydrogen, halo or C_{1-4} alkyl; R^4 is 2-furanyl, 2-thienyl or 3-thienyl;

10


k)



wherein R^4 is pyridyl, pyrimidinyl, thiazolyl, pyrazinyl, pyridazinyl, or imidazolyl, each of said rings optionally substituted with one or more substituents selected from halo, cyano, aminocarbonyl, -C(=O)-O- $R^{4'}$, -C(=O)- $R^{4'}$, -S(=O)₂-NR^{4'}R^{4''}, NR^{4'}R^{4''}, -O- $R^{4'}$ or C_{1-6} alkyl optionally substituted with fluoro wherein $R^{4'}$ and $R^{4''}$ each independently represent hydrogen or C_{1-6} alkyl optionally substituted with mono- or di(C_{1-6} alkyl)amino; R^1 , R^3 and s are as defined hereinabove;

20


l)



wherein R^4 is 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-methyl-3-pyridyl, 6-methyl-3-pyridyl, 2-furanyl, 5-methyl-2-furanyl, 2,5-dimethyl-3-furanyl, 2-thienyl, 3-thienyl, 5-methyl-2-thienyl, 2-pheno-thiazinyl, 2-pyrazinyl, 2-benzofuranyl, 2-pyridyl-*N*-oxide, 3-pyridyl-*N*-oxide, 4-pyridyl-*N*-oxide, 1 *H*-indol-2-yl, 1 *H*-indol-3-yl, 1-methyl-1 *H*-pyrrol-2-yl, 4-quinolinyl, 4-pyridyl methyl iodide, dimethylaminophenyl; R^1 is hydrogen or C_{1-3} alkyl; s is 1 to 3; X , R^2 and R^3 are as defined hereinabove.

25

m)



wherein R^4 is 4-pyrazinyl, 1-methyl-1*H*-pyrrolyl, pyridyl optionally substituted with C_{1-6} alkyl, pyridyl *N*-oxide optionally substituted with C_{1-6} alkyl; X is $-O-$, $-NR^1-C(=O)-O-$, $-NR^1-C(=O)-$, $-NR^1-C(=S)-$, $-NR^1-C(=O)-NR^1-$, $-NR^1-C(=S)-NR^1-$ or a direct bond; R^2 is fluoro-substituted C_{1-10} alkyl, optionally substituted phenyl or naphthyl, optionally substituted phenyl C_{1-6} alkyl, a monocyclic, bicyclic or tricyclic saturated carbocycle consisting of from 3 to 10 carbon atoms, a monocyclic, bicyclic or tricyclic partially saturated carbocycle consisting of from 3 to 10 carbon, C_{1-6} alkyl substituted with a monocyclic, bicyclic or tricyclic saturated carbocycle consisting of from 3 to 10 carbon atoms or a monocyclic, bicyclic or tricyclic partially saturated carbocycle consisting of from 3 to 10 carbon, a 5 or 6-membered heterocycle containing from 1 to 3 heteroatoms wherein the heteroatom is selected from O, N or S to which 5 or 6-membered heterocycle one or two benzene radicals may be fused, C_{1-6} alkyl substituted by a 5 or 6-membered heterocycle containing from 1 to 3 heteroatoms wherein the heteroatom is selected from O, N or S to which 5 or 6-membered heterocycle one or two benzene radicals may be fused; R^3 is nitro, $R^7-C(=O)-NH-$; $R^{21}-C(=O)-NH-$; s is as defined hereinabove.

Further preferred compounds are those compounds of formula (I) or (I') wherein one of the following restrictions apply :

- X is a direct bond and R^2 is hydrogen;
- R^2 and R^3 are other than hydrogen;
- R^3 is hydrogen;
- Z is a direct bond.

Also preferred compounds are those compounds of formula (I) or (I') wherein ring A is pyridyl, pyrimidinyl or pyridazinyl, in particular pyrimidinyl or pyridazinyl.

Other preferred compounds are those compounds of formula (I) or (I') wherein ring A is pyridyl, pyrimidinyl or pyridazinyl; in particular pyrimidinyl or pyridazinyl; R^1 is hydrogen; aryl; formyl; C_{1-6} alkylcarbonyl; C_{1-6} alkyl; C_{1-6} alkyloxycarbonyl; C_{1-6} alkyl substituted with formyl, C_{1-6} alkylcarbonyl, C_{1-6} alkyloxycarbonyl, C_{1-6} alkylcarbonyloxy; C_{1-6} alkyloxy C_{1-6} alkylcarbonyl optionally substituted with C_{1-6} alkyloxycarbonyl;

- X is $\text{-NR}^1\text{-}$; -NH-NH- ; -N=N- ; -O- ; -C(=O)- ; -C(=S)- ; -O-C(=O)- ; -C(=O)-O- ;
 $\text{-O-C(=O)-C}_{1-6}\text{alkyl-}$; $\text{-C(=O)-O-C}_{1-6}\text{alkyl-}$; $\text{-O-C}_{1-6}\text{alkyl-C(=O)-}$;
 $\text{-C(=O)-C}_{1-6}\text{alkyl-O-}$; $\text{-O-C(=O)-NR}^1\text{-}$; $\text{-NR}^1\text{-C(=O)-O-}$; -O-C(=O)-C(=O)- ;
 $\text{-C(=O)-NR}^1\text{-}$; $\text{-NR}^1\text{-C(=O)-}$; $\text{-C(=S)-NR}^1\text{-}$; $\text{-NR}^1\text{-C(=S)-}$; $\text{-NR}^1\text{-C(=O)-NR}^1\text{-}$;
5 $\text{-NR}^1\text{-C(=S)-NR}^1\text{-}$; $\text{-NR}^1\text{-S(=O)-NR}^1\text{-}$; $\text{-NR}^1\text{-S(=O)}_2\text{-NR}^1\text{-}$; $\text{-C}_{1-6}\text{alkyl-C(=O)-NR}^1\text{-}$;
 $\text{-O-C}_{1-6}\text{alkyl-C(=O)-NR}^1\text{-}$; $\text{-C}_{1-6}\text{alkyl-O-C(=O)-NR}^1\text{-}$; $\text{-C}_{1-6}\text{alkyl-}$; $\text{-O-C}_{1-6}\text{alkyl-}$;
 $\text{-C}_{1-6}\text{alkyl-O-}$; $\text{-NR}^1\text{-C}_{1-6}\text{alkyl-}$; $\text{-C}_{1-6}\text{alkyl-NR}^1\text{-}$; $\text{-NR}^1\text{-C}_{1-6}\text{alkyl-NR}^1\text{-}$;
 $\text{-NR}^1\text{-C}_{1-6}\text{alkyl-C}_{3-7}\text{cycloalkyl-}$; $\text{-C}_{2-6}\text{alkenyl-}$; $\text{-C}_{2-6}\text{alkynyl-}$; $\text{-O-C}_{2-6}\text{alkenyl-}$;
 $\text{-C}_{2-6}\text{alkenyl-O-}$; $\text{-NR}^1\text{-C}_{2-6}\text{alkenyl-}$; $\text{-C}_{2-6}\text{alkenyl-NR}^1\text{-}$; $\text{-NR}^1\text{-C}_{2-6}\text{alkenyl-NR}^1\text{-}$;
10 $\text{-NR}^1\text{-C}_{2-6}\text{alkenyl-C}_{3-7}\text{cycloalkyl-}$; $\text{-O-C}_{2-6}\text{alkynyl-}$; $\text{-C}_{2-6}\text{alkynyl-O-}$;
 $\text{-NR}^1\text{-C}_{2-6}\text{alkynyl-}$; $\text{-C}_{2-6}\text{alkynyl-NR}^1\text{-}$; $\text{-NR}^1\text{-C}_{2-6}\text{alkynyl-NR}^1\text{-}$;
 $\text{-NR}^1\text{-C}_{2-6}\text{alkynyl-C}_{3-7}\text{cycloalkyl-}$; $\text{-O-C}_{1-6}\text{alkyl-O-}$; $\text{-O-C}_{2-6}\text{alkenyl-O-}$;
 $\text{-O-C}_{2-6}\text{alkynyl-O-}$; -CHOH- ; -S- ; -S(=O)- ; $\text{-S(=O)}_2\text{-}$; $\text{-S(=O)-NR}^1\text{-}$; $\text{-S(=O)}_2\text{-NR}^1\text{-}$;
 $\text{-NR}^1\text{-S(=O)-}$; $\text{-NR}^1\text{-S(=O)}_2\text{-}$; $\text{-S-C}_{1-6}\text{alkyl-}$; $\text{-C}_{1-6}\text{alkyl-S-}$; $\text{-S-C}_{2-6}\text{alkenyl-}$;
15 $\text{-C}_{2-6}\text{alkenyl-S-}$; $\text{-S-C}_{2-6}\text{alkynyl-}$; $\text{-C}_{2-6}\text{alkynyl-S-}$; $\text{-O-C}_{1-6}\text{alkyl-S(=O)}_2\text{-}$ or a direct
bond;
- Z is a direct bond, $\text{C}_{1-6}\text{alkanediyl}$, $\text{C}_{2-6}\text{alkenediyl}$, $\text{C}_{2-6}\text{alkynediyl}$; -O- ; $\text{-O-C}_{1-6}\text{alkyl-}$;
 -C(=O)- ; -C(=O)-O- ; -O-C(=O)- ; -C(=S)- ; -S(=O)- ; $\text{-S(=O)}_2\text{-}$; $\text{-NR}^1\text{-}$; $\text{-NR}^1\text{-C}_{1-6}\text{alkyl-}$;
 $\text{-NR}^1\text{-C(=O)-}$; $\text{-O-C(=O)-NR}^1\text{-}$; $\text{-NR}^1\text{-C(=O)-O-}$; $\text{-NR}^1\text{-C(=S)-}$; $\text{-S(=O)-NR}^1\text{-}$;
20 $\text{-S(=O)}_2\text{-NR}^1\text{-}$; $\text{-NR}^1\text{-S(=O)-}$; $\text{-NR}^1\text{-S(=O)}_2\text{-}$; $\text{-NR}^1\text{-(C=O)-NR}^1\text{-}$; $\text{-NR}^1\text{-C(=S)-NR}^1\text{-}$;
 $\text{-NR}^1\text{-S(=O)-NR}^1\text{-}$; $\text{-NR}^1\text{-S(=O)}_2\text{-NR}^1\text{-}$;
- R^2 is hydrogen, $\text{C}_{1-10}\text{alkyl}$, $\text{C}_{2-10}\text{alkenyl}$, $\text{C}_{2-10}\text{alkynyl}$, R^{20} , each of said groups
representing R^2 may optionally be substituted where possible with one or more
substituents each independently being selected from =S ; =O ; R^{15} ; hydroxy; halo;
25 nitro; cyano; $\text{R}^{15}\text{-O-}$; SH ; $\text{R}^{15}\text{-S-}$; formyl; carboxyl; $\text{R}^{15}\text{-C(=O)-}$; $\text{R}^{15}\text{-O-C(=O)-}$;
 $\text{R}^{15}\text{-C(=O)-O-}$; $\text{R}^{15}\text{-O-C(=O)-O-}$; $\text{-SO}_3\text{H}$; $\text{R}^{15}\text{-S(=O)-}$; $\text{R}^{15}\text{-S(=O)}_2\text{-}$; $\text{R}^5\text{R}^6\text{N}$;
 $\text{R}^5\text{R}^6\text{N-C}_{1-6}\text{alkyl}$; $\text{R}^5\text{R}^6\text{N-C}_{3-7}\text{cycloalkyl}$; $\text{R}^5\text{R}^6\text{N-C}_{1-6}\text{alkyloxy}$; $\text{R}^{5a}\text{R}^{6a}\text{N-C(=O)-}$;
 $\text{R}^5\text{R}^6\text{N-C(=S)-}$; $\text{R}^5\text{R}^6\text{N-C(=O)-NH-}$; $\text{R}^5\text{R}^6\text{N-C(=S)-NH-}$; $\text{R}^5\text{R}^6\text{N-S(=O)}_n\text{-}$;
 $\text{R}^5\text{R}^6\text{N-S(=O)}_n\text{-NH-}$; $\text{R}^{15}\text{-C(=S)-}$; $\text{R}^{15}\text{-C(=O)-NH-}$; $\text{R}^{15}\text{-O-C(=O)-NH-}$;
30 $\text{R}^{15}\text{-S(=O)}_n\text{-NH-}$; $\text{R}^{15}\text{-O-S(=O)}_n\text{-NH-}$; $\text{R}^{15}\text{-C(=S)-NH-}$; $\text{R}^{15}\text{-O-C(=S)-NH-}$;
 $\text{R}^{17}\text{R}^{18}\text{N-Y}_{1a}\text{-}$; $\text{R}^{17}\text{R}^{18}\text{N-Y}_2\text{-NR}^{16}\text{-Y}_{1-}$; $\text{R}^{15}\text{-Y}_2\text{-NR}^{19}\text{-Y}_{1-}$; $\text{H-Y}_2\text{-NR}^{19}\text{-Y}_{1-}$;
- R^3 is hydrogen; hydroxy; halo; $\text{C}_{1-6}\text{alkyl}$; $\text{C}_{1-6}\text{alkyl}$ substituted with cyano, hydroxy or
 -C(=O)R^7 ; $\text{C}_{2-6}\text{alkenyl}$; $\text{C}_{2-6}\text{alkenyl}$ substituted with one or more halogen atoms or
cyano; $\text{C}_{2-6}\text{alkynyl}$; $\text{C}_{2-6}\text{alkynyl}$ substituted with one or more halogen atoms or
35 cyano; $\text{C}_{1-6}\text{alkylthio}$; $\text{C}_{1-6}\text{alkyloxycarbonyl}$; $\text{C}_{1-6}\text{alkylcarbonyloxy}$; carboxyl; cyano;
nitro; amino; mono- or di($\text{C}_{1-6}\text{alkyl}$)amino; polyhalo $\text{C}_{1-6}\text{alkyl}$; polyhalo $\text{C}_{1-6}\text{alkylthio}$;
 R^{21} ; $\text{R}^{21}\text{-C}_{1-6}\text{alkyl}$; $\text{R}^{21}\text{-O-}$; $\text{R}^{21}\text{-S-}$;

$R^{21}-C(=O)-$; $R^{21}-S(=O)_p-$; $R^7-S(=O)_p-$; $R^7-S(=O)_p-NH-$; $R^{21}-S(=O)_p-NH-$;
 $R^7-C(=O)-$; $-NHC(=O)H$; $-C(=O)NHNH_2$; $R^7-C(=O)-NH-$; $R^{21}-C(=O)-NH-$;
 $-C(=NH)R^7$; $-C(=NH)R^{21}$;

- R^4 is tetrahydrofuranyl, dihydrofuranyl, pyrrolinyl, pyrrolidinyl, imidazolyl,
 5 imidazolinyl, imidazolidinyl, oxazolyl, pyrimidinyl, pyridyl, piperidinyl,
 piperazinyl, pyridazinyl, triazinyl, morpholinyl, dioxolanyl or dioxanyl, each of said
 heterocycles optionally being substituted where possible with one or more
 substituents each independently being selected from $=S$; $=O$; R^{15} ; hydroxy; halo;
 nitro; cyano; $R^{15}-O-$; SH ; $R^{15}-S-$; formyl; carboxyl;
 10 $R^{15}-C(=O)-$; $R^{15}-O-C(=O)-$; $R^{15}-C(=O)-O-$; $R^{15}-O-C(=O)-O-$; $-SO_3H$; $R^{15}-S(=O)-$;
 $R^{15}-S(=O)_2-$; R^5R^6N ; $R^5R^6NC_{1-6}alkyl$; $R^5R^6NC_{3-7}cycloalkyl$; $R^5R^6NC_{1-6}alkyloxy$;
 $R^5R^6N-C(=O)-$; $R^5R^6N-C(=S)-$; $R^5R^6N-C(=O)-NH-$; $R^5R^6N-C(=S)-NH-$;
 $R^5R^6N-S(=O)_n-$; $R^5R^6N-S(=O)_n-NH-$; $R^{15}-C(=S)-$; $R^{15}-C(=O)-NH-$;
 $R^{15}-O-C(=O)-NH-$; $R^{15}-S(=O)_n-NH-$; $R^{15}-O-S(=O)_n-NH-$; $R^{15}-C(=S)-NH-$;
 15 $R^{15}-O-C(=S)-NH-$; $R^{17}R^{18}N-Y_{1a}-$; $R^{17}R^{18}N-Y_2-NR^{16}-Y_1-$; $R^{15}-Y_2-NR^{19}-Y_1-$;
 $H-Y_2-NR^{19}-Y_1-$;
 R^5 and R^6 each independently are hydrogen, R^8 , $-Y_1-NR^9-Y_2-NR^{10}R^{11}$, $-Y_1-NR^9-Y_1-R^8$,
 $-Y_1-NR^9R^{10}$, or
 R^{5a} and R^{6a} each independently are hydrogen, $C_{1-6}alkyl$; $C_{2-6}alkenyl$ or $C_{2-6}alkynyl$,
 20 each of said groups representing R^{5a} and R^{6a} may optionally be substituted with one
 or more substituents selected from R^{12} , R^{13} and R^{14} ;
 R^5 and R^6 may together with the nitrogen to which they are attached form a saturated or
 partially saturated monocyclic 3 to 8 membered heterocycle or an aromatic 4 to 8
 membered monocyclic heterocycle, each of said heterocycles may optionally be
 25 substituted with one or more substituents selected from R^{12} , R^{13} and R^{14} , or each of
 said heterocycles may optionally be fused with a benzene ring, said benzene ring
 being optionally substituted with one or more substituents selected from R^{12} , R^{13} and
 R^{14} ;
 R^7 is $C_{1-6}alkyl$, $C_{1-6}alkyloxy$, amino, mono- or di($C_{1-6}alkyl$)amino or polyhalo $C_{1-6}alkyl$;
 30 R^8 is $C_{1-6}alkyl$; $C_{2-6}alkenyl$; $C_{2-6}alkynyl$; a monocyclic, bicyclic or tricyclic saturated
 carbocycle; a monocyclic, bicyclic or tricyclic partially saturated carbocycle; a
 monocyclic, bicyclic or tricyclic aromatic carbocycle; a monocyclic, bicyclic or
 tricyclic saturated heterocycle; a monocyclic, bicyclic or tricyclic partially saturated
 heterocycle; a monocyclic, bicyclic or tricyclic aromatic heterocycle; $C_{1-6}alkyl$
 35 substituted with a monocyclic, bicyclic or tricyclic saturated carbocycle or with a
 monocyclic, bicyclic or tricyclic partially saturated carbocycle or with a monocyclic,
 bicyclic or tricyclic aromatic carbocycle or with a monocyclic, bicyclic or tricyclic

saturated heterocycle or with a monocyclic, bicyclic or tricyclic partially saturated heterocycle or with a monocyclic, bicyclic or tricyclic aromatic heterocycle; each of said groups representing R^8 may optionally be substituted with one or more substituents selected from R^{12} , R^{13} and R^{14} ;

5 R^9 , R^{10} and R^{11} each independently are hydrogen or R^8 , or any two of R^9 , R^{10} and R^{11} may together be C_{1-6} alkanediyl or C_{2-6} alkenediyl thereby forming a saturated or partially saturated monocyclic 3 to 8 membered heterocycle or an aromatic 4 to 8 membered monocyclic heterocycle together with the nitrogen atoms to which they are attached, each of said heterocycles may optionally be

10 substituted with one or more substituents selected from R^{12} , R^{13} and R^{14} ;

R^{12} , R^{13} and R^{14} each independently are hydrogen; R^{15} ; hydroxy; halo; nitro; cyano; R^{15} -O-; SH; R^{15} -S-; formyl; carboxyl; R^{15} -C(=O)-; R^{15} -O-C(=O)-; R^{15} -C(=O)-O-; R^{15} -O-C(=O)-O-; $-SO_3H$; R^{15} -S(=O)-; R^{15} -S(=O)₂-; $R^{15}R^{16}N$ -S(=O)-; $R^{15}R^{16}N$ -S(=O)₂-; $R^{17}R^{18}N$ -Y₁-; $R^{17}R^{18}N$ -Y₂-NR¹⁶-Y₁-; R^{15} -Y₂-NR¹⁹-Y₁-;

15 H-Y₂-NR¹⁹-Y₁-; oxo, or any two of R^{12} , R^{13} and R^{14} may together be C_{1-6} alkanediyl or C_{2-6} alkenediyl thereby forming a saturated or partially saturated monocyclic 3 to 8 membered carbo – or heterocycle or an aromatic 4 to 8 membered monocyclic carbo – or heterocycle together with the atoms to which they are attached, or

20 any two of R^{12} , R^{13} and R^{14} may together be $-O-(CH_2)_r-O-$ thereby forming a saturated, partially saturated or aromatic monocyclic 4 to 8 membered carbo – or heterocycle together with the atoms to which they are attached;

R^{15} is C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, a monocyclic, bicyclic or tricyclic saturated carbocycle; a monocyclic, bicyclic or tricyclic partially saturated carbocycle; a

25 monocyclic, bicyclic or tricyclic aromatic carbocycle; a monocyclic, bicyclic or tricyclic saturated heterocycle; a monocyclic, bicyclic or tricyclic partially saturated heterocycle; a monocyclic, bicyclic or tricyclic aromatic heterocycle; C_{1-6} alkyl substituted with a monocyclic, bicyclic or tricyclic saturated carbocycle or with a monocyclic, bicyclic or tricyclic partially saturated carbocycle or with a monocyclic, bicyclic or tricyclic aromatic carbocycle or with a monocyclic, bicyclic or tricyclic

30 saturated heterocycle or with a monocyclic, bicyclic or tricyclic partially saturated heterocycle or with a monocyclic, bicyclic or tricyclic aromatic heterocycle; each of said substituents representing R^{15} may optionally be substituted with one or more substituents selected from R^{12} , R^{13} and R^{14} ; or each of said carbocycles or

35 heterocycles may optionally be fused with a benzene ring, said benzene ring being optionally substituted with one or more substituents selected from R^{12} , R^{13} and R^{14} ;

R^{16} , R^{17} , R^{18} and R^{19} each independently are hydrogen or R^{15} , or

- R^{17} and R^{18} , or R^{15} and R^{19} may together be C_{1-6} alkanediyl or C_{2-6} alkenediyl thereby forming a saturated or partially saturated monocyclic 3 to 8 membered heterocycle or an aromatic 4 to 8 membered monocyclic heterocycle, each of said heterocycles may optionally be substituted with one or more substituents selected from R^{12} , R^{13} and R^{14} ; or
- R^{17} and R^{18} together with R^{16} may be C_{1-6} alkanediyl or C_{2-6} alkenediyl thereby forming a saturated or partially saturated monocyclic 3 to 8 membered heterocycle or an aromatic 4 to 8 membered monocyclic heterocycle together with the nitrogen atoms to which they are attached, each of said heterocycles may optionally be substituted with one or more substituents selected from R^{12} , R^{13} and R^{14} ;
- R^{20} is a monocyclic, bicyclic or tricyclic saturated carbocycle; a monocyclic, bicyclic or tricyclic partially saturated carbocycle; a monocyclic, bicyclic or tricyclic aromatic carbocycle; a monocyclic, bicyclic or tricyclic saturated heterocycle; a monocyclic, bicyclic or tricyclic partially saturated heterocycle; a monocyclic, bicyclic or tricyclic aromatic heterocycle;
- R^{21} is a monocyclic, bicyclic or tricyclic saturated carbocycle; a monocyclic, bicyclic or tricyclic partially saturated carbocycle; a monocyclic, bicyclic or tricyclic aromatic carbocycle; a monocyclic, bicyclic or tricyclic saturated heterocycle; a monocyclic, bicyclic or tricyclic partially saturated heterocycle; a monocyclic, bicyclic or tricyclic aromatic heterocycle, each of said carbocycles or heterocycles representing R^{21} may optionally be substituted with one or more substituents selected from R^{12} , R^{13} and R^{14} ;
- Y_{1a} is $-Y_3-S(=O)-Y_4-$; $-Y_3-S(=O)_2-Y_4-$; $-Y_3-C(=O)-Y_4-$; $-Y_3-C(=S)-Y_4-$; $-Y_3-O-Y_4-$; $-Y_3-S-Y_4-$; $-Y_3-O-C(=O)-Y_4-$ or $-Y_3-C(=O)-O-Y_4-$;
- Y_1 or Y_2 each independently are a direct bond, $-Y_3-S(=O)-Y_4-$; $-Y_3-S(=O)_2-Y_4-$; $-Y_3-C(=O)-Y_4-$; $-Y_3-C(=S)-Y_4-$; $-Y_3-O-Y_4-$; $-Y_3-S-Y_4-$; $-Y_3-O-C(=O)-Y_4-$ or $-Y_3-C(=O)-O-Y_4-$;
- Y_3 or Y_4 each independently are a direct bond, C_{1-6} alkanediyl, C_{2-6} alkenediyl or C_{2-6} alkynediyl;
- n is 1 or 2;
- m is 1 or 2;
- p is 1 or 2;
- r is 1 to 5;
- s is 1 to 3;
- aryl is phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from halo, C_{1-6} alkyl, C_{3-7} cycloalkyl, C_{1-6} alkyloxy, cyano, nitro, polyhalo C_{1-6} alkyl and polyhalo C_{1-6} alkyloxy;

provided that $-X-R^2$ and/or R^3 is other than hydrogen; and
 provided that R^4 is other than optionally substituted pyridyl when ring A represents
 pyrimidinyl.

- 5 Still other preferred compounds are those compounds of formula (I) or (I') wherein
 ring A is pyridyl, pyrimidinyl or pyridazinyl; in particular pyrimidinyl or pyridazinyl;
 R^1 is hydrogen; aryl; formyl; C_{1-6} alkylcarbonyl; C_{1-6} alkyl; C_{1-6} alkyloxycarbonyl;
 C_{1-6} alkyl substituted with formyl, C_{1-6} alkylcarbonyl, C_{1-6} alkyloxycarbonyl,
 C_{1-6} alkylcarbonyloxy; C_{1-6} alkyloxy C_{1-6} alkylcarbonyl optionally substituted with
 10 C_{1-6} alkyloxycarbonyl;
 X is $-NR^1$ -, $-O$ -, $-C(=O)$ -, $-O-C(=O)$ -, $-C(=O)-O$ -, $-O-C(=O)-C_{1-6}$ alkyl-, $-C(=O)-O-$
 C_{1-6} alkyl-, $-O-C_{1-6}$ alkyl- $C(=O)$ -, $-C(=O)-C_{1-6}$ alkyl- O -, $-O-C(=O)-NR^1$ -, $-NR^1-$
 $C(=O)-O$ -, $-C(=O)-NR^1$ -, $-NR^1-C(=O)$ -, $-C_{1-6}$ alkyl-, $-O-C_{1-6}$ alkyl-, $-C_{1-6}$ alkyl- O -,
 $-NR^1-C_{1-6}$ alkyl-, $-C_{1-6}$ alkyl- NR^1 -, $-NR^1-C_{1-6}$ alkyl- NR^1 -, $-C_{2-6}$ alkenyl-, $-C_{2-6}$ alkynyl-,
 15 $-O-C_{2-6}$ alkenyl-, $-C_{2-6}$ alkenyl- O -, $-NR^1-C_{2-6}$ alkenyl-, $-C_{2-6}$ alkenyl- NR^1 -, $-NR^1-C_{2-6}$
 $alkenyl-NR^1$ -, $-O-C_{2-6}$ alkynyl-, $-C_{2-6}$ alkynyl- O -, $-NR^1-C_{2-6}$ alkynyl-, $-C_{2-6}$ alkynyl- NR^1 -,
 $-NR^1-C_{2-6}$ alkynyl- NR^1 -, $-O-C_{1-6}$ alkyl- O -, $-O-C_{2-6}$ alkenyl- O -, $-O-C_{2-6}$ alkynyl- O -,
 $-CHOH$ -, $-S$ -, $-S(=O)$ -, $-S(=O)_2$ -, $-S(=O)-NR^1$ -, $-S(=O)_2-NR^1$ -,
 $-NR^1-S(=O)$ -, $-NR^1-S(=O)_2$ -, $-S-C_{1-6}$ alkyl-, $-C_{1-6}$ alkyl- S -, $-S-C_{2-6}$ alkenyl-,
 20 $-C_{2-6}$ alkenyl- S -, $-S-C_{2-6}$ alkynyl-, $-C_{2-6}$ alkynyl- S -, or a direct bond;
 Z is a direct bond, C_{1-6} alkanediyl, C_{2-6} alkenediyl, C_{2-6} alkynediyl; $-O$ -, $-O-C_{1-6}$ alkyl-;
 $-C(=O)$ -, $-C(=O)-O$ -, $-O-C(=O)$ -, $-S(=O)$ -, $-S(=O)_2$ -, $-NR^1$ -, $-NR^1-C_{1-6}$ alkyl-, $-NR^1-$
 $C(=O)$ -, $-O-C(=O)-NR^1$ -, $-NR^1C(=O)-O$ -, $-S(=O)-NR^1$ -, $-S(=O)_2-NR^1$ -,
 $-NR^1-S(=O)$ -, $-NR^1-S(=O)_2$ -,
 25 R^2 is hydrogen, C_{1-10} alkyl, C_{2-10} alkenyl, C_{2-10} alkynyl, R^{20} , each of said groups
 representing R^2 may optionally be substituted where possible with one or more
 substituents each independently being selected from $=O$; R^{15} ; hydroxy; halo; nitro;
 cyano; $R^{15}-O$ -, SH ; $R^{15}-S$ -, formyl; carboxyl; $R^{15}-C(=O)$ -, $R^{15}-O-C(=O)$ -,
 $R^{15}-C(=O)-O$ -, $R^{15}-O-C(=O)-O$ -, $-SO_3H$; $R^{15}-S(=O)$ -, $R^{15}-S(=O)_2$ -, R^5R^6N ;
 30 $R^5R^6N-C_{1-6}$ alkyl; $R^5R^6N-C_{1-6}$ alkyloxy; $R^{5a}R^{6a}N-C(=O)$ -, $R^5R^6N-S(=O)_n$ -,
 $R^5R^6N-S(=O)_n-NH$ -, $R^{15}-C(=O)-NH$ -,
 R^3 is hydrogen; hydroxy; halo; C_{1-6} alkyl; C_{1-6} alkyl substituted with cyano, hydroxy or
 $-C(=O)R^7$; C_{2-6} alkenyl; C_{2-6} alkenyl substituted with one or more halogen atoms or
 cyano; C_{2-6} alkynyl; C_{2-6} alkynyl substituted with one or more halogen atoms or
 35 cyano; C_{1-6} alkylthio; C_{1-6} alkyloxycarbonyl; C_{1-6} alkylcarbonyloxy; carboxyl; cyano;
 nitro; amino; mono- or di(C_{1-6} alkyl)amino; polyhalo C_{1-6} alkyl; polyhalo C_{1-6} alkylthio;
 R^{21} ; $R^{21}-C_{1-6}$ alkyl; $R^{21}-O$ -, $R^{21}-S$ -;

$R^{21}-C(=O)-$; $R^{21}-S(=O)_p-$; $R^7-S(=O)_p-$; $R^7-C(=O)-$; $-NHC(=O)H$; $-C(=O)NHNH_2$;
 $R^7-C(=O)-NH-$; $R^{21}-C(=O)-NH-$; $-C(=NH)R^7$; $-C(=NH)R^{21}$;

R^4 is tetrahydrofuranyl, dihydrofuranyl, pyrrolinyl, pyrrolidinyl, imidazolyl, imidazoliny, imidazolidinyl, oxazolyl, pyrimidinyl, pyridyl, piperidinyl, piperazinyl, pyridazinyl, triazinyl, morpholinyl, dioxolanyl or dioxanyl, each of said heterocycles optionally being substituted where possible with one or more substituents each independently being selected from $=O$; R^{15} ; hydroxy; halo; nitro; cyano; $R^{15}-O-$; SH ; $R^{15}-S-$; formyl; carboxyl; $R^{15}-C(=O)-$; $R^{15}-O-C(=O)-$; $R^{15}-C(=O)-O-$; $R^{15}-O-C(=O)-O-$; $-SO_3H$; $R^{15}-S(=O)-$; $R^{15}-S(=O)_2-$; R^5R^6N ;
 $R^5R^6N-C_{1-6}alkyl$; $R^5R^6N-C_{1-6}alkyloxy$; $R^{5a}R^{6a}N-C(=O)-$; $R^5R^6N-S(=O)_n-$;
 $R^{15}-C(=O)-NH-$;

R^5 and R^6 each independently are hydrogen or R^8 ;

R^{5a} and R^{6a} each independently are hydrogen, $C_{1-6}alkyl$; $C_{2-6}alkenyl$ or $C_{2-6}alkynyl$, each of said groups representing R^{5a} and R^{6a} may optionally be substituted with one or more substituents selected from R^{12} , R^{13} and R^{14} ;

R^7 is $C_{1-6}alkyl$, $C_{1-6}alkyloxy$, amino, mono- or di($C_{1-6}alkyl$)amino or polyhalo $C_{1-6}alkyl$;

R^8 is $C_{1-6}alkyl$; $C_{2-6}alkenyl$; $C_{2-6}alkynyl$; a monocyclic, bicyclic or tricyclic saturated carbocycle; a monocyclic, bicyclic or tricyclic partially saturated carbocycle; a monocyclic, bicyclic or tricyclic aromatic carbocycle; a monocyclic, bicyclic or tricyclic saturated heterocycle; a monocyclic, bicyclic or tricyclic partially saturated heterocycle; a monocyclic, bicyclic or tricyclic aromatic heterocycle; $C_{1-6}alkyl$ substituted with a monocyclic, bicyclic or tricyclic saturated carbocycle or with a monocyclic, bicyclic or tricyclic partially saturated carbocycle or with a monocyclic, bicyclic or tricyclic aromatic carbocycle or with a monocyclic, bicyclic or tricyclic saturated heterocycle or with a monocyclic, bicyclic or tricyclic partially saturated heterocycle or with a monocyclic, bicyclic or tricyclic aromatic heterocycle; each of said groups representing R^8 may optionally be substituted with one or more substituents selected from R^{12} , R^{13} and R^{14} ;

R^{12} , R^{13} and R^{14} each independently are hydrogen; R^{15} ; hydroxy; halo; nitro; cyano; $R^{15}-O-$; SH ; $R^{15}-S-$; formyl; carboxyl; $R^{15}-C(=O)-$; $R^{15}-O-C(=O)-$; $R^{15}-C(=O)-O-$; $R^{15}-O-C(=O)-O-$; $-SO_3H$; $R^{15}-S(=O)-$; $R^{15}-S(=O)_2-$; $R^{15}R^{16}N-S(=O)-$;
 $R^{15}R^{16}N-S(=O)_2-$;

R^{15} is $C_{1-6}alkyl$, $C_{2-6}alkenyl$, $C_{2-6}alkynyl$, a monocyclic, bicyclic or tricyclic saturated carbocycle; a monocyclic, bicyclic or tricyclic partially saturated carbocycle; a monocyclic, bicyclic or tricyclic aromatic carbocycle; a monocyclic, bicyclic or tricyclic saturated heterocycle; a monocyclic, bicyclic or tricyclic partially saturated heterocycle; a monocyclic, bicyclic or tricyclic aromatic heterocycle; $C_{1-6}alkyl$

substituted with a monocyclic, bicyclic or tricyclic saturated carbocycle or with a monocyclic, bicyclic or tricyclic partially saturated carbocycle or with a monocyclic, bicyclic or tricyclic aromatic carbocycle or with a monocyclic, bicyclic or tricyclic saturated heterocycle or with a monocyclic, bicyclic or tricyclic partially saturated heterocycle or with a monocyclic, bicyclic or tricyclic aromatic heterocycle; each of
5 said substituents representing R^{15} may optionally be substituted with one or more substituents selected from R^{12} , R^{13} and R^{14} ;

R^{16} is hydrogen or R^{15} ;

R^{20} is a monocyclic, bicyclic or tricyclic saturated carbocycle; a monocyclic, bicyclic
10 or tricyclic partially saturated carbocycle; a monocyclic, bicyclic or tricyclic aromatic carbocycle; a monocyclic, bicyclic or tricyclic saturated heterocycle; a monocyclic, bicyclic or tricyclic partially saturated heterocycle; a monocyclic, bicyclic or tricyclic aromatic heterocycle;

R^{21} is a monocyclic, bicyclic or tricyclic saturated carbocycle; a monocyclic, bicyclic
15 or tricyclic partially saturated carbocycle; a monocyclic, bicyclic or tricyclic aromatic carbocycle; a monocyclic, bicyclic or tricyclic saturated heterocycle; a monocyclic, bicyclic or tricyclic partially saturated heterocycle; a monocyclic, bicyclic or tricyclic aromatic heterocycle, each of said carbocycles or heterocycles representing R^{21} may optionally be substituted with one or more substituents
20 selected from R^{12} , R^{13} and R^{14} ;

n is 1 or 2;

m is 1 or 2;

p is 1 or 2;

s is 1 to 3;


25 aryl is phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from halo, C_{1-6} alkyl, C_{3-7} cycloalkyl, C_{1-6} alkyloxy, cyano, nitro, polyhalo C_{1-6} alkyl and polyhalo C_{1-6} alkyloxy;

provided that $-X-R^2$ and/or R^3 is other than hydrogen; and


30 provided that R^4 is other than optionally substituted pyridyl when ring A represents pyrimidinyl.

Further preferred are those compounds of formula (I) or (I') wherein the compounds are compounds from one of the following formulae :

1)



2)



- Also preferred are those compounds of formula (a-1) wherein one or where possible more, preferably all of the following restrictions apply :
- (a) s is 1 and said R^3 substituent is placed at the para position compared to the NR^1 linker;
 - (b) s is 1 and said R^3 substituent is placed at the para position of the NR^1 linker and is other than C_{1-6} alkyloxy or polyhalo C_{1-6} alkyloxy;
 - (c) X is other than a direct bond or C_{1-6} alkyl;
 - (d) Z is other than S;
 - (e) $X-R^2$ is other than hydroxy, C_{1-6} alkyl, C_{1-6} alkyloxy, trihalomethyl, trihalomethyloxy, cyano C_{1-6} alkyl, aminocarbonyl;
 - (f) R^4 is an optionally substituted 5-membered heterocycle with at least 2 nitrogen atoms;
 - (g) R^2 is other than hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, and X is other than O, S, $C(=O)$, $S(=O)$, $S(=O)_2$, $-NH-S(=O)-$, $-NH-S(=O)_2-$, $-NH-C(=O)-$;
 - (h) R^2 is other than hydrogen.

20

Also preferred are those compounds of formula (a-2) wherein one or more, preferably all of the following restrictions apply

- (a) X is other than a direct bond or C_{1-6} alkyl;
- (b) R^2 is other than hydrogen, trifluoromethyl or C_{1-4} alkyl;
- (c) $X-R^2$ is other than hydroxy, C_{1-6} alkyl, C_{1-6} alkyloxy, trihalomethyl, trihalomethyloxy, cyano C_{1-6} alkyl, aminocarbonyl;

25


(d) R⁴ is an optionally substituted 5-membered heterocycle.

Further interesting compounds are those compounds of formula (I), (I'), (a-1) or (a-2) wherein R⁴ is an optionally substituted 5-membered heterocycle, in particular an optionally substituted imidazolyl or an optionally substituted triazolyl and/or wherein Z is a direct bond.

Particular preferred compounds of formula (I) or (I') are selected from
 N²-(1*H*-indazol-5-yl)-N⁴-(2,4,6-trimethylphenyl)-2,4-pyrimidinediamine;
 4-[[4-(1-methyl-1*H*-imidazol-2-yl)-2-pyrimidinyl]amino]-2-(phenylmethoxy)-benzonitrile;
 4-[[4-(1-methyl-1*H*-imidazol-2-yl)-2-pyrimidinyl]amino]-benzonitrile;
 a *N*-oxide, a pharmaceutically acceptable addition salt, a quaternary amine and a stereochemically isomeric form thereof.


Other preferred compounds of formula (I) or (I') are selected from
 N²-(6-morpholinyl-4-yl-pyridin-3-yl)-N⁴-(2,4,6-trimethyl-phenyl)-2,4-pyrimidinediamine;
 N²-(3*H*-benzimidazol-5-yl)-N⁴-(2,4,6-trimethyl-phenyl)-2,4-pyrimidinediamine;
 N²-(1*H*-indazol-6-yl)-N⁴-(2,4,6-trimethyl-phenyl)-2,4-pyrimidinediamine;
 N²-(5-bromo-pyridin-2-yl)-N⁴-(2,4,6-trimethyl-phenyl)-2,4-pyrimidinediamine;
 N²-(6-methoxy-pyridin-3-yl)-N⁴-(2,4,6-trimethyl-phenyl)-2,4-pyrimidinediamine;
 N²-benzothiazol-6-yl-N⁴-(2,4,6-trimethyl-phenyl)-2,4-pyrimidinediamine;
 N²-(1*H*-indazol-5-yl)-N⁴-(2,4,6-trimethyl-phenyl)-2,4-pyrimidinediamine;
 N²-(1*H*-benzotriazol-5-yl)-N⁴-(2,4,6-trimethyl-phenyl)-2,4-pyrimidinediamine;
 N²-benzo[1,3]dioxol-5-yl-N⁴-(2,4,6-trimethyl-phenyl)-2,4-pyrimidinediamine;
 N²-(6-chloro-pyridin-3-yl)-N⁴-(2,4,6-trimethyl-phenyl)-2,4-pyrimidinediamine;
 N²-(1*H*-indol-5-yl)-N⁴-(2,4,6-trimethyl-phenyl)-2,4-pyrimidinediamine;
 N²-quinolin-6-yl-N⁴-(2,4,6-trimethyl-phenyl)-2,4-pyrimidinediamine;
 4-[4-[(benzo[1,3]dioxol-5-ylmethyl)-amino]-pyrimidin-2-ylamino]-benzonitrile;
 4-[4-[(quinolin-3-methyl)-amino]-pyrimidin-2-ylamino]-benzonitrile;
 4-[4-[(furan-2-ylmethyl)-amino]-pyrimidin-2-ylamino]-benzonitrile;
 4-[4-[(thiophen-2-ylmethyl)-amino]-pyrimidin-2-ylamino]-benzonitrile;
 a *N*-oxide, a pharmaceutically acceptable addition salt, a quaternary amine and a stereochemically isomeric form thereof.

Compounds of formula (I) can be prepared by reacting an intermediate of formula (II) with an intermediate of formula (III) wherein W_1 represents a suitable leaving group, such as for example a halo atom, e.g. chloro, bromo and the like, in the presence of a suitable solvent, such as for example *N,N*-dimethylacetamide, acetonitrile, tetrahydrofuran, water, an alcohol, e.g. methanol, ethanol, isopropanol and the like, and optionally in the presence of a suitable acid, such as for example hydrochloric acid and the like.




Alternatively, the above reaction may also be performed in the presence of a suitable solvent, such as for example toluene, a suitable catalyst, such as tris (dibenzylidene acetone)dipalladium (0), a suitable ligand such as for example 2,2-bis(diphenylphosphino)-1,1'-binaphthyl, and a suitable base, such as for example sodium tert.butoxide.


Compounds of formula (I) can also be prepared by reacting an intermediate of formula (IV) wherein W_2 represents a suitable leaving group, such as for example a halo atom, e.g. chloro and the like, with an intermediate of formula (V) in the presence of a suitable solvent, such as for example toluene, a suitable catalyst, such as tris (dibenzylidene acetone)dipalladium (0), a suitable ligand such as for example 2,2-bis(diphenylphosphino)-1,1'-binaphthyl, and a suitable base, such as for example sodium tert.butoxide.




Compounds of formula (I) may also be prepared by reacting an intermediate of formula (VI), wherein W_3 represents a suitable leaving group, such as a halo atom, e.g. chloro and the like, with an intermediate of formula (VII) in the presence of a suitable solvent, such as 1,4-dioxane or an alcohol, e.g. methanol, ethanol, isopropanol and the like, or water, optionally in the presence of a suitable acid, such as hydrochloric acid and the like, or a suitable base, such as for example *N,N*-diisopropylethanamine.



- Compounds of formula (I) wherein Z is C(=O), said compounds being represented by formula (I-a), may be prepared by reacting an intermediate of formula (VIII), wherein
- 5 W₄ represents a suitable leaving group, such as a halo atom, e.g. chloro and the like, or an alcoholate, such as methanolate, ethanolate and the like, with an intermediate of formula (IX) in the presence of a suitable solvent, such as for example an alcohol, e.g. methanol, ethanol and the like.




- 10 Compounds of formula (I) wherein Z is a direct bond, said compounds being represented by formula (I-b), can be prepared by reacting an intermediate of formula (VI) with an intermediate of formula (X) in the presence of a suitable catalyst, such as for example palladium tetrakis(triphenylphosphine), a suitable base, such as for example disodium carbonate, and a suitable solvent, such as for example acetonitrile
- 15 and water.




- Compounds of formula (I) wherein Z is a direct bond and R⁴ represents 5-tetrazolyl, said compounds being represented by formula (I-c), can be prepared by reacting an intermediate of formula (XI) with sodium azide in the presence of a suitable salt, such
- 20 as for example *N,N*-diethylethanamine hydrochloric acid salt, and a suitable solvent, such as for example 1-methyl-2-pyrrolidinone.

-39-



Compounds of formula (I) wherein Z is a direct bond and ring A is pyrimidinyl with the NR¹ linker placed in position 2, said compounds being represented by formula (I-d), may be prepared by reacting an intermediate of formula (XX) with an intermediate of formula (XXI) in the presence of a suitable solvent, such as for example *N,N*-dimethylacetamide and a suitable base, such as for example sodium ethanolate.



In the above reaction, if R⁴ in a compound of formula (I-d) represents a heterocycle substituted with amino or aminocarbonyl, then R⁴ in an intermediate of formula (XXI) may represent a heterocycle substituted with -N=CH-N(CH₃)₂ or -C(=O)-N=CH-N(CH₃)₂.

In this and the following preparations, the reaction products may be isolated from the reaction medium and, if necessary, further purified according to methodologies generally known in the art such as, for example, extraction, crystallization, distillation, trituration and chromatography.

The compounds of formula (I) may further be prepared by converting compounds of formula (I) into each other according to art-known group transformation reactions.

The compounds of formula (I) may be converted to the corresponding *N*-oxide forms following art-known procedures for converting a trivalent nitrogen into its *N*-oxide form. Said *N*-oxidation reaction may generally be carried out by reacting the starting material of formula (I) with an appropriate organic or inorganic peroxide. Appropriate inorganic peroxides comprise, for example, hydrogen peroxide, alkali metal or earth alkaline metal peroxides, e.g. sodium peroxide, potassium peroxide; appropriate organic peroxides may comprise peroxy acids such as, for example, benzenecarboxylic acid or halo substituted benzenecarboxylic acid, e.g. 3-chlorobenzenecarboxylic acid, peroxyalkanoic acids, e.g. peroxyacetic acid, alkylhydroperoxides, e.g.

t.butyl hydro-peroxide. Suitable solvents are, for example, water, lower alcohols, e.g. ethanol and the like, hydrocarbons, e.g. toluene, ketones, e.g. 2-butanone, halogenated hydrocarbons, e.g. dichloromethane, and mixtures of such solvents.

- 5 Compounds of formula (I) wherein R^3 is halo, or wherein R^2 is substituted with halo, can be converted into a compound of formula (I) wherein R^3 is cyano, or wherein R^2 is substituted with cyano, by reaction with a suitable cyano-introducing agent, such as sodium cyanide or CuCN, optionally in the presence of a suitable catalyst, such as for example tetrakis(triphenylphosphine)palladium and a suitable solvent, such as
- 10 *N,N*-dimethylacetamide or *N,N*-dimethylformamide. A compound of formula (I) wherein R^3 is cyano, or wherein R^2 is substituted with cyano, can further be converted into a compound of formula (I) wherein R^3 is aminocarbonyl, or wherein R^2 is substituted with aminocarbonyl, by reaction with HCOOH, in the presence of a suitable acid, such as hydrochloric acid. A compound of formula (I) wherein R^3 is cyano, or
- 15 wherein R^2 is substituted with cyano, can also further be converted into a compound of formula (I) wherein R^3 is tetrazolyl, or wherein R^2 is substituted with tetrazolyl, by reaction with sodium azide in the presence of ammonium chloride and *N,N*-dimethylacetoacetamide.
- 20 Compounds of formula (I) wherein R^2 is substituted with halo, can also be converted into a compound of formula (I) wherein R^2 is substituted with mercapto, by reaction with disodium sulfide in the presence of a suitable solvent, such as, for example, 1,4-dioxane.
- 25 Compounds of formula (I) wherein R^2 is substituted with halo, can also be converted into a compound of formula (I) wherein R^2 is substituted with C_{1-6} alkylthio, by reaction with a reagent of formula alkaline metal⁺ S-C₁₋₆alkyl, e.g. Na⁺ S-C₁₋₆alkyl, in the presence of a suitable solvent, such as dimethylsulfoxide. The latter compounds can further be converted into a compound of formula (I) wherein R^2 is substituted with
- 30 C_{1-6} alkyl-S(=O)-, by reaction with a suitable oxidizing agent, such as a peroxide, e.g. 3-chlorobenzenecarboperoxoic acid, in the presence of a suitable solvent, such as an alcohol, e.g. ethanol.
- 35 Compounds of formula (I) wherein R^3 is halo, or wherein R^2 is substituted with halo, can also be converted into a compound of formula (I) wherein R^3 is C_{1-6} alkyloxy, or wherein R^2 is substituted with C_{1-6} alkyloxy, by reaction with alcoholate salt, such as,

for example, $\text{LiOC}_{1-6}\text{alkyl}$, in the presence of a suitable solvent, such as an alcohol, e.g. methanol.

Compounds of formula (I) wherein R^3 is halo, or wherein R^2 is substituted with halo, can also be converted into a compound of formula (I) wherein R^3 is hydroxy, or wherein R^2 is substituted with hydroxy, by reaction with a suitable carboxylate, e.g. sodium acetate, in a suitable reaction-inert solvent, such as, for example, dimethylsulfoxide, followed by treating the obtained reaction product with a suitable base, such as pyridine, and acetyl chloride.

Compounds of formula (I) wherein R^3 is halo, or wherein R^2 is substituted with halo, can also be converted into a compound of formula (I) wherein R^3 is a monocyclic, bicyclic or tricyclic saturated carbocycle; a monocyclic, bicyclic or tricyclic partially saturated carbocycle; a monocyclic, bicyclic or tricyclic aromatic carbocycle; a monocyclic, bicyclic or tricyclic saturated heterocycle; a monocyclic, bicyclic or tricyclic partially saturated heterocycle; a monocyclic, bicyclic or tricyclic aromatic heterocycle, or wherein R^2 is substituted with a monocyclic, bicyclic or tricyclic saturated carbocycle; a monocyclic, bicyclic or tricyclic partially saturated carbocycle; a monocyclic, bicyclic or tricyclic aromatic carbocycle; a monocyclic, bicyclic or tricyclic saturated heterocycle; a monocyclic, bicyclic or tricyclic partially saturated heterocycle; a monocyclic, bicyclic or tricyclic aromatic heterocycle, said substituents being represented by -L, by reaction with H-L in the presence of a suitable base, such as for example sodium hydroxide, dipotassium carbonate, sodium hydride, in the presence of a suitable solvent, such as, for example, 1,4-dioxane, *N,N*-dimethylacetamide, *N,N*-dimethylformamide.

Compounds of formula (I) wherein R^3 is chloro, or wherein R^2 is substituted with chloro, can be converted into a compound of formula (I) wherein R^3 is fluoro, or wherein R^2 is substituted with fluoro, by reaction with a suitable fluoride salt, such as for example potassium fluoride, in the presence of a suitable solvent, e.g. sulfolane.

Compounds of formula (I) wherein X-R^2 is hydrogen and wherein the R^3 substituent positioned at the meta position compared to the NR^1 linker, is halo, can be converted into a compound of formula (I) wherein said R^3 substituent is replaced by X-R^2 wherein X is other than a direct bond when R^2 is hydrogen, by reaction with H-X-R^2 in the presence of a suitable solvent, such as *N,N*-dimethylacetamide or

N,N-dimethylformamide optionally in the presence of a suitable base, such as for example *N,N*-diisopropylethanamine.

5 Compounds of formula (I) wherein R^2 is substituted with C_{1-4} alkyloxy C_{1-6} alkyl, can be converted into a compound of formula (I) wherein R^2 is substituted with hydroxy C_{1-6} alkyl, by dealkylating the ether in the presence of a suitable dealkylating agent, such as, for example, tribromoborane, and a suitable solvent, such as methylene chloride.

10 Compounds of formula (I) wherein R^3 or $X-R^2$ are C_{1-6} alkyloxycarbonyl, or wherein R^2 is substituted with C_{1-6} alkyloxycarbonyl, can be converted into a compound of formula (I) wherein R^3 or $X-R^2$ are aminocarbonyl, or wherein R^2 is substituted with aminocarbonyl or mono- or di(C_{1-6} alkyl)aminocarbonyl, by reaction with a suitable agent such as ammonia, $NH_2(C_{1-6}alkyl)$, $AlCH_3[N(C_{1-6}alkyl)_2]Cl$ optionally in the presence of a suitable acid, such as for example hydrochloric acid, and in the presence of a suitable solvent such as an alcohol, e.g. methanol; tetrahydrofuran; *N,N*-diisopropylethane.

20 Compounds of formula (I) wherein R^3 is hydrogen or wherein R^2 is unsubstituted, can be converted into a compound wherein R^3 is halo or wherein R^2 is substituted with halo, by reaction with a suitable halogenating agent, such as, for example Br_2 or 1-(chloromethyl)-4-fluoro-1,4-diazoniabicyclo[2,2,2]octane bis[tetrafluoroborate], in the presence of a suitable solvent, such as tetrahydrofuran, water, acetonitrile, chloroform and optionally in the presence of a suitable base such as *N,N*-diethylethanamine.

30 Compounds of formula (I) wherein R^3 or $-X-R^2$ are C_{1-6} alkyloxycarbonyl or wherein R^2 is substituted with C_{1-6} alkyloxycarbonyl, can be converted into a compound of formula (I) wherein R^3 or $X-R^2$ are hydroxymethyl or wherein R^2 is substituted with hydroxymethyl, by reaction with a suitable reducing agent, such as for example $LiAlH_4$.

35 Compounds of formula (I) wherein $-X-R^2$ is $-O-CH_2-(optionally\ substituted)phenyl$ may be converted into a compound of formula (I) wherein $-X-R^2$ represents OH, by reaction with a suitable reducing agent, such as H_2 , in the presence of a suitable catalyst, such as for example palladium on charcoal, and a suitable solvent, such as for example an alcohol, e.g. methanol, ethanol and the like, or *N,N*-dimethylacetamide.

- Compounds of formula (I) wherein $-X-R^2$ represents OH, may be converted into a compound of formula (I) wherein $-X-R^2$ represents $-O-X_1-R^2$ by reaction with $W_1-X_1-R^2$ wherein W_1 represents a suitable leaving group, such as for example a halo atom, e.g. chloro, and wherein $-O-X_1$ represents those linkers falling under the definition of X which are attached to the phenyl ring via a O atom (in said definition X_1 represents that part of the linker wherein the O atom is not included), in the presence of a suitable base, such as for example dipotassium carbonate, and a suitable solvent, such as for example *N,N*-dimethylacetamide.
- Compounds of formula (I) wherein R^3 is nitro, or wherein R^2 is substituted with nitro, may be converted into a compound of formula (I) wherein R^3 is amino or wherein R^2 is substituted with amino, by reaction with a suitable reducing agent, such as for example H_2 , in the presence of a suitable catalyst, such as for example palladium on charcoal, a suitable catalyst poison, such as for example a thiophene solution, and a suitable solvent, such as for example an alcohol, e.g. methanol, ethanol and the like.

- Compounds of formula (I) wherein R^2 is substituted with NH_2 , can be converted into a compound of formula (I) wherein R^2 is substituted with $NH-S(=O)_2-NR^5R^6$, by reaction with $W_1-S(=O)_2-NR^5R^6$ wherein W_1 represents a suitable leaving group such as for example a halo atom, e.g. chloro, in the presence of a suitable solvent, such as for example *N,N*-dimethylacetamide and a suitable base, such as for example *N,N*-diethylethanamine.


- Some of the compounds of formula (I) and some of the intermediates in the present invention may contain an asymmetric carbon atom. Pure stereochemically isomeric forms of said compounds and said intermediates can be obtained by the application of art-known procedures. For example, diastereoisomers can be separated by physical methods such as selective crystallization or chromatographic techniques, e.g. counter current distribution, liquid chromatography and the like methods. Enantiomers can be obtained from racemic mixtures by first converting said racemic mixtures with suitable resolving agents such as, for example, chiral acids, to mixtures of diastereomeric salts or compounds; then physically separating said mixtures of diastereomeric salts or compounds by, for example, selective crystallization or chromatographic techniques, e.g. liquid chromatography and the like methods; and finally converting said separated diastereomeric salts or compounds into the corresponding enantiomers. Pure stereochemically isomeric forms may also be obtained from the pure stereochemically

isomeric forms of the appropriate intermediates and starting materials, provided that the intervening reactions occur stereospecifically.


5 An alternative manner of separating the enantiomeric forms of the compounds of formula (I) and intermediates involves liquid chromatography, in particular liquid chromatography using a chiral stationary phase.

10 Some of the intermediates and starting materials are known compounds and may be commercially available or may be prepared according to art-known procedures, such as those described in WO 99/50250, WO 00/27825 or EP 0,834,507.

Intermediates of formula (II) wherein R^1 is hydrogen, said intermediates being represented by formula (II-a), can be prepared by reducing an intermediate of formula (XII) in the presence of a suitable reducing agent, such as for example H_2 , a suitable catalyst, such as for example palladium on charcoal, a suitable catalyst poison, such as for example a thiophene solution, and a suitable solvent, such as for example tetrahydrofuran or an alcohol, e.g. methanol, ethanol and the like.




20 Intermediates of formula (III) can be prepared by reacting an intermediate of formula (XIII) wherein W_1 is as defined hereinabove, with an intermediate of formula (XIV) in the presence of a suitable solvent, such as for example acetonitrile or dioxane, and optionally in the presence of a suitable base, such as for example *N,N*-diisopropylethanamine.




25 Intermediates of formula (IV) can be prepared by reacting an intermediate of formula (XV) wherein W_2 is as defined hereinabove, with an intermediate of formula (XVI) wherein W_2 is as defined hereinabove.


-45-




Intermediates of formula (XVI) can be prepared by reacting an intermediate of formula (XVII) with a leaving group introducing agent of formula (XVIII) wherein W₂ represents the leaving group and R represents the remaining of the leaving group introducing agent, such as for example POCl₃.



Intermediates of formula (VI) can be prepared by reacting an intermediate of formula (XIX) wherein W₃ is as defined hereinabove, with an intermediate of formula (III) in the presence of a suitable solvent, such as for example an alcohol, e.g. methanol, ethanol, isopropanol and the like, and a suitable acid, such as for example hydrochloric acid.




Intermediates of formula (VIII) wherein ring A is pyrimidinyl with the NR¹ linker in position 2 and W₄ represents an alcoholate, i.e. C₁₋₆alkylo-, said intermediates being represented by formula (VIII-a), may be prepared by reacting an intermediate of formula (XX) with an intermediate of formula (XXII) in the presence of a suitable solvent, such as for example *N,N*-dimethylacetamide.




Intermediates of formula (XXII) can be prepared by reacting an intermediate of formula (XXIII) with 1,1-diethoxy-*N,N*-dimethyl-methanamine.


-46-



Intermediates of formula (XX) can be prepared by reacting an intermediate of formula (V) with cyanamide in the presence of a suitable solvent, such as for example diglyme.



- 5 Intermediates of formula (XXI) can be prepared by reacting an intermediate of formula (XXIV) with 1,1-diethoxy-*N,N*-dimethyl-methanamine.



- 10 The compounds of formula (I) or (I') inhibit Glycogen synthase kinase 3 (GSK3), in particular glycogen synthase kinase 3 beta (GSK3β). They are selective Glycogen synthase kinase 3 inhibitors. Specific inhibitory compounds are superior therapeutic agents since they are characterized by a greater efficacy and lower toxicity by virtue of their specificity.

Synonyms for GSK3 are tau protein kinase I (TPK I), FA (Factor A) kinase, kinase FA and ATP-citrate lysase kinase (ACLK).

15

- Glycogen synthase kinase 3 (GSK3), which exists in two isoforms, i.e. GSK3α and GSK3β, is a proline-directed serine/threonine kinase originally identified as an enzyme that phosphorylates glycogen synthase. However, it has been demonstrated that GSK3 phosphorylates numerous proteins in vitro such as glycogen synthase, phosphatase inhibitor I-2, the type-II subunit of cAMP-dependent protein kinase, the G-subunit of phosphatase-1, ATP-citrate lyase, acetyl coenzyme A carboxylase, myelin basic protein, a microtubule-associated protein, a neurofilament protein, an N-CAM cell adhesion molecule, nerve growth factor receptor, c-Jun transcription factor, JunD transcription factor, c-Myb transcription factor, c-Myc transcription factor, L-Myc transcription factor, adenomatous polyposis coli tumor suppressor protein, tau protein and β-catenin.
- 20
- 25

The above-indicated diversity of proteins which may be phosphorylated by GSK3 implies that GSK3 is implicated in numerous metabolic and regulatory processes in cells.

5 GSK3 inhibitors may therefore be useful in the prevention or treatment of diseases mediated through GSK3 activity such as bipolar disorder (in particular manic depression), diabetes, Alzheimer's disease, leukopenia, FTDP-17 (Fronto-temporal dementia associated with Parkinson's disease), cortico-basal degeneration, progressive supranuclear palsy, multiple system atrophy, Pick's disease, Niemann Pick's disease
10 type C, Dementia Pugilistica, dementia with tangles only, dementia with tangles and calcification, Down syndrome, myotonic dystrophy, Parkinsonism-dementia complex of Guam, aids related dementia, Postencephalic Parkinsonism, prion diseases with tangles, subacute sclerosing panencephalitis, frontal lobe degeneration (FLD), argyrophilic grains disease, subacute sclerotizing panencephalitis (SSPE) (late
15 complication of viral infections in the central nervous system), inflammatory diseases, cancer, dermatological disorders such as baldness, neuronal damage, schizophrenia, pain, in particular neuropathic pain. GSK3 inhibitors can also be used to inhibit sperm motility and can therefore be used as male contraceptives.

In particular, the compounds of the present invention are useful in the prevention or
20 treatment of Alzheimer's disease, diabetes, especially type 2 diabetes (non insulin dependent diabetes).

The major neuropathological landmarks in Alzheimer's disease are neuronal loss, the deposition of amyloid fibers and paired helical filaments (PHF) or neurofibrillary
25 tangles (NFT). Tangle formation appears to be the consequence of accumulation of aberrantly phosphorylated tau protein. This aberrant phosphorylation destabilizes neuronal cytoskeleton, which leads to reduced axonal transport, deficient functioning and ultimately neuronal death. The density of neurofibrillary tangles has been shown to parallel duration and severity of Alzheimer's disease. Reduction of the degree of tau
30 phosphorylation can provide for neuroprotection and can prevent or treat Alzheimer's disease or can slow the progression of the disease. As mentioned hereinabove, GSK3 phosphorylates tau protein. Thus compounds having an inhibitory activity for GSK3 may be useful for the prevention or the treatment of Alzheimer's disease.

35 Insulin regulates the synthesis of the storage polysaccharide glycogen. The rate-limiting step in the glycogen synthesis is catalyzed by the enzyme glycogen synthase. It is believed that glycogen synthase is inhibited by phosphorylation and that insulin

stimulates glycogen synthase by causing a net decrease in the phosphorylation of this enzyme. Thus, in order to activate glycogen synthase, insulin must either activate phosphatases or inhibit kinases, or both.

It is believed that glycogen synthase is a substrate for glycogen synthase kinase 3 and that insulin inactivates GSK3 thereby promoting the dephosphorylation of glycogen synthase.

In addition to the role of GSK3 in insulin-induced glycogen synthesis, GSK3 may also play a role in insulin resistance. It is believed that GSK3 dependent Insulin Receptor Substrate-1 phosphorylation contributes to insulin resistance.

Therefore, GSK3 inhibition may result in the increased deposition of glycogen and a concomitant reduction of blood glucose, thus mimicking the hypoglycemic effect of insulin. GSK3 inhibition provides an alternative therapy to manage insulin resistance commonly observed in non insulin dependent diabetes mellitus and obesity. GSK3 inhibitors may thus provide a novel modality for the treatment of type 1 and type 2 diabetes.

GSK3 inhibitors, in particular GSK3 β inhibitors, may also be indicated for use in the prevention or the treatment of pain, in particular neuropathic pain.

After axotomy or CCI, neuronal cells die through an apoptotic pathway and the morphological changes correlate with the onset of hyperalgesia and/or allodynia.

The induction of apoptosis is probably triggered by a reduced supply of neurotrophic factors as the time course of neuronal loss is positively altered by administration of neurotrophins. GSK, in particular GSK3 β , has been shown to be involved in the initiation of the apoptotic cascade and trophic factor withdrawal stimulates the GSK3 β apoptosis pathway.

In view of the above, GSK3 β inhibitors might reduce signals of and even prevent levels of neuropathic pain.

Due to their GSK3 inhibitory properties, particularly their GSK3 β inhibitory properties, the compounds of formula (I) or (I'), their *N*-oxides, pharmaceutically acceptable addition salts, quaternary amines and stereochemically isomeric forms thereof, are useful to prevent or treat GSK3 mediated diseases, in particular GSK3 β mediated diseases, such as bipolar disorder (in particular manic depression), diabetes, Alzheimer's disease, leukopenia, FTDP-17 (Fronto-temporal dementia associated with Parkinson's disease), cortico-basal degeneration, progressive supranuclear palsy, multiple system atrophy, Pick's disease, Niemann Pick's disease type C, Dementia Pugilistica, dementia with tangles only, dementia with tangles and calcification, Down

syndrome, myotonic dystrophy, Parkinsonism-dementia complex of Guam, aids related dementia, Postencephalic Parkinsonism, prion diseases with tangles, subacute sclerosing panencephalitis, frontal lobe degeneration (FLD), argyrophilic grains disease, subacute sclerotizing panencephalitis (SSPE) (late complication of viral
5 infections in the central nervous system), inflammatory diseases, cancer, dermatological disorders such as baldness, neuronal damage, schizophrenia, pain, in particular neuropathic pain. The present compounds are also useful as male contraceptives. In general, the compounds of the present invention may be useful in the treatment of warm-blooded animals suffering from disease mediated through
10 GSK3, in particular GSK3 β , or they may be useful to prevent warm-blooded animals to suffer from disease mediated through GSK3, in particular GSK3 β . More in particular, the compounds of the present invention may be useful in the treatment of warm-blooded animals suffering from Alzheimer's disease, diabetes, especially type 2 diabetes, cancer, inflammatory diseases or bipolar disorder.

15 In view of the above described pharmacological properties, the compounds of formula (I) or any subgroup thereof, their N-oxides, pharmaceutically acceptable addition salts, quaternary amines and stereochemically isomeric forms, may be used as a medicine. In particular, the present compounds can be used for the manufacture of a medicament for
20 treating or preventing diseases mediated through GSK3, in particular GSK3 β . More in particular, the present compounds can be used for the manufacture of a medicament for treating or preventing Alzheimer's disease, diabetes, especially type 2 diabetes, cancer, inflammatory diseases or bipolar disorder.

25 In view of the utility of the compounds of formula (I) or (I'), there is provided a method of treating warm-blooded animals, including humans, suffering from or a method of preventing warm-blooded animals, including humans, to suffer from diseases mediated through GSK3, in particular GSK3 β , more in particular a method of
30 treating or preventing Alzheimer's disease, diabetes, especially type 2 diabetes, cancer, inflammatory diseases or bipolar disorder. Said method comprises the administration, preferably oral administration, of an effective amount of a compound of formula (I) or (I'), a N-oxide form, a pharmaceutically acceptable addition salt, a quaternary amine or a possible stereoisomeric form thereof, to warm-blooded animals, including humans.

35 The present invention also provides compositions for preventing or treating diseases mediated through GSK3, in particular GSK3 β , comprising a therapeutically effective amount of a compound of formula (I) or (I') and a pharmaceutically acceptable carrier

or diluent.

The compounds of the present invention or any subgroup thereof may be formulated into various pharmaceutical forms for administration purposes. As appropriate
5 compositions there may be cited all compositions usually employed for systemically administering drugs. To prepare the pharmaceutical compositions of this invention, an effective amount of the particular compound, optionally in addition salt form, as the active ingredient is combined in intimate admixture with a pharmaceutically acceptable carrier, which carrier may take a wide variety of forms depending on the form of
10 preparation desired for administration. These pharmaceutical compositions are desirable in unitary dosage form suitable, particularly, for administration orally, rectally, percutaneously, or by parenteral injection. For example, in preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed such as, for example, water, glycols, oils, alcohols and the like in the case of
15 oral liquid preparations such as suspensions, syrups, elixirs, emulsions and solutions; or solid carriers such as starches, sugars, kaolin, diluents, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules, and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit forms, in which case solid pharmaceutical carriers are
20 obviously employed. For parenteral compositions, the carrier will usually comprise sterile water, at least in large part, though other ingredients, for example, to aid solubility, may be included. Injectable solutions, for example, may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution. Injectable suspensions may also be prepared in which case
25 appropriate liquid carriers, suspending agents and the like may be employed. Also included are solid form preparations which are intended to be converted, shortly before use, to liquid form preparations. In the compositions suitable for percutaneous administration, the carrier optionally comprises a penetration enhancing agent and/or a suitable wetting agent, optionally combined with suitable additives of any nature in
30 minor proportions, which additives do not introduce a significant deleterious effect on the skin. Said additives may facilitate the administration to the skin and/or may be helpful for preparing the desired compositions. These compositions may be administered in various ways, e.g., as a transdermal patch, as a spot-on, as an ointment. The compounds of the present invention may also be administered via inhalation or
35 insufflation by means of methods and formulations employed in the art for administration via this way. Thus, in general the compounds of the present invention may be administered to the lungs in the form of a solution, a suspension or a dry

powder. Any system developed for the delivery of solutions, suspensions or dry powders via oral or nasal inhalation or insufflation are suitable for the administration of the present compounds.

5 It is especially advantageous to formulate the aforementioned pharmaceutical compositions in unit dosage form for ease of administration and uniformity of dosage. Unit dosage form as used herein refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required
10 pharmaceutical carrier. Examples of such unit dosage forms are tablets (including scored or coated tablets), capsules, pills, powder packets, wafers, suppositories, injectable solutions or suspensions and the like, and segregated multiples thereof.

The present compounds are orally active compounds, and are preferably orally
15 administered.

The exact dosage, the therapeutically effective amount and frequency of administration depends on the particular compound of formula (I) or (I') used, the particular condition being treated, the severity of the condition being treated, the age, weight, sex, extent of disorder and general physical condition of the particular patient as well as other
20 medication the individual may be taking, as is well known to those skilled in the art. Furthermore, it is evident that said effective daily amount may be lowered or increased depending on the response of the treated subject and/or depending on the evaluation of the physician prescribing the compounds of the instant invention.

25 When used as a medicament to prevent or treat Alzheimer's disease, the compounds of formula (I) or (I') may be used in combination with other conventional drugs used to combat Alzheimer's disease, such as galantamine, donepezil, rivastigmine or tacrine. Thus, the present invention also relates to the combination of a compound of formula (I) or (I') and another agent capable of preventing or treating Alzheimer's disease. Said
30 combination may be used as a medicine. The present invention also relates to a product containing (a) a compound of formula (I) or (I'), and (b) another agent capable of preventing or treating Alzheimer's disease, as a combined preparation for simultaneous, separate or sequential use in the prevention or treatment of Alzheimer's disease. The different drugs may be combined in a single preparation together with
35 pharmaceutically acceptable carriers.

When used as a medicament to prevent or treat type 2 diabetes, the compounds of formula (I) or (I') may be used in combination with other conventional drugs used to combat type 2 diabetes, such as glibenclamide, chlorpropamide, gliclazide, glipizide, gliquidon, tolbutamide, metformin, acarbose, miglitol, nateglinide, repaglinide, 5 acetohexamide, glimepiride, glyburide, tolazamide, troglitazone, rosiglitazone, pioglitazone, isaglitazone.

Thus, the present invention also relates to the combination of a compound of formula (I) or (I') and another agent capable of preventing or treating type 2 diabetes. Said combination may be used as a medicine. The present invention also relates to a product 10 containing (a) a compound of formula (I) or (I'), and (b) another agent capable of preventing or treating type 2 diabetes, as a combined preparation for simultaneous, separate or sequential use in the prevention or treatment of type 2 diabetes. The different drugs may be combined in a single preparation together with pharmaceutically acceptable carriers.

15 When used as a medicament to prevent or treat cancer, the compounds of formula (I) or (I') may be used in combination with other conventional drugs used to combat cancer such as platinum coordination compounds for example cisplatin or carboplatin; taxane compounds for example paclitaxel or docetaxel; camptothecin compounds for example 20 irinotecan or topotecan; anti-tumour vinca alkaloids for example vinblastine, vincristine or vinorelbine; anti-tumour nucleoside derivatives for example 5-fluorouracil, gemcitabine or capecitabine; nitrogen mustard or nitrosourea alkylating agents for example cyclophosphamide, chlorambucil, carmustine or lomustine; anti-tumour anthracycline derivatives for example daunorubicin, doxorubicin or idarubicin; HER2 25 antibodies for example trastuzumab; and anti-tumour podophyllotoxin derivatives for example etoposide or teniposide; and antiestrogen agents including estrogen receptor antagonists or selective estrogen receptor modulators preferably tamoxifen, or alternatively toremifene, droloxifene, faslodex and raloxifene; aromatase inhibitors such as exemestane, anastrozole, letrozole and vorozole; differentiating agents for 30 example retinoids, vitamin D and DNA methyl transferase inhibitors for example azacytidine; kinase inhibitors for example flavoperidol and imatinib mesylate or farnesyltransferase inhibitors for example R115777.

Thus, the present invention also relates to the combination of a compound of formula (I) or (I') and another agent capable of preventing or treating cancer. Said combination 35 may be used as a medicine. The present invention also relates to a product containing (a) a compound of formula (I) or (I'), and (b) another agent capable of preventing or treating cancer, as a combined preparation for simultaneous, separate or sequential use

in the prevention or treatment of cancer. The different drugs may be combined in a single preparation together with pharmaceutically acceptable carriers.

When used as a medicament to prevent or treat bipolar disorder, the compounds of formula (I) or (I') may be used in combination with other conventional drugs used to combat bipolar disorder such as atypical antipsychotics, anti-epileptics, benzodiazepines, lithium salts, for example olanzapine, risperidone, carbamazepine, valproate, topiramate.

Thus, the present invention also relates to the combination of a compound of formula (I) or (I') and another agent capable of preventing or treating bipolar disorder. Said combination may be used as a medicine. The present invention also relates to a product containing (a) a compound of formula (I) or (I'), and (b) another agent capable of preventing or treating bipolar disorder, as a combined preparation for simultaneous, separate or sequential use in the prevention or treatment of bipolar disorder. The different drugs may be combined in a single preparation together with pharmaceutically acceptable carriers.

When used as a medicament to prevent or treat inflammatory diseases, the compounds of formula (I) or (I') may be used in combination with other conventional drugs used to combat inflammatory diseases such as steroids, cyclooxygenase-2 inhibitors, non-steroidal-anti-inflammatory drugs, TNF- α antibodies, such as for example acetylsalicylic acid, bufexamac, diclofenac potassium, sulindac, diclofenac sodium, ketorolac trometamol, tolmetine, ibuprofen, naproxen, naproxen sodium, tiaprofen acid, flurbiprofen, mefenamic acid, niflumonic acid, meclofenamate, indomethacin, proglumetacine, ketoprofen, nabumetone, paracetamol, piroxicam, tenoxicam, nimesulide, fenylbutazon, tramadol, beclomethasone dipropionate, betamethasone, beclomethasone, budesonide, fluticasone, mometasone, dexamethasone, hydrocortisone, methylprednisolone, prednisolone, prednisone, triamcinolone, celecoxib, rofecoxib, infliximab, leflunomide, etanercept, CPH 82, methotrexate, sulfasalazine.

Thus, the present invention also relates to the combination of a compound of formula (I) or (I') and another agent capable of preventing or treating inflammatory diseases. Said combination may be used as a medicine. The present invention also relates to a product containing (a) a compound of formula (I) or (I'), and (b) another agent capable of preventing or treating inflammatory diseases, as a combined preparation for simultaneous, separate or sequential use in the prevention or treatment of inflammatory

disorders. The different drugs may be combined in a single preparation together with pharmaceutically acceptable carriers.

Experimental part

5

Hereinafter, "DIPE" is defined as diisopropyl ether, "DMA" is defined as *N,N*-dimethylacetamide, "DMF" is defined as *N,N*-dimethylformamide.

A. Preparation of the intermediate compounds

10 Example A1


Reaction under Argon atmosphere. 2,4,6-Trimethylaniline (0.0678 mol) was added to 2,4-dichloropyrimidine (0.0664 mol) in 1,4-dioxane (100 ml). *N,N*-di(1-methylethyl)-ethaneamine (*N,N*-diisopropylethanamine) (0.0830mol) was added. The reaction mixture was stirred and refluxed for 4 days and the solvent was evaporated. The residue
15 was dissolved in CH₂Cl₂, washed with a saturated NaHCO₃ solution, then dried (Na₂SO₄), filtered and the solvent was evaporated to give 17.1 g solid residue. This solid was dissolved in CH₂Cl₂:hexane (1:1; 150 ml), and the resulting solution was concentrated to 100 ml, then filtered. The residue was purified by column chromatography on KP-Sil (eluent: CH₂Cl₂). The desired fractions were collected and
20 the solvent was evaporated. The less polar fraction was stirred in CH₂Cl₂ for 3 hours and filtered, yielding 0.44 g 4-chloro-*N*-(2,4,6-trimethylphenyl)-2-pyrimidinamine. A second fraction was recrystallized from acetonitrile, filtered off and dried, yielding 2-chloro-*N*-(2,4,6-trimethyl-phenyl)-4-pyrimidinamine (intermediate 1).

Example A2

25 A mixture of 4-[(4-hydroxy-2-pyrimidinyl)amino]-benzonitrile (0.12 mol) in POCl₃ (90 ml) was stirred and refluxed under Argon for 20 minutes. The reaction mixture was slowly poured onto 750 ml ice/water, and the solid was separated by filtration. The solid was suspended in 500 ml water, and the pH of the suspension was adjusted to neutral by adding a 20% NaOH solution. The solid was again separated by filtration,
30 suspended in 200 ml 2-propanone, and 1 L methylene chloride was added. The mixture was heated till all solid had dissolved. After cooling to room temperature, the aqueous layer was separated, and the organic layer was dried over magnesium sulfate. During removal of the drying agent by filtration, a solid formed in the filtrate. Further cooling of the filtrate in the freezer, followed by filtration, yielded 21.38 g of
35 4-[(4-chloro-2-pyrimidinyl)amino]-benzonitrile (intermediate 2).


Example A3

a) The preparation of intermediate 3



A mixture of 4-amino-2-(2-phenylethoxy)benzonitrile (0.012 mol) in 1,1'-oxybis[2-methoxyethane] (50 ml) was stirred at 100°C, cyanamide (1 ml) was added dropwise. The reaction mixture was stirred at 100°C for 30 minutes and at room temperature overnight. Extra cyanamide (1ml) was added and the reaction mixture was stirred at 100°C for 24 hours. Extra cyanamide (1ml) was added and the reaction mixture was stirred further at 100°C for 24 hours. The solvent was evaporated. The residue (6.3g) was purified by high-performance liquid chromatography over Hyperprep C18 HS BDS (eluent : (0.5% NH₄Ac in H₂O/CH₃CN 90/10)/MeOH/CH₃CN 75/25/0; 0/50/50; 0/0/100). The first fraction was collected and the solvent was evaporated, yielding 1.36g (42.6%) of intermediate 3.


b) The preparation of intermediate 4



Cyanamide (0.0444 mol) was added portionwise at 80°C to a solution of 4-amino-2-(phenylmethoxy)-benzonitrile hydrochloric acid (1:1) (0.0444 mol) in 1,1'-oxybis[2-methoxyethane] (90 ml). The mixture was stirred at 100°C for 3 hours, cooled to room temperature and poured out into ice water. The precipitate was filtered. The filtrate was evaporated. The residue was taken up in CH₂Cl₂ and crystallized. The precipitate was filtered off and dried, yielding 12.5 g of intermediate 4 (90%) 9mp. 132°C).

Example A4

a) The preparation of intermediate 5




1,1-Diethoxy-*N,N*-dimethylmethanamine (0.153 mol) was added over 15 minutes to ethyl 2-oxopropanoate (0.153 mol) at room temperature while vigorously stirring. The temperature was kept below 30°C. The reaction mixture was heated to 80°C for 24

hours. The residue was purified by distillation, yielding 9.8 g (37.4%) of intermediate 5.

Example A5


The preparation of intermediate 6



To a solution of intermediate 3 (0.00477 mol) in DMA (30 ml), intermediate 5 (0.0057 mol) was added. The reaction mixture was stirred for 1 hour at room temperature and overnight at 100°C. This mixture was again stirred at 100°C for 24 hours and then cooled to room temperature. The residue was poured out in a saturated NaCl-solution (300 ml), filtered and washed with H₂O. The precipitate was dissolved in 2-propanone and this solution was concentrated in vacuum. The obtained solid was crystallized from EtOH, filtered and dried at 40°C under vacuum, yielding 0.64 g (35.8%) of intermediate 6.


Example A6

a) The preparation of intermediate 7



1-(1-Methyl-1H-imidazol-2-yl)ethanone (0.0028 mol) in 1,1-diethoxy-*N,N*-dimethylmethanamine (10 ml) was stirred and refluxed for 12 hours; then allowed to cool to room temperature. The precipitate was filtered off and dried (50°C, vacuum), yielding 0.42 g (82.3%) of intermediate 7.

b) The preparation of intermediate 8




A mixture of 5-acetyl-3-pyridinecarboxamide in DMF/DMA (100 ml) was stirred at 80°C overnight. The precipitate was filtered off and dried (vacuum), yielding 4g of intermediate 8.

B. Preparation of the final compounds

Example B1


The preparation of compound 1



A suspension of 6-bromo-2,3'-bipyridine (0.00042 mol), tris (dibenzylidene acetone)dipalladium (0) (0.0085 mmol), 2,2-bis(diphenylphosphino)-1,1'-binaphthyl (0.0128 mmol) and sodium tert. butoxide (0.00051 mol) in toluene (4 ml) was degassed with N₂. 3-(Trifluoromethyl)-benzenamine (0.00051 mol) was added while stirring at
5 room temperature. The resulting reaction mixture was stirred for 18 hours at 90 °C. The reaction mixture was washed with water (1 ml), then filtered through Extrelut and the filtrate was evaporated, yielding 0.027 g of compound 1.


Example B2

a) The preparation of compound 2



10 A mixture of methanol (4 ml), water (4 ml) and HCl/2-propanol (0.2 ml) was added to a mixture of intermediate 2 (0.000242 mol) and 1*H*-indazol-5-amine (0.000242 mol). The reaction mixture was stirred overnight at 60 °C. The desired compound was isolated and purified by high performance liquid chromatography over RP C-18 (eluent: (0.5% NH₄OAc in H₂O/CH₃CN 90/10)/CH₃OH/CH₃CN 70/15/15; 0/50/50;
15 0/0/100). The desired fractions were collected and the solvent was evaporated, yielding 0.017 g of compound 2.

20 b) The preparation of compound 3




A mixture of intermediate 2 (0.000325 mol), 3-quinolinemethanamine (0.000357 mol) and *N,N*-diisopropylethanamine (0.0005 mmol) in 1,4-dioxane (4 ml) was stirred at 95 °C for 3 days. The solvent was evaporated and the residue was taken up in methylene chloride. Water (1 ml) was added. The mixture was stirred for 30 minutes; then
25 extracted through Extrelut. The Extrelut was washed twice with methylene chloride. The extract was purified by high performance liquid chromatography over silica gel (eluent : methylene chloride/methanol 100/0; 90/10). The desired fractions were collected and the solvent was evaporated, yielding 0.048 g of compound 3.

-58-

Example B3


c) The preparation of compound 4



A mixture of intermediate 6 (0.002 mol) and piperazine (0.002 mol) in methanol (15 ml) was stirred at room temperature for 1 day; then stirred at 50°C for 1 day. The solvent was evaporated. The residue was dissolved in CH₂Cl₂/MeOH (95/5) and washed with H₂O. The separated organic layer was dried (MgSO₄), filtered and the solvent was evaporated. The residue was purified over silica gel on a glass filter (eluent : CH₂Cl₂/MeOH 92.5/7.5). The desired fractions were collected and the solvent was evaporated. The residue was stirred in diethyl ether. The precipitate was filtered off, washed and dried (50°C, vacuum), yielding 0.32g of compound 4.

Example B4


d) The preparation of compound 5



A mixture of 6-chloro-*N*-(2,3-dichlorophenyl)-3-pyridazinamine (0.00037 mol) and palladium tetrakis(triphenylphosphine) (0.000018 mol) in acetonitrile (10 ml) was stirred (and degassed) under N₂ atmosphere and heated to 90 °C. A solution of 3-pyridinylboronic acid (2 equiv, 0.00074 mol) in 0.4 M Na₂CO₃ in H₂O (10 ml) (previously degassed under N₂) was added dropwise and the resulting reaction mixture was stirred for 18 hours under N₂ atmosphere. The mixture was filtered warm and the filter residue was washed with CH₃CN (1 ml). The filtrate was diluted with CH₂Cl₂ (4 ml), then filtered/dried through Extrelut and the filtrate was evaporated. The residue was purified by preparative column chromatography. The product fractions were collected and the solvent was evaporated, yielding 0.027 g of compound 5.

Example B5


a) The preparation of compound 6



NaOEt (0.68g) was added to a solution of intermediate 4 (0.01 mol) in DMA (25 ml).

The reaction mixture was stirred at room temperature for 1 hour. Intermediate 4 (0.01 mol) was dissolved in DMA (5 ml) and EtOH (15 ml). This solution was added dropwise to the reaction mixture at room temperature. The mixture was stirred at room temperature for 2 hours; then gently heated to 100°C and stirred for 3 days at this temperature. This fraction was purified by high performance liquid chromatography over hyperprep C18 (0.5% NH₄OAc in H₂O/CH₃CN 90/10)/CH₃CN 63/37; 25/75; 0/100). The desired fractions were collected and the solvent was evaporated. The residue was suspended in DIPE and stirred overnight. The precipitate was filtered off and dried (40°C, vacuum), yielding 1.34g (35%) of compound 6.



b) The preparation of compound 37



A mixture of guanidine, [3-(trifluoromethyl)phenyl]-, mononitrate (250 mg), intermediate 8 (220 mg), sodium methanolate (0.05g) and methoxyethanol (20 ml) was stirred at 110°C for 1 day. The temperature was raised to 160°C overnight. The reaction mixture was cooled, the solvent was evaporated and the residue was suspended in acetone. The precipitate was filtered off, washed and dried (vacuum), yielding 248,1 mg of compound 37.

Example B6

The preparation of compound 7




(compound 8) (0.013 mol) (prepared according to Example B5)

in methanol and DMA (50 ml) was hydrogenated at 50°C with Pd/C 10% (1 g) as a catalyst. After uptake of hydrogen (1 equiv), the catalyst was filtered off and the mixture was concentrated till 100 ml. The formed precipitate was filtered off, washed with DIPE and dried, yielding 2.6 g of compound 7.

Tables 1 to 4 list the compounds of formula (I) which were prepared according to one of the above examples.


Table 1:



5


Co. No.	Ex. No.	R ⁴	Physical data
9	B2a		
10	B2a	1 <i>H</i> -benzimidazol-5-yl	
11	B2a	1 <i>H</i> -indazol-6-yl	
12	B2a	5-bromo-2-pyrimidinyl	H ₂ O(1:1)
13	B2a	5-bromo-2-pyridinyl	
14	B2a	6-methoxy-3-pyridinyl	
15	B2a	6-benzothiazolyl	
2	B2a	1 <i>H</i> -indazol-5-yl	
16	B2a	1 <i>H</i> -benzotriazol-5-yl	
17	B2a	1,3-benzodioxol-5-yl	
18	B2a	6-chloro-3-pyridinyl	
19	B2a	1 <i>H</i> -indol-5-yl	
20	B2a	6-quinolinyl	

Table 2:




Co. No.	Ex. No.	R ⁴	Z
21	B2b	2-tetrahydrofuranyl	-CH ₂ -NH-
22	B2b	2-thienyl	-CH ₂ -NH-
23	B2b		-CH ₂ -NH-
24	B2b	2,2-dimethyl-1,3-dioxolan-4-yl	-CH ₂ -NH-
25	B2b	1-ethylpyrrolidin-2-yl	-CH ₂ -NH-
26	B2b	2-furanyl	-CH ₂ -NH-
3	B2b	3-quinolinyl	-CH ₂ -NH-
27	B2b		-CH ₂ -NH-
28	B2b	4-morpholinyl	-(CH ₂) ₂ -NH-
29	B2b	1,3-benzodioxol-5-yl	-CH ₂ -NH-
30	B2b	4-methyl-1-piperazinyl	direct bond
31	B2b		direct bond
32	B2b	4-morpholinyl	direct bond
33	B5a	1-methyl-1 <i>H</i> -imidazol-2-yl	direct bond

Table 3:




Co. No.	Ex. No.	R ⁴		R ^{3a}	R ^{3b}	Physical data
34				4-C ₆ H ₁₃	H	
5	B4	3-pyridinyl		2-Cl	3-Cl	
35	B4	3-pyridinyl		3-CF ₃	H	
1	B1	3-pyridinyl		3-CF ₃	H	
36	B5b			3-CF ₃	H	
37	B5b			3-CF ₃	H	

5 Table 4:



Co. No.	Ex. No.	R ⁴	Z	X- R ²	R ³	Physical data
6	B5a		db*	-O-CH ₂ -C ₆ H ₅	4-CN	
4	B3	1-piperazinyl	-(C=O)-	-O-CH ₂ -C ₆ H ₅	4-CN	
8	B5a		db*	-O-CH ₂ -C ₆ H ₅	H	

Co. No.	Ex. No.	R ⁴	Z	X- R ²	R ³	Physical data
7	B6		db*	-O-H	H	

*db = direct bond

C. Pharmacological Example

The pharmacological activity of the present compounds was examined using the following test.

GSK3 β assays were performed at 25°C in a 100 μ l reaction volume of 25mM Tris (pH 7.4) containing 10 mM MgCl₂, 1 mM DTT, 0.1 mg/ml BSA, 5% glycerol and containing 19 nM GSK3 β , 5 μ M biotinylated phosphorylated CREB peptide, 1 μ M ATP, 2nM ATP-P³³ and a suitable amount of a test compound of formula (I) or (I'). After one hour, the reaction was terminated by adding 70 μ l of Stop mix (1 mM ATP, 18 mg/ml streptavidin coated PVT SPA bead pH 11.0). The beads to which the phosphorylated CREB peptide is attached were allowed to settle for 30 minutes and the radioactivity of the beads was counted in a microtiterplate scintillation counter and compared with the results obtained in a control experiment (without the presence of a test compound) in order to determine the percentage of GSK3 β inhibition. The IC₅₀ value, i.e. the concentration (M) of the test compound at which 50 % of GSK3 β is inhibited, was calculated from the dose response curve obtained by performing the above-described GSK3 β assay in the presence of different amounts of the test compound.

Table 5 lists pIC₅₀ values (-log IC₅₀ (M)) obtained in the above-described test for the present compounds.

Table 5


Comp. No.	pIC ₅₀
22	5.74
24	5.36
25	5.72
26	5.81
2	6.28
17	5.30

-64-

Comp. No.	pIC ₅₀
20	5.44
6	7.01
4	5.53
33	7.11

Claims

1. A compound of formula



a *N*-oxide, a pharmaceutically acceptable addition salt, a quaternary amine and a stereochemically isomeric form thereof, wherein

ring A is pyridyl, pyrimidinyl, pyrazinyl or pyridazinyl;

R^1 is hydrogen; aryl; formyl; C_{1-6} alkylcarbonyl; C_{1-6} alkyl; C_{1-6} alkyloxycarbonyl; C_{1-6} alkyl substituted with formyl, C_{1-6} alkylcarbonyl, C_{1-6} alkyloxycarbonyl, C_{1-6} alkylcarbonyloxy; C_{1-6} alkyloxy C_{1-6} alkylcarbonyl optionally substituted with C_{1-6} alkyloxycarbonyl;

X is $-NR^1-$; $-NH-NH-$; $-N=N-$; $-O-$; $-C(=O)-$; $-C(=S)-$; $-O-C(=O)-$; $-C(=O)-O-$; $-O-C(=O)-C_{1-6}alkyl-$; $-C(=O)-O-C_{1-6}alkyl-$; $-O-C_{1-6}alkyl-C(=O)-$; $-C(=O)-C_{1-6}alkyl-O-$; $-O-C(=O)-NR^1-$; $-NR^1-C(=O)-O-$; $-O-C(=O)-C(=O)-$; $-C(=O)-NR^1-$; $-NR^1-C(=O)-$; $-C(=S)-NR^1-$; $-NR^1-C(=S)-$; $-NR^1-C(=O)-NR^1-$; $-NR^1-C(=S)-NR^1-$; $-NR^1-S(=O)-NR^1-$; $-NR^1-S(=O)_2-NR^1-$; $-C_{1-6}alkyl-C(=O)-NR^1-$; $-O-C_{1-6}alkyl-C(=O)-NR^1-$; $-C_{1-6}alkyl-O-C(=O)-NR^1-$; $-C_{1-6}alkyl-$; $-O-C_{1-6}alkyl-$; $-C_{1-6}alkyl-O-$; $-NR^1-C_{1-6}alkyl-$; $-C_{1-6}alkyl-NR^1-$; $-NR^1-C_{1-6}alkyl-NR^1-$; $-NR^1-C_{1-6}alkyl-C_{3-7}cycloalkyl-$; $-C_{2-6}alkenyl-$; $-C_{2-6}alkynyl-$; $-O-C_{2-6}alkenyl-$; $-C_{2-6}alkenyl-O-$; $-NR^1-C_{2-6}alkenyl-$; $-C_{2-6}alkenyl-NR^1-$; $-NR^1-C_{2-6}alkenyl-NR^1-$; $-NR^1-C_{2-6}alkenyl-C_{3-7}cycloalkyl-$; $-O-C_{2-6}alkynyl-$; $-C_{2-6}alkynyl-O-$; $-NR^1-C_{2-6}alkynyl-$; $-C_{2-6}alkynyl-NR^1-$; $-NR^1-C_{2-6}alkynyl-NR^1-$; $-NR^1-C_{2-6}alkynyl-C_{3-7}cycloalkyl-$; $-O-C_{1-6}alkyl-O-$; $-O-C_{2-6}alkenyl-O-$; $-O-C_{2-6}alkynyl-O-$; $-CHOH-$; $-S-$; $-S(=O)-$; $-S(=O)_2-$; $-S(=O)-NR^1-$; $-S(=O)_2-NR^1-$; $-NR^1-S(=O)-$; $-NR^1-S(=O)_2-$; $-S-C_{1-6}alkyl-$; $-C_{1-6}alkyl-S-$; $-S-C_{2-6}alkenyl-$; $-C_{2-6}alkenyl-S-$; $-S-C_{2-6}alkynyl-$; $-C_{2-6}alkynyl-S-$; $-O-C_{1-6}alkyl-S(=O)_2-$ or a direct bond;

Z is a direct bond, $C_{1-6}alkanediyl$, $C_{2-6}alkenediyl$, $C_{2-6}alkynediyl$; $-O-$;

$-O-C_{1-6}alkyl-$; $-S-$; $-C(=O)-$; $-C(=O)-O-$; $-O-C(=O)-$; $-C(=S)-$; $-S(=O)-$; $-S(=O)_2-$; $-NR^1-$; $-NR^1-C_{1-6}alkyl-$; $-NR^1-C(=O)-$; $-O-C(=O)-NR^1-$; $-NR^1-C(=O)-O-$; $-NR^1-C(=S)-$; $-S(=O)-NR^1-$; $-S(=O)_2-NR^1-$; $-NR^1-S(=O)-$; $-NR^1-S(=O)_2-$; $-NR^1-C(=O)-NR^1-$; $-NR^1-C(=S)-NR^1-$; $-NR^1-S(=O)-NR^1-$; $-NR^1-S(=O)_2-NR^1-$;

R^2 is hydrogen, $C_{1-10}alkyl$, $C_{2-10}alkenyl$, $C_{2-10}alkynyl$, R^{20} , each of said groups representing R^2 may optionally be substituted where possible with one or more substituents each independently being selected from $=S$; $=O$; R^{15} ; hydroxy; halo;

- nitro; cyano; R^{15} -O-; SH; R^{15} -S-; formyl; carboxyl; R^{15} -C(=O)-; R^{15} -O-C(=O)-; R^{15} -C(=O)-O-; R^{15} -O-C(=O)-O-; -SO₃H; R^{15} -S(=O)-; R^{15} -S(=O)₂-; R^5R^6N ; R^5R^6N -C₁₋₆alkyl; R^5R^6N -C₃₋₇cycloalkyl; R^5R^6N -C₁₋₆alkyloxy; R^5R^6N -C(=O)-; R^5R^6N -C(=S)-; R^5R^6N -C(=O)-NH-; R^5R^6N -C(=S)-NH-; R^5R^6N -S(=O)_n-; R^5R^6N -S(=O)_n-NH-; R^{15} -C(=S)-; R^{15} -C(=O)-NH-; R^{15} -O-C(=O)-NH-; R^{15} -S(=O)_n-NH-; R^{15} -O-S(=O)_n-NH-; R^{15} -C(=S)-NH-; R^{15} -O-C(=S)-NH-; $R^{17}R^{18}N$ -Y_{1a}-; $R^{17}R^{18}N$ -Y₂-NR¹⁶-Y₁-; R^{15} -Y₂-NR¹⁹-Y₁-; H-Y₂-NR¹⁹-Y₁-;
- R^3 is hydrogen; hydroxy; halo; C₁₋₆alkyl; C₁₋₆alkyl substituted with cyano, hydroxy or -C(=O)R⁷; C₂₋₆alkenyl; C₂₋₆alkenyl substituted with one or more halogen atoms or cyano; C₂₋₆alkynyl; C₂₋₆alkynyl substituted with one or more halogen atoms or cyano; C₁₋₆alkyloxy; C₁₋₆alkylthio; C₁₋₆alkyloxycarbonyl; C₁₋₆alkylcarbonyloxy; carboxyl; cyano; nitro; amino; mono- or di(C₁₋₆alkyl)amino; polyhaloC₁₋₆alkyl; polyhaloC₁₋₆alkyloxy; polyhaloC₁₋₆alkylthio; R²¹; R²¹-C₁₋₆alkyl; R²¹-O-; R²¹-S-; R²¹-C(=O)-; R²¹-S(=O)_p-; R⁷-S(=O)_p-; R⁷-S(=O)_p-NH-; R²¹-S(=O)_p-NH-; R⁷-C(=O)-; -NHC(=O)H; -C(=O)NHNH₂; R⁷-C(=O)-NH-; R²¹-C(=O)-NH-; -C(=NH)R⁷; -C(=NH)R²¹;
- R^4 is a monocyclic, bicyclic or tricyclic saturated heterocycle; a monocyclic, bicyclic or tricyclic partially saturated heterocycle or a monocyclic, bicyclic or tricyclic aromatic heterocycle, each of said heterocycles optionally being substituted where possible with one or more substituents each independently being selected from =S; =O; R¹⁵; hydroxy; halo; nitro; cyano; R¹⁵-O-; SH; R^{15} -S-; formyl; carboxyl; R^{15} -C(=O)-; R^{15} -O-C(=O)-; R^{15} -C(=O)-O-; R^{15} -O-C(=O)-O-; -SO₃H; R^{15} -S(=O)-; R^{15} -S(=O)₂-; R^5R^6N ; R^5R^6N -C₁₋₆alkyl; R^5R^6N -C₃₋₇cycloalkyl; R^5R^6N -C₁₋₆alkyloxy; R^5R^6N -C(=O)-; R^5R^6N -C(=S)-; R^5R^6N -C(=O)-NH-; R^5R^6N -C(=S)-NH-; R^5R^6N -S(=O)_n-; R^5R^6N -S(=O)_n-NH-; R^{15} -C(=S)-; R^{15} -C(=O)-NH-; R^{15} -O-C(=O)-NH-; R^{15} -S(=O)_n-NH-; R^{15} -O-S(=O)_n-NH-; R^{15} -C(=S)-NH-; R^{15} -O-C(=S)-NH-; $R^{17}R^{18}N$ -Y_{1a}-; $R^{17}R^{18}N$ -Y₂-NR¹⁶-Y₁-; R^{15} -Y₂-NR¹⁹-Y₁-; H-Y₂-NR¹⁹-Y₁-;
- R^5 and R^6 each independently are hydrogen, R⁸, -Y₁-NR⁹-Y₂-NR¹⁰R¹¹, -Y₁-NR⁹-Y₁-R⁸, -Y₁-NR⁹R¹⁰, or
- R^5 and R^6 may together with the nitrogen to which they are attached form a saturated or partially saturated monocyclic 3 to 8 membered heterocycle or an aromatic 4 to 8 membered monocyclic heterocycle, each of said heterocycles may optionally be substituted with one or more substituents selected from R¹², R¹³ and R¹⁴, or each of said heterocycles may optionally be fused with a benzene ring, said benzene ring being optionally substituted with one or more substituents selected from R¹², R¹³ and R¹⁴;

- R^7 is C_{1-6} alkyl, C_{1-6} alkyloxy, amino, mono- or di(C_{1-6} alkyl)amino or polyhalo C_{1-6} alkyl;
 R^8 is C_{1-6} alkyl; C_{2-6} alkenyl; C_{2-6} alkynyl; a monocyclic, bicyclic or tricyclic saturated carbocycle; a monocyclic, bicyclic or tricyclic partially saturated carbocycle; a monocyclic, bicyclic or tricyclic aromatic carbocycle; a monocyclic, bicyclic or tricyclic saturated heterocycle; a monocyclic, bicyclic or tricyclic partially saturated heterocycle; a monocyclic, bicyclic or tricyclic aromatic heterocycle; C_{1-6} alkyl substituted with a monocyclic, bicyclic or tricyclic saturated carbocycle or with a monocyclic, bicyclic or tricyclic partially saturated carbocycle or with a monocyclic, bicyclic or tricyclic aromatic carbocycle or with a monocyclic, bicyclic or tricyclic saturated heterocycle or with a monocyclic, bicyclic or tricyclic partially saturated heterocycle or with a monocyclic, bicyclic or tricyclic aromatic heterocycle; each of said groups representing R^8 may optionally be substituted with one or more substituents selected from R^{12} , R^{13} and R^{14} ;
 R^9 , R^{10} and R^{11} each independently are hydrogen or R^8 , or
 any two of R^9 , R^{10} and R^{11} may together be C_{1-6} alkanediyl or C_{2-6} alkenediyl thereby forming a saturated or partially saturated monocyclic 3 to 8 membered heterocycle or an aromatic 4 to 8 membered monocyclic heterocycle together with the nitrogen atoms to which they are attached, each of said heterocycles may optionally be substituted with one or more substituents selected from R^{12} , R^{13} and R^{14} ;
 R^{12} , R^{13} and R^{14} each independently are hydrogen; R^{15} ; hydroxy; halo; nitro; cyano; R^{15} -O-; SH; R^{15} -S-; formyl; carboxyl; R^{15} -C(=O)-; R^{15} -O-C(=O)-; R^{15} -C(=O)-O-; R^{15} -O-C(=O)-O-; $-SO_3H$; R^{15} -S(=O)-; R^{15} -S(=O)₂-; $R^{15}R^{16}N$ -S(=O)-; $R^{15}R^{16}N$ -S(=O)₂-; $R^{17}R^{18}N$ -Y₁-; $R^{17}R^{18}N$ -Y₂-NR¹⁶-Y₁-; R^{15} -Y₂-NR¹⁹-Y₁-; H-Y₂-NR¹⁹-Y₁-; oxo, or
 any two of R^{12} , R^{13} and R^{14} may together be C_{1-6} alkanediyl or C_{2-6} alkenediyl thereby forming a saturated or partially saturated monocyclic 3 to 8 membered carbo – or heterocycle or an aromatic 4 to 8 membered monocyclic carbo – or heterocycle together with the atoms to which they are attached, or
 any two of R^{12} , R^{13} and R^{14} may together be $-O-(CH_2)_r-O-$ thereby forming a saturated, partially saturated or aromatic monocyclic 4 to 8 membered carbo – or heterocycle together with the atoms to which they are attached;
 R^{15} is C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, a monocyclic, bicyclic or tricyclic saturated carbocycle; a monocyclic, bicyclic or tricyclic partially saturated carbocycle; a monocyclic, bicyclic or tricyclic aromatic carbocycle; a monocyclic, bicyclic or tricyclic saturated heterocycle; a monocyclic, bicyclic or tricyclic partially saturated heterocycle; a monocyclic, bicyclic or tricyclic aromatic heterocycle; C_{1-6} alkyl substituted with a monocyclic, bicyclic or tricyclic saturated carbocycle or with a

- monocyclic, bicyclic or tricyclic partially saturated carbocycle or with a monocyclic, bicyclic or tricyclic aromatic carbocycle or with a monocyclic, bicyclic or tricyclic saturated heterocycle or with a monocyclic, bicyclic or tricyclic aromatic heterocycle; each of
- 5 said substituents representing R^{15} may optionally be substituted with one or more substituents selected from R^{12} , R^{13} and R^{14} ; or each of said carbocycles or heterocycles may optionally be fused with a benzene ring, said benzene ring being optionally substituted with one or more substituents selected from R^{12} , R^{13} and R^{14} ; R^{16} , R^{17} , R^{18} and R^{19} each independently are hydrogen or R^{15} , or
- 10 R^{17} and R^{18} , or R^{15} and R^{19} may together be C_{1-6} alkanediyl or C_{2-6} alkenediyl thereby forming a saturated or partially saturated monocyclic 3 to 8 membered heterocycle or an aromatic 4 to 8 membered monocyclic heterocycle, each of said heterocycles may optionally be substituted with one or more substituents selected from R^{12} , R^{13} and R^{14} ; or
- 15 R^{17} and R^{18} together with R^{16} may be C_{1-6} alkanediyl or C_{2-6} alkenediyl thereby forming a saturated or partially saturated monocyclic 3 to 8 membered heterocycle or an aromatic 4 to 8 membered monocyclic heterocycle together with the nitrogen atoms to which they are attached, each of said heterocycles may optionally be substituted with one or more substituents selected from R^{12} , R^{13} and R^{14} ;
- 20 R^{20} is a monocyclic, bicyclic or tricyclic saturated carbocycle; a monocyclic, bicyclic or tricyclic partially saturated carbocycle; a monocyclic, bicyclic or tricyclic aromatic carbocycle; a monocyclic, bicyclic or tricyclic saturated heterocycle; a monocyclic, bicyclic or tricyclic partially saturated heterocycle; a monocyclic, bicyclic or tricyclic aromatic heterocycle;
- 25 R^{21} is a monocyclic, bicyclic or tricyclic saturated carbocycle; a monocyclic, bicyclic or tricyclic partially saturated carbocycle; a monocyclic, bicyclic or tricyclic aromatic carbocycle; a monocyclic, bicyclic or tricyclic saturated heterocycle; a monocyclic, bicyclic or tricyclic partially saturated heterocycle; a monocyclic, bicyclic or tricyclic aromatic heterocycle, each of said carbocycles or heterocycles
- 30 representing R^{21} may optionally be substituted with one or more substituents selected from R^{12} , R^{13} and R^{14} ;
- Y_{1a} is $-Y_3-S(=O)-Y_4-$; $-Y_3-S(=O)_2-Y_4-$; $-Y_3-C(=O)-Y_4-$; $-Y_3-C(=S)-Y_4-$; $-Y_3-O-Y_4-$; $-Y_3-S-Y_4-$; $-Y_3-O-C(=O)-Y_4-$ or $-Y_3-C(=O)-O-Y_4-$;
- Y_1 or Y_2 each independently are a direct bond, $-Y_3-S(=O)-Y_4-$; $-Y_3-S(=O)_2-Y_4-$;
- 35 $-Y_3-C(=O)-Y_4-$; $-Y_3-C(=S)-Y_4-$; $-Y_3-O-Y_4-$; $-Y_3-S-Y_4-$; $-Y_3-O-C(=O)-Y_4-$ or $-Y_3-C(=O)-O-Y_4-$;

-69-

Y_3 or Y_4 each independently are a direct bond, C_{1-6} alkanediyl, C_{2-6} alkenediyl or C_{2-6} alkynediyl;

n is 1 or 2;

m is 1 or 2;

5 p is 1 or 2;

r is 1 to 5;


s is 1 to 3;

aryl is phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from halo, C_{1-6} alkyl, C_{3-7} cycloalkyl, C_{1-6} alkyloxy, cyano,

10 nitro, polyhalo C_{1-6} alkyl and polyhalo C_{1-6} alkyloxy;


provided that $-X-R^2$ and/or R^3 is other than hydrogen; and

provided that when




$-Z$ is other than a direct bond or NH when R^1 is hydrogen or methyl, s is 2, R^3 is methoxy, and $-X-R^2$ is methoxy;

15 $-Z-R^4$ is other than 3-pyridyl, 4-pyridyl or 4-pyridyl *N*-oxide when R^1 is hydrogen or methyl, s is 1, R^3 is 3-chloro or 4-methoxy, and $-X-R^2$ is hydrogen;


 when R^1 is hydrogen;

$-R^3$ and $-X-R^2$ are other than hydrogen when R^1 is hydrogen and $-Z-R^4$ is 3-pyridyl or substituted 4-pyridyl;



20 and provided that when



$-R^4$ is other than pyridyl optionally substituted with methyl, pyridyl *N*-oxide, 1-methylpyridinium, thienyl optionally substituted with one or two methyl groups, furanyl optionally substituted with one or two methyl groups, benzofuranyl, quinoliny, indolyl, pyrrolyl optionally substituted with methyl, pyrimidinyl, phenothiazinyl;

25 and provided that the following compounds

-70-



are not included.

2. A compound as claimed in claim 1 wherein ring A is pyridyl, pyrimidinyl or pyridazinyl.

5

3. A compound as claimed in claim 2 wherein

Z is a direct bond, C₁₋₆alkanediyl, C₂₋₆alkenediyl, C₂₋₆alkynediyl; -O-; -O-C₁₋₆alkyl-; -C(=O)-; -C(=O)-O-; -O-C(=O)-; -C(=S)-; -S(=O)-; -S(=O)₂-; -NR¹-; -NR¹-C₁₋₆alkyl-; -NR¹-C(=O)-; -O-C(=O)-NR¹-; -NR¹C(=O)-O-; -NR¹-C(=S)-; -S(=O)-NR¹-; -S(=O)₂-NR¹-; -NR¹-S(=O)-; -NR¹-S(=O)₂-; -NR¹-(C=O)-NR¹-; -NR¹-C(=S)-NR¹-; -NR¹-S(=O)-NR¹-; -NR¹-S(=O)₂-NR¹-;

10

R² is hydrogen, C₁₋₁₀alkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, R²⁰, each of said groups representing R² may optionally be substituted where possible with one or more substituents each independently being selected from =S; =O; R¹⁵; hydroxy; halo; nitro; cyano; R¹⁵-O-; SH; R¹⁵-S-; formyl; carboxyl; R¹⁵-C(=O)-; R¹⁵-O-C(=O)-; R¹⁵-C(=O)-O-; R¹⁵-O-C(=O)-O-; -SO₃H; R¹⁵-S(=O)-; R¹⁵-S(=O)₂-; R⁵R⁶N; R⁵R⁶N-C₁₋₆alkyl; R⁵R⁶N-C₃₋₇cycloalkyl; R⁵R⁶N-C₁₋₆alkyloxy; R^{5a}R^{6a}N-C(=O)-; R⁵R⁶N-C(=S)-; R⁵R⁶N-C(=O)-NH-; R⁵R⁶N-C(=S)-NH-; R⁵R⁶N-S(=O)_n-; R⁵R⁶N-S(=O)_n-NH-; R¹⁵-C(=S)-; R¹⁵-C(=O)-NH-; R¹⁵-O-C(=O)-NH-; R¹⁵-S(=O)_n-NH-; R¹⁵-O-S(=O)_n-NH-; R¹⁵-C(=S)-NH-; R¹⁵-O-C(=S)-NH-; R¹⁷R¹⁸N-Y_{1a}-; R¹⁷R¹⁸N-Y₂-NR¹⁶-Y₁-; R¹⁵-Y₂-NR¹⁹-Y₁-; H-Y₂-NR¹⁹-Y₁-;

15

20

R³ is hydrogen; hydroxy; halo; C₁₋₆alkyl; C₁₋₆alkyl substituted with cyano, hydroxy or -C(=O)R⁷; C₂₋₆alkenyl; C₂₋₆alkenyl substituted with one or more halogen atoms or cyano; C₂₋₆alkynyl; C₂₋₆alkynyl substituted with one or more halogen atoms or cyano; C₁₋₆alkylthio; C₁₋₆alkyloxycarbonyl; C₁₋₆alkylcarbonyloxy; carboxyl; cyano; nitro; amino; mono- or di(C₁₋₆alkyl)amino; polyhaloC₁₋₆alkyl; polyhaloC₁₋₆alkylthio; R²¹; R²¹-C₁₋₆alkyl; R²¹-O-; R²¹-S-;


25

-71-

$R^{21}-C(=O)-$; $R^{21}-S(=O)_p-$; $R^7-S(=O)_p-$; $R^7-S(=O)_p-NH-$; $R^{21}-S(=O)_p-NH-$;
 $R^7-C(=O)-$; $-NHC(=O)H$; $-C(=O)NHNH_2$; $R^7-C(=O)-NH-$; $R^{21}-C(=O)-NH-$;
 $-C(=NH)R^7$; $-C(=NH)R^{21}$;

- R^4 is tetrahydrofuranyl, dihydrofuranyl, pyrrolinyl, pyrrolidinyl, imidazolyl,
 5 imidazolinyl, imidazolidinyl, oxazolyl, pyrimidinyl, pyridyl, piperidinyl,
 piperazinyl, pyridazinyl, triazinyl, morpholinyl, dioxolanyl or dioxanyl, each of said
 heterocycles optionally being substituted where possible with one or more
 substituents each independently being selected from $=S$; $=O$; R^{15} ; hydroxy; halo;
 nitro; cyano; $R^{15}-O-$; SH ; $R^{15}-S-$; formyl; carboxyl;
 10 $R^{15}-C(=O)-$; $R^{15}-O-C(=O)-$; $R^{15}-C(=O)-O-$; $R^{15}-O-C(=O)-O-$; $-SO_3H$; $R^{15}-S(=O)-$;
 $R^{15}-S(=O)_2-$; R^5R^6N ; $R^5R^6NC_{1-6}alkyl$; $R^5R^6NC_{3-7}cycloalkyl$; $R^5R^6NC_{1-6}alkyloxy$;
 $R^5R^6N-C(=O)-$; $R^5R^6N-C(=S)-$; $R^5R^6N-C(=O)-NH-$; $R^5R^6N-C(=S)-NH-$;
 $R^5R^6N-S(=O)_n-$; $R^5R^6N-S(=O)_n-NH-$; $R^{15}-C(=S)-$; $R^{15}-C(=O)-NH-$;
 $R^{15}-O-C(=O)-NH-$; $R^{15}-S(=O)_n-NH-$; $R^{15}-O-S(=O)_n-NH-$; $R^{15}-C(=S)-NH-$;
 15 $R^{15}-O-C(=S)-NH-$; $R^{17}R^{18}N-Y_{1a}-$; $R^{17}R^{18}N-Y_2-NR^{16}-Y_1-$; $R^{15}-Y_2-NR^{19}-Y_1-$;
 $H-Y_2-NR^{19}-Y_1-$;
 R^{5a} and R^{6a} each independently are hydrogen, $C_{1-6}alkyl$; $C_{2-6}alkenyl$ or $C_{2-6}alkynyl$,
 each of said groups representing R^{5a} and R^{6a} may optionally be substituted with one
 or more substituents selected from R^{12} , R^{13} and R^{14} ;
 20 provided that R^4 is other than optionally substituted pyridyl when ring A represents
 pyrimidinyl.


4. A compound as claimed in any one of claims 1 to 3 wherein the compound has the
 following formula



25

5. A compound as claimed in any one of claims 1 to 3 wherein the compound has the
 following formula

-72-



6. A compound as claimed in any one of claims 1 to 5 wherein R^4 is a 5-membered aromatic heterocycle optionally being substituted where possible with one or more substituents each independently being selected from =S; =O; R^{15} ; hydroxy; halo; nitro; cyano; R^{15} -O-; SH; R^{15} -S-; formyl; carboxyl; R^{15} -C(=O)-; R^{15} -O-C(=O)-; R^{15} -C(=O)-O-; R^{15} -O-C(=O)-O-; -SO₃H; R^{15} -S(=O)-; R^{15} -S(=O)₂-; R^5R^6N ; $R^5R^6NC_{1-6}$ alkyl; $R^5R^6NC_{3-7}$ cycloalkyl; $R^5R^6NC_{1-6}$ alkyloxy; R^5R^6N -C(=O)-; R^5R^6N -C(=S)-; R^5R^6N -C(=O)-NH-; R^5R^6N -C(=S)-NH-; R^5R^6N -S(=O)_n-; R^5R^6N -S(=O)_n-NH-; R^{15} -C(=S)-; R^{15} -C(=O)-NH-; R^{15} -O-C(=O)-NH-; R^{15} -S(=O)_n-NH-; R^{15} -O-S(=O)_n-NH-; R^{15} -C(=S)-NH-; R^{15} -O-C(=S)-NH-; $R^{17}R^{18}N$ -Y_{1a}-; $R^{17}R^{18}N$ -Y₂-NR¹⁶-Y₁-; R^{15} -Y₂-NR¹⁹-Y₁-; H-Y₂-NR¹⁹-Y₁-.

7. A compound as claimed in claim 6 wherein Z is a direct bond.

15

8. A compound as claimed in claim 1 wherein the compound is
 N^2 -(1*H*-indazol-5-yl)- N^4 -(2,4,6-trimethylphenyl)-2,4-pyrimidinediamine;
 4-[[4-(1-methyl-1*H*-imidazol-2-yl)-2-pyrimidinyl]amino]-2-(phenylmethoxy)-benzonitrile;
 4-[[4-(1-methyl-1*H*-imidazol-2-yl)-2-pyrimidinyl]amino]-benzonitrile;
 a *N*-oxide, a pharmaceutically acceptable addition salt, a quaternary amine and a stereochemically isomeric form thereof.

20


9. A compound as claimed in claim 1 wherein the compound is
 N^2 -(6-morpholinyl-4-yl-pyridin-3-yl)- N^4 -(2,4,6-trimethyl-phenyl)-2,4-pyrimidinediamine;
 N^2 -(3*H*-benzimidazol-5-yl)- N^4 -(2,4,6-trimethyl-phenyl)-2,4-pyrimidinediamine;
 N^2 -(1*H*-indazol-6-yl)- N^4 -(2,4,6-trimethyl-phenyl)-2,4-pyrimidinediamine;
 N^2 -(5-bromo-pyridin-2-yl)- N^4 -(2,4,6-trimethyl-phenyl)-2,4-pyrimidinediamine;
 N^2 -(6-methoxy-pyridin-3-yl)- N^4 -(2,4,6-trimethyl-phenyl)-2,4-pyrimidinediamine;
 N^2 -benzothiazol-6-yl- N^4 -(2,4,6-trimethyl-phenyl)-2,4-pyrimidinediamine;
 N^2 -(1*H*-indazol-5-yl)- N^4 -(2,4,6-trimethyl-phenyl)-2,4-pyrimidinediamine;

25

30

- N^2 -(1H-benzotriazol-5-yl)- N^4 -(2,4,6-trimethyl-phenyl)-2,4-pyrimidinediamine;
 N^2 -benzo[1,3]dioxol-5-yl- N^4 -(2,4,6-trimethyl-phenyl)-2,4-pyrimidinediamine;
 N^2 -(6-chloro-pyridin-3-yl)- N^4 -(2,4,6-trimethyl-phenyl)-2,4-pyrimidinediamine;
 N^2 -(1H-indol-5-yl)- N^4 -(2,4,6-trimethyl-phenyl)-2,4-pyrimidinediamine;
 5 N^2 -quinolin-6-yl- N^4 -(2,4,6-trimethyl-phenyl)-2,4-pyrimidinediamine;
 4-[4-[(benzo[1,3]dioxol-5-ylmethyl)-amino]-pyrimidin-2-ylamino]-benzonitrile;
 4-[4-[(quinolin-3-methyl)-amino]-pyrimidin-2-ylamino]-benzonitrile;
 4-[4-[(furan-2-ylmethyl)-amino]-pyrimidin-2-ylamino]-benzonitrile;
 4-[4-[(thiophen-2-ylmethyl)-amino]-pyrimidin-2-ylamino]-benzonitrile;
 10 a *N*-oxide, a pharmaceutically acceptable addition salt, a quaternary amine and a
 stereochemically isomeric form thereof.

10. A compound as claimed in any one of claims 1 to 9 for use as a medicine.
 15 11. The use of a compound for the manufacture of a medicament for the prevention or
 the treatment of diseases mediated through GSK3, said compound being a compound of
 formula of formula (I')



- a *N*-oxide, a pharmaceutically acceptable addition salt, a quaternary amine and a
 20 stereochemically isomeric form thereof, wherein
 ring A is pyridyl, pyrimidinyl, pyrazinyl or pyridazinyl;
 R^1 is hydrogen; aryl; formyl; C_{1-6} alkylcarbonyl; C_{1-6} alkyl; C_{1-6} alkyloxycarbonyl;
 C_{1-6} alkyl substituted with formyl, C_{1-6} alkylcarbonyl, C_{1-6} alkyloxycarbonyl,
 C_{1-6} alkylcarbonyloxy; C_{1-6} alkyloxy C_{1-6} alkylcarbonyl optionally substituted with
 25 C_{1-6} alkyloxycarbonyl;
 X is $-NR^1$ -; $-NH-NH$ -; $-N=N$ -; $-O$ -; $-C(=O)$ -; $-C(=S)$ -; $-O-C(=O)$ -; $-C(=O)-O$ -;
 $-O-C(=O)-C_{1-6}alkyl$ -; $-C(=O)-O-C_{1-6}alkyl$ -; $-O-C_{1-6}alkyl-C(=O)$ -;
 $-C(=O)-C_{1-6}alkyl-O$ -; $-O-C(=O)-NR^1$ -; $-NR^1-C(=O)-O$ -; $-O-C(=O)-C(=O)$ -;
 $-C(=O)-NR^1$ -; $-NR^1-C(=O)$ -; $-C(=S)-NR^1$ -; $-NR^1-C(=S)$ -; $-NR^1-C(=O)-NR^1$ -;
 30 $-NR^1-C(=S)-NR^1$ -; $-NR^1-S(=O)-NR^1$ -; $-NR^1-S(=O)_2-NR^1$ -; $-C_{1-6}alkyl-C(=O)-NR^1$ -;
 $-O-C_{1-6}alkyl-C(=O)-NR^1$ -; $-C_{1-6}alkyl-O-C(=O)-NR^1$ -; $-C_{1-6}alkyl$ -; $-O-C_{1-6}alkyl$ -;
 $-C_{1-6}alkyl-O$ -; $-NR^1-C_{1-6}alkyl$ -; $-C_{1-6}alkyl-NR^1$ -; $-NR^1-C_{1-6}alkyl-NR^1$ -;
 $-NR^1-C_{1-6}alkyl-C_{3-7}cycloalkyl$ -; $-C_{2-6}alkenyl$ -; $-C_{2-6}alkynyl$ -; $-O-C_{2-6}alkenyl$ -;
 $-C_{2-6}alkenyl-O$ -; $-NR^1-C_{2-6}alkenyl$ -; $-C_{2-6}alkenyl-NR^1$ -; $-NR^1-C_{2-6}alkenyl-NR^1$ -;

-NR¹-C₂₋₆alkenyl-C₃₋₇cycloalkyl-; -O-C₂₋₆alkynyl-; -C₂₋₆alkynyl-O-;
 -NR¹-C₂₋₆alkynyl-; -C₂₋₆alkynyl-NR¹-; -NR¹-C₂₋₆alkynyl-NR¹-;
 -NR¹-C₂₋₆alkynyl-C₃₋₇cycloalkyl-; -O-C₁₋₆alkyl-O-; -O-C₂₋₆alkenyl-O-;
 -O-C₂₋₆alkynyl-O-; -CHOH-; -S-; -S(=O)-; -S(=O)₂-; -S(=O)-NR¹-; -S(=O)₂-NR¹-;
 5 -NR¹-S(=O)-; -NR¹-S(=O)₂-; -S-C₁₋₆alkyl-; -C₁₋₆alkyl-S-; -S-C₂₋₆alkenyl-;
 -C₂₋₆alkenyl-S-; -S-C₂₋₆alkynyl-; -C₂₋₆alkynyl-S-; -O-C₁₋₆alkyl-S(=O)₂- or a direct
 bond;

Z is a direct bond, C₁₋₆alkanediyl, C₂₋₆alkenediyl, C₂₋₆alkynediyl; -O-; -O-C₁₋₆alkyl-;
 -S-; -C(=O)-; -C(=O)-O-; -O-C(=O)-; -C(=S)-; -S(=O)-; -S(=O)₂-; -NR¹-;
 10 -NR¹-C₁₋₆alkyl-; -NR¹-C(=O)-; -O-C(=O)-NR¹-; -NR¹-C(=O)-O-; -NR¹-C(=S)-;
 -S(=O)-NR¹-; -S(=O)₂-NR¹-; -NR¹-S(=O)-; -NR¹-S(=O)₂-; -NR¹-(C=O)-NR¹-;
 -NR¹-C(=S)-NR¹-; -NR¹-S(=O)-NR¹-; -NR¹-S(=O)₂-NR¹-;

R² is hydrogen, C₁₋₁₀alkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, R²⁰, each of said groups
 representing R² may optionally be substituted where possible with one or more
 15 substituents each independently being selected from =S; =O; R¹⁵; hydroxy; halo;
 nitro; cyano; R¹⁵-O-; SH; R¹⁵-S-; formyl; carboxyl; R¹⁵-C(=O)-; R¹⁵-O-C(=O)-;
 R¹⁵-C(=O)-O-; R¹⁵-O-C(=O)-O-; -SO₃H; R¹⁵-S(=O)-; R¹⁵-S(=O)₂-; R⁵R⁶N;
 R⁵R⁶N-C₁₋₆alkyl; R⁵R⁶N-C₃₋₇cycloalkyl; R⁵R⁶N-C₁₋₆alkyloxy; R⁵R⁶N-C(=O)-;
 R⁵R⁶N-C(=S)-; R⁵R⁶N-C(=O)-NH-; R⁵R⁶N-C(=S)-NH-; R⁵R⁶N-S(=O)_n-;
 20 R⁵R⁶N-S(=O)_n-NH-; R¹⁵-C(=S)-; R¹⁵-C(=O)-NH-; R¹⁵-O-C(=O)-NH-;
 R¹⁵-S(=O)_n-NH-; R¹⁵-O-S(=O)_n-NH-; R¹⁵-C(=S)-NH-; R¹⁵-O-C(=S)-NH-;
 R¹⁷R¹⁸N-Y_{1a}-; R¹⁷R¹⁸N-Y₂-NR¹⁶-Y₁-; R¹⁵-Y₂-NR¹⁹-Y₁-; H-Y₂-NR¹⁹-Y₁-;

R³ is hydrogen; hydroxy; halo; C₁₋₆alkyl; C₁₋₆alkyl substituted with cyano, hydroxy or
 -C(=O)R⁷; C₂₋₆alkenyl; C₂₋₆alkenyl substituted with one or more halogen atoms or
 25 cyano; C₂₋₆alkynyl; C₂₋₆alkynyl substituted with one or more halogen atoms or
 cyano; C₁₋₆alkyloxy; C₁₋₆alkylthio; C₁₋₆alkyloxycarbonyl; C₁₋₆alkylcarbonyloxy;
 carboxyl; cyano; nitro; amino; mono- or di(C₁₋₆alkyl)amino; polyhaloC₁₋₆alkyl;
 polyhaloC₁₋₆alkyloxy; polyhaloC₁₋₆alkylthio; R²¹; R²¹-C₁₋₆alkyl; R²¹-O-; R²¹-S-;
 R²¹-C(=O)-; R²¹-S(=O)_p-; R⁷-S(=O)_p-; R⁷-S(=O)_p-NH-; R²¹-S(=O)_p-NH-;
 30 R⁷-C(=O)-; -NHC(=O)H; -C(=O)NHNH₂; R⁷-C(=O)-NH-; R²¹-C(=O)-NH-;
 -C(=NH)R⁷; -C(=NH)R²¹;

R⁴ is a monocyclic, bicyclic or tricyclic saturated heterocycle; a monocyclic, bicyclic or
 tricyclic partially saturated heterocycle or a monocyclic, bicyclic or tricyclic
 aromatic heterocycle, each of said heterocycles optionally being substituted where
 35 possible with one or more substituents each independently being selected from =S;
 =O; R¹⁵; hydroxy; halo; nitro; cyano; R¹⁵-O-; SH; R¹⁵-S-; formyl; carboxyl;
 R¹⁵-C(=O)-; R¹⁵-O-C(=O)-; R¹⁵-C(=O)-O-; R¹⁵-O-C(=O)-O-; -SO₃H; R¹⁵-S(=O)-;

- $R^{15}-S(=O)_2-$; R^5R^6N ; $R^5R^6NC_{1-6}alkyl$; $R^5R^6NC_{3-7}cycloalkyl$; $R^5R^6NC_{1-6}alkyloxy$;
 $R^5R^6N-C(=O)-$; $R^5R^6N-C(=S)-$; $R^5R^6N-C(=O)-NH-$; $R^5R^6N-C(=S)-NH-$;
 $R^5R^6N-S(=O)_n-$; $R^5R^6N-S(=O)_n-NH-$; $R^{15}-C(=S)-$; $R^{15}-C(=O)-NH-$;
 $R^{15}-O-C(=O)-NH-$; $R^{15}-S(=O)_n-NH-$; $R^{15}-O-S(=O)_n-NH-$; $R^{15}-C(=S)-NH-$;
 $R^{15}-O-C(=S)-NH-$; $R^{17}R^{18}N-Y_{1a}-$; $R^{17}R^{18}N-Y_2-NR^{16}-Y_1-$; $R^{15}-Y_2-NR^{19}-Y_1-$;
 $H-Y_2-NR^{19}-Y_1-$;
 R^5 and R^6 each independently are hydrogen, R^8 , $-Y_1-NR^9-Y_2-NR^{10}R^{11}$, $-Y_1-NR^9-Y_1-R^8$,
 $-Y_1-NR^9R^{10}$, or
 R^5 and R^6 may together with the nitrogen to which they are attached form a saturated or
partially saturated monocyclic 3 to 8 membered heterocycle or an aromatic 4 to 8
membered monocyclic heterocycle, each of said heterocycles may optionally be
substituted with one or more substituents selected from R^{12} , R^{13} and R^{14} , or each of
said heterocycles may optionally be fused with a benzene ring, said benzene ring
being optionally substituted with one or more substituents selected from R^{12} , R^{13} and
 R^{14} ;
 R^7 is $C_{1-6}alkyl$, $C_{1-6}alkyloxy$, amino, mono- or di($C_{1-6}alkyl$)amino or polyhalo $C_{1-6}alkyl$;
 R^8 is $C_{1-6}alkyl$; $C_{2-6}alkenyl$; $C_{2-6}alkynyl$; a monocyclic, bicyclic or tricyclic saturated
carbocycle; a monocyclic, bicyclic or tricyclic partially saturated carbocycle; a
monocyclic, bicyclic or tricyclic aromatic carbocycle; a monocyclic, bicyclic or
tricyclic saturated heterocycle; a monocyclic, bicyclic or tricyclic partially saturated
heterocycle; a monocyclic, bicyclic or tricyclic aromatic heterocycle; $C_{1-6}alkyl$
substituted with a monocyclic, bicyclic or tricyclic saturated carbocycle or with a
monocyclic, bicyclic or tricyclic partially saturated carbocycle or with a monocyclic,
bicyclic or tricyclic aromatic carbocycle or with a monocyclic, bicyclic or tricyclic
saturated heterocycle or with a monocyclic, bicyclic or tricyclic partially saturated
heterocycle or with a monocyclic, bicyclic or tricyclic aromatic heterocycle; each of
said groups representing R^8 may optionally be substituted with one or more
substituents selected from R^{12} , R^{13} and R^{14} ;
 R^9 , R^{10} and R^{11} each independently are hydrogen or R^8 , or
any two of R^9 , R^{10} and R^{11} may together be $C_{1-6}alkanediyl$ or $C_{2-6}alkenediyl$ thereby
forming a saturated or partially saturated monocyclic 3 to 8 membered heterocycle
or an aromatic 4 to 8 membered monocyclic heterocycle together with the nitrogen
atoms to which they are attached, each of said heterocycles may optionally be
substituted with one or more substituents selected from R^{12} , R^{13} and R^{14} ;
 R^{12} , R^{13} and R^{14} each independently are hydrogen; R^{15} ; hydroxy; halo; nitro; cyano;
 $R^{15}-O-$; SH ; $R^{15}-S-$; formyl; carboxyl; $R^{15}-C(=O)-$; $R^{15}-O-C(=O)-$; $R^{15}-C(=O)-O-$;
 $R^{15}-O-C(=O)-O-$; $-SO_3H$; $R^{15}-S(=O)-$; $R^{15}-S(=O)_2-$; $R^{15}R^{16}N-S(=O)-$;

- $R^{15}R^{16}N-S(=O)_2-$; $R^{17}R^{18}N-Y_1-$; $R^{17}R^{18}N-Y_2-NR^{16}-Y_1-$; $R^{15}-Y_2-NR^{19}-Y_1-$;
 $H-Y_2-NR^{19}-Y_1-$; oxo, or
 any two of R^{12} , R^{13} and R^{14} may together be C_{1-6} alkanediyl or C_{2-6} alkenediyl thereby
 forming a saturated or partially saturated monocyclic 3 to 8 membered carbo – or
 5 heterocycle or an aromatic 4 to 8 membered monocyclic carbo – or heterocycle
 together with the atoms to which they are attached, or
 any two of R^{12} , R^{13} and R^{14} may together be $-O-(CH_2)_r-O-$ thereby forming a saturated,
 partially saturated or aromatic monocyclic 4 to 8 membered carbo – or heterocycle
 together with the atoms to which they are attached;
- 10 R^{15} is C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, a monocyclic, bicyclic or tricyclic saturated
 carbocycle; a monocyclic, bicyclic or tricyclic partially saturated carbocycle; a
 monocyclic, bicyclic or tricyclic aromatic carbocycle; a monocyclic, bicyclic or
 tricyclic saturated heterocycle; a monocyclic, bicyclic or tricyclic partially saturated
 heterocycle; a monocyclic, bicyclic or tricyclic aromatic heterocycle; C_{1-6} alkyl
 15 substituted with a monocyclic, bicyclic or tricyclic saturated carbocycle or with a
 monocyclic, bicyclic or tricyclic partially saturated carbocycle or with a monocyclic,
 bicyclic or tricyclic aromatic carbocycle or with a monocyclic, bicyclic or tricyclic
 saturated heterocycle or with a monocyclic, bicyclic or tricyclic partially saturated
 heterocycle or with a monocyclic, bicyclic or tricyclic aromatic heterocycle; each of
 20 said substituents representing R^{15} may optionally be substituted with one or more
 substituents selected from R^{12} , R^{13} and R^{14} ; or each of said carbocycles or
 heterocycles may optionally be fused with a benzene ring, said benzene ring being
 optionally substituted with one or more substituents selected from R^{12} , R^{13} and R^{14} ;
 R^{16} , R^{17} , R^{18} and R^{19} each independently are hydrogen or R^{15} , or
 25 R^{17} and R^{18} , or R^{15} and R^{19} may together be C_{1-6} alkanediyl or C_{2-6} alkenediyl thereby
 forming a saturated or partially saturated monocyclic 3 to 8 membered heterocycle
 or an aromatic 4 to 8 membered monocyclic heterocycle, each of said heterocycles
 may optionally be substituted with one or more substituents selected from R^{12} , R^{13}
 and R^{14} ; or
 30 R^{17} and R^{18} together with R^{16} may be C_{1-6} alkanediyl or C_{2-6} alkenediyl thereby forming
 a saturated or partially saturated monocyclic 3 to 8 membered heterocycle or an
 aromatic 4 to 8 membered monocyclic heterocycle together with the nitrogen atoms
 to which they are attached, each of said heterocycles may optionally be substituted
 with one or more substituents selected from R^{12} , R^{13} and R^{14} ;
 35 R^{20} is a monocyclic, bicyclic or tricyclic saturated carbocycle; a monocyclic, bicyclic
 or tricyclic partially saturated carbocycle; a monocyclic, bicyclic or tricyclic
 aromatic carbocycle; a monocyclic, bicyclic or tricyclic saturated heterocycle; a

monocyclic, bicyclic or tricyclic partially saturated heterocycle; a monocyclic, bicyclic or tricyclic aromatic heterocycle;

R^{21} is a monocyclic, bicyclic or tricyclic saturated carbocycle; a monocyclic, bicyclic or tricyclic partially saturated carbocycle; a monocyclic, bicyclic or tricyclic aromatic carbocycle; a monocyclic, bicyclic or tricyclic saturated heterocycle; a monocyclic, bicyclic or tricyclic partially saturated heterocycle; a monocyclic, bicyclic or tricyclic aromatic heterocycle, each of said carbocycles or heterocycles representing R^{21} may optionally be substituted with one or more substituents selected from R^{12} , R^{13} and R^{14} ;

Y_{1a} is $-Y_3-S(=O)-Y_{4-}$; $-Y_3-S(=O)_2-Y_{4-}$, $-Y_3-C(=O)-Y_{4-}$, $-Y_3-C(=S)-Y_{4-}$, $-Y_3-O-Y_{4-}$, $-Y_3-S-Y_{4-}$, $-Y_3-O-C(=O)-Y_{4-}$ or $-Y_3-C(=O)-O-Y_{4-}$;

Y_1 or Y_2 each independently are a direct bond, $-Y_3-S(=O)-Y_{4-}$; $-Y_3-S(=O)_2-Y_{4-}$, $-Y_3-C(=O)-Y_{4-}$, $-Y_3-C(=S)-Y_{4-}$, $-Y_3-O-Y_{4-}$, $-Y_3-S-Y_{4-}$, $-Y_3-O-C(=O)-Y_{4-}$ or $-Y_3-C(=O)-O-Y_{4-}$;

Y_3 or Y_4 each independently are a direct bond, C_{1-6} alkanediyl, C_{2-6} alkenediyl or C_{2-6} alkynediyl;

n is 1 or 2;

m is 1 or 2;

p is 1 or 2;

r is 1 to 5;

s is 1 to 3;

aryl is phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from halo, C_{1-6} alkyl, C_{3-7} cycloalkyl, C_{1-6} alkyloxy, cyano, nitro, polyhalo C_{1-6} alkyl and polyhalo C_{1-6} alkyloxy;

provided that $-X-R^2$ and/or R^3 is other than hydrogen.

12. The use of a compound as defined in any one of claims 1 to 9 for the manufacture of a medicament for the prevention or the treatment of diseases mediated through GSK3.

30

13. The use of a compound as defined in any one of claims 1 to 9 or 12 for the manufacture of a medicament for the prevention or the treatment of bipolar disorder (in particular manic depression), diabetes, Alzheimer's disease, leukopenia, FTDP-17 (Fronto-temporal dementia associated with Parkinson's disease), cortico-basal degeneration, progressive supranuclear palsy, multiple system atrophy, Pick's disease, Niemann Pick's disease type C, Dementia Pugilistica, dementia with tangles only, dementia with tangles and calcification, Down syndrome, myotonic dystrophy,

35

Parkinsonism-dementia complex of Guam, aids related dementia, Postencephalic Parkinsonism, prion diseases with tangles, subacute sclerosing panencephalitis, frontal lobe degeneration (FLD), argyrophilic grains disease, subacute sclerotizing panencephalitis (SSPE) (late complication of viral infections in the central nervous system), inflammatory diseases, cancer, dermatological disorders, neuronal damage, schizophrenia, pain.


14. The use of a compound as claimed in claim 13 for the prevention or the treatment of Alzheimer's disease, diabetes, cancer, inflammatory diseases or bipolar disorder.

15. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and as active ingredient a therapeutically effective amount of a compound as claimed in any one of claims 1 to 9.

16. A process for preparing a pharmaceutical composition as claimed in claim 15 characterized in that a therapeutically effective amount of a compound as claimed in any one of claims 1 to 9 is intimately mixed with a pharmaceutically acceptable carrier.


17. A process for preparing a compound as claimed in claim 1, characterized by

a) by reacting an intermediate of formula (II) with an intermediate of formula (III) in the presence of a suitable solvent and optionally in the presence of a suitable acid,




with W_1 representing a suitable leaving group, and s , Z , R^1 , R^2 , R^3 , R^4 , X and ring A as defined in claim 1;

b) by reacting an intermediate of formula (II) with an intermediate of formula (III) in the presence of a suitable solvent, a suitable catalyst, a suitable ligand and a suitable base



with W_1 representing a suitable leaving group, and s , Z , R^1 , R^2 , R^3 , R^4 , X and ring A as defined in claim 1;

c) reacting an intermediate of formula (IV) with an intermediate of formula (V) in the presence of a suitable solvent, a suitable catalyst, a suitable ligand and a suitable base,




5

with W_2 representing a suitable leaving group, and s , Z , R^1 , R^2 , R^3 , R^4 , X and ring A as defined in claim 1;

d) reacting an intermediate of formula (VI) with an intermediate of formula (VII) in the presence of a suitable solvent and optionally in the presence of a suitable acid or a suitable base


10



with W_3 representing a suitable leaving group, and s , Z , R^1 , R^2 , R^3 , R^4 , X and ring A as defined in claim 1;

e) reacting an intermediate of formula (VIII) with an intermediate of formula (IX) in the presence of a suitable solvent

15




with W_4 representing a suitable leaving group, and s , R^1 , R^2 , R^3 , R^4 , X and ring A as defined in claim 1;

f) reacting an intermediate of formula (VI) with an intermediate of formula (X) in the presence of a suitable catalyst, a suitable base and a suitable solvent


20

-80-




with W_3 representing a suitable leaving group, and s , R^1 , R^2 , R^3 , R^4 , X and ring A as defined in claim 1;

- g) reacting an intermediate of formula (XI) with sodium azide in the presence of a suitable salt and a suitable solvent



with s , R^1 , R^2 , R^3 , X and ring A as defined in claim 1;

- h) reacting an intermediate of formula (XX) with an intermediate of formula (XXI) in the presence of a suitable solvent and a suitable base



10

with s , R^1 , R^2 , R^3 , R^4 and X as defined in claim 1;

- and, if desired, converting compounds of formula (I) into each other following art-known transformations, and further, if desired, converting the compounds of formula (I), into a therapeutically active non-toxic acid addition salt by treatment with an acid, or into a therapeutically active non-toxic base addition salt by treatment with a base, or conversely, converting the acid addition salt form into the free base by treatment with alkali, or converting the base addition salt into the free acid by treatment with acid; and, if desired, preparing stereochemically isomeric forms, quaternary amines or N -oxide forms thereof.

20

INTERNATIONAL SEARCH REPORT

International application No

PCT/EP 02/12077

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D403/12 C07D401/04 C07D213/53 A61K31/435 A61K31/50
A61K31/505 A61P3/10

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 01 72745 A (CYCLACEL LTD ;WANG SHUDONG (GB); FISCHER PETER MARTIN (GB)) 4 October 2001 (2001-10-04) * overlap of chemical formula * the whole document ---	1-17
X	WO 97 19065 A (CELLTECH THERAPEUTICS LTD ;DAVIS PETER DAVID (GB); MOFFAT DAVID FE) 29 May 1997 (1997-05-29) * overlap of chemical formula * the whole document ---	1-17
X	WO 98 41512 A (CELLTECH THERAPEUTICS LTD ;DAVIS PETER DAVID (GB); MOFFAT DAVID FE) 24 September 1998 (1998-09-24) * overlap of chemical formula * the whole document --- -/--	1-17

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

27 January 2003

Date of mailing of the international search report

04/02/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5618 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Stellmach, J

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 02/12077

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 95 09851 A (CIBA GEIGY AG ;ZIMMERMANN JUERG (CH)) 13 April 1995 (1995-04-13) * overlap of chemical formula * the whole document ---	1-17
X	WO 95 09853 A (CIBA GEIGY AG ;ZIMMERMANN JUERG (CH)) 13 April 1995 (1995-04-13) * overlap of chemical formula * the whole document ---	1-17
X	WO 01 29009 A (CELLTECH CHIROSCIENCE LTD ;DAVIS JEREMY MARTIN (GB); MOFFAT DAVID) 26 April 2001 (2001-04-26) * overlap of chemical formula * the whole document ---	1-17
X	WO 01 12621 A (BAKER CHRISTOPHER ;HARRINGTON EDMUND (US); BEMIS GUY (US); LEDEBOE) 22 February 2001 (2001-02-22) * overlap of chemical formula * the whole document ---	1-17
X	WO 01 60816 A (AMGEN INC) 23 August 2001 (2001-08-23) * overlap * the whole document ---	1-17
X	WO 01 47897 A (SQUIBB BRISTOL MYERS CO ;PHARMACOPEIA INC (US)) 5 July 2001 (2001-07-05) * overlap of chemical formula * the whole document ---	1-17
X	WO 00 62788 A (MANDEL ARKADY ;SAUDER DANIEL (CA); BOLTON ANTHONY E (GB); VASOGEN) 26 October 2000 (2000-10-26) cited in the application * see claim 1, definition of Z = bond * the whole document ---	1-17
Y	WO 99 65897 A (RAMURTHY SAVITHRY ;CHIRON CORP (US); GOFF DANE (US); NUSS JOHN M () 23 December 1999 (1999-12-23) * see the definition of R6, X and A * the whole document --- -/--	1-17

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>HERS I ET AL: "The protein kinase C inhibitors bisindolylmaleimide I (GF 109203x) and IX (Ro 31-8220) are potent inhibitors of glycogen synthase kinase-3 activity"</p> <p>FEBS LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 460, no. 3, 5 November 1999 (1999-11-05), pages 433-436, XP004260484 ISSN: 0014-5793 * see p.435, last par. bridging * the whole document</p> <p>----</p>	1-17
Y	<p>SMITH D G ET AL: "3-Anilino-4-arylmaleimides: potent and selective inhibitors of glycogen synthase kinase-3 (GSK-3)"</p> <p>BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 11, no. 5, 12 March 2001 (2001-03-12), pages 635-639, XP004230079 ISSN: 0960-894X * see p.635, left. col., last par. * the whole document</p> <p>----</p>	1-17
Y	<p>WO 97 41854 A (UNIV PENNSYLVANIA ;HARVARD COLLEGE (US)) 13 November 1997 (1997-11-13) * see claim 1 * the whole document</p> <p>-----</p>	1-17

INTERNATIONAL SEARCH REPORT

International application No.
r 02/EP 02/12077

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Present claims 1-3 relate to an extremely large number of possible compounds. Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the compounds claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts relating to the compounds of claims 4 and 5 and the claims 1-3 and 6-17 partially insofar they include the structures of claims 4 and 5 (see also page 35, formula (a-1) and (a-2) and these compounds recited in the examples and closely related homologous compounds.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

International application No

PCT/EP 02/12077

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0172745	A	04-10-2001	AU 4262901 A EP 1274705 A1 WO 0172745 A1 GB 2361236 A ,B US 2002019404 A1	08-10-2001 15-01-2003 04-10-2001 17-10-2001 14-02-2002
WO 9719065	A	29-05-1997	AU 7631496 A EP 0862560 A1 WO 9719065 A1 US 6235746 B1 US 5958935 A	11-06-1997 09-09-1998 29-05-1997 22-05-2001 28-09-1999
WO 9841512	A	24-09-1998	AU 6411698 A EP 0970056 A1 WO 9841512 A1 JP 2001516356 T US 6048866 A US 6337335 B1	12-10-1998 12-01-2000 24-09-1998 25-09-2001 11-04-2000 08-01-2002
WO 9509851	A	13-04-1995	AU 693114 B2 AU 7783394 A CA 2149147 A1 WO 9509851 A1 EP 0672042 A1 JP 8503970 T SG 45240 A1 US 5705502 A	25-06-1998 01-05-1995 13-04-1995 13-04-1995 20-09-1995 30-04-1996 16-01-1998 06-01-1998
WO 9509853	A	13-04-1995	AT 208772 T AU 691834 B2 AU 7697794 A CA 2148928 A1 CN 1115982 A ,B CZ 9501722 A3 DE 69429078 D1 DE 69429078 T2 DK 672041 T3 WO 9509853 A1 EP 0672041 A1 ES 2167377 T3 FI 952607 A HU 72609 A2 IL 111077 A JP 2983636 B2 JP 8504215 T NO 952132 A NZ 273617 A PL 309225 A1 PT 672041 T RU 2135491 C1 SG 45183 A1 SI 672041 T1 TW 378208 B US 5728708 A ZA 9407657 A	15-11-2001 28-05-1998 01-05-1995 13-04-1995 31-01-1996 13-03-1996 20-12-2001 11-07-2002 25-02-2002 13-04-1995 20-09-1995 16-05-2002 29-05-1995 28-05-1996 28-10-1999 29-11-1999 07-05-1996 30-05-1995 26-11-1996 02-10-1995 29-04-2002 27-08-1999 16-01-1998 30-04-2002 01-01-2000 17-03-1998 03-04-1995
WO 0129009	A	26-04-2001	AU 7935100 A EP 1222175 A1	30-04-2001 17-07-2002

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 02/12077

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0129009 A		WO 0129009 A1	26-04-2001
WO 0112621 A	22-02-2001	AU 6909600 A	13-03-2001
		CN 1378541 T	06-11-2002
		CZ 20020534 A3	17-07-2002
		EP 1218369 A1	03-07-2002
		NO 20020713 A	12-04-2002
		SK 3572002 A3	02-07-2002
		WO 0112621 A1	22-02-2001
WO 0160816 A	23-08-2001	AU 3704101 A	27-08-2001
		EP 1257546 A1	20-11-2002
		WO 0160816 A1	23-08-2001
		US 2002052386 A1	02-05-2002
WO 0147897 A	05-07-2001	AU 2457201 A	09-07-2001
		AU 2735201 A	09-07-2001
		EP 1242385 A1	25-09-2002
		EP 1246823 A1	09-10-2002
		WO 0147921 A1	05-07-2001
		WO 0147897 A1	05-07-2001
		US 2002065270 A1	30-05-2002
		US 2002137747 A1	26-09-2002
WO 0062788 A	26-10-2000	AU 4278200 A	02-11-2000
		WO 0062788 A2	26-10-2000
		EP 1171140 A2	16-01-2002
WO 9965897 A	23-12-1999	AU 4956699 A	05-01-2000
		CN 1312807 T	12-09-2001
		EP 1087963 A1	04-04-2001
		WO 9965897 A1	23-12-1999
		US 6417185 B1	09-07-2002
		US 6489344 B1	03-12-2002
WO 9741854 A	13-11-1997	AU 2819397 A	26-11-1997
		EP 1019043 A1	19-07-2000
		WO 9741854 A1	13-11-1997
		US 6441053 B1	27-08-2002